

JC559 U.S. PTO
06/24/98

Please type a plus sign (+) inside this box +

Attorney Docket P0706P2C2D2
PATENT

JC526 U.S. PTO
09/104063
06/24/98

CERTIFICATION UNDER 37 CFR 1.10

EL142012237US Express Mail Number

June 24, 1998: Date of Deposit

I hereby certify that this Non-provisional Application Transmittal and the documents referred to as enclosed therein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.

[Signature]
Yvonne E. Carter

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX PATENT APPLICATION
Assistant Commissioner of Patents
Washington, D.C. 20231

NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)

Transmitted herewith for filing is a non-provisional patent application:

Inventor(s) (or Application "Identifier"):

James Lee
William I. Wood

Title: NUCLEIC ACIDS ENCODING PF4A RECEPTOR

1. Type of Application

- This application is for an original, non-provisional application.
- This is a non-provisional application claiming priority to provisional application no. ___, filed ___, the entire disclosure of which is hereby incorporated by reference.
- This is a [] continuation-in-part [] continuation [X] divisional application of copending U.S. Serial Number 08/701,265, filed 22 August 1996, which is a continuation application of U.S. Serial No. 08/664,228, filed June 6, 1996, now abandoned, which is a continuation application of U.S. Serial No. 08/076,093, filed June 11, 1993, now U.S. Pat. No. 5,543,503, which is a continuation-in-part application of U.S. Serial No. 07/810,782, filed December 19, 1991, now abandoned, the entire disclosures of which applications are hereby incorporated by reference, and to which applications priority is claimed under 35 U.S.C §120.

**2. Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b)
(Non-provisional)**

- 88 pages of specification
2 pages of claims
1 page(s) of abstract
17 sheet(s) of drawings
[] formal [X] informal

3. Declaration or Oath

(for new and CIP applications; also for Cont./Div. where inventor(s) are being added)

- An executed declaration of the inventor(s) [] is enclosed [] will follow.

(for Cont./Div. where inventorship is the same or inventor(s) being deleted)

- A copy of the executed declaration/oath filed in the prior application is enclosed (37 CFR 1.63(d)).

(for Cont./Div. where inventor(s) being deleted)

- A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).

4. Assignment

(for new and CIP applications)

- An Assignment of the invention to GENENTECH, INC. [] is enclosed with attached Recordation Form Cover Sheet [] will follow.

(for cont./div.)

- The prior application is assigned of record to Genentech, Inc.

5. Amendments (for continuation and divisional applications)

- Cancel in this application original claims ___ of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

- A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)

Relate Back -- 35 U.S.C. 120 or 35 U.S.C. 119

- Amend the specification by inserting before the first line the sentence:

--This is a

- non-provisional application
 continuation
 divisional
 continuation-in-part

of co-pending application(s)

- Serial No. _____ filed on_____, which application(s) is(are) incorporated herein by reference and to which application(s) priority is claimed under 35 USC §120. --

- International Application _____ filed on _____ which designated the U.S., which application(s)

is(are) incorporated herein by reference and to which application(s) priority is claimed under 35 USC §120.--
 _____ provisional application No. _____ filed _____, the entire disclosure of which is hereby incorporated by reference and to which application(s) priority is claimed under 35 USC §119.--.

6. Fee Calculation (37 CFR 1.16)

The fee has been calculated as follows:

CLAIMS FOR FEE CALCULATION					
Number Filed		Number Extra		Rate	Basic Fee 37 CFR 1.16(a)
					\$790.00
Total Claims	14	- 20 =	0	X \$22.00	\$0.00
Independent Claims	4	- 3 =	1	X \$82.00	\$82.00
Multiple dependent claim(s), if any				+ \$270.00	\$790.00
Filing Fee Calculation					\$872.00

7. Method of Payment of Fees

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$872.00. A duplicate copy of this transmittal is enclosed.

8. Authorization to Charge Additional Fees

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. A duplicate copy of this sheet is enclosed.

9. Additional Papers Enclosed

- Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449 and citations
- Submission of "Sequence Listing", computer readable copy, certificate re: sequence listing, and/or amendment pertaining thereto for biological invention containing nucleotide and/or amino acid sequence.
- A new Power of Attorney or authorization of agent.
- Other:

10. Maintenance of Copendency of Prior Application (for continuation and divisional applications)

[This item must be completed and the necessary papers filed in the prior application if the period set in the prior application has run]

- _____ A petition, fee and/or response has been filed to extend the term in the pending prior application until _____
- _____ A copy of the petition for extension of time in the *prior* application is attached.

11. Correspondence Address:

X Address all future communications to:

GENENTECH, INC.
Attn: Richard B. Love
1 DNA Way
South San Francisco, CA 94080-4990
(650) 225-5530

Respectfully submitted,
GENENTECH, INC.

Date: June 24, 1998

By: Richard B. Love
Richard B. Love
Reg. No. 34,659

1 DNA Way
So. San Francisco, CA 94080-4990
Phone: (650) 225-5530
Fax: (650) 952-9881

2025 RELEASE UNDER E.O. 14176

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<p>In re Rule 53(b) Divisional Application of Lee et al.</p> <p>Serial No.: 08/701,265</p> <p>Filed: 22 August 1996</p> <p>For: ANTIBODIES TO HUMAN PF4A RECEPTOR AND COMPOSITIONS THEREOF</p>	<p>Previous Group Art Unit: 1644 Previous Examiner: P. Nolan</p> <p>CERTIFICATION UNDER 37 CFR 1.10</p> <p>EL142012237US: Express Mail Number Date of Deposit: June 24, 1998</p> <p>I hereby certify that this Preliminary Amendment is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.</p> <p style="text-align: right;">Yvonne E. Carter</p>
--	---

PRELIMINARY AMENDMENT UNDER 37 C.F.R. §115

BOX SEQUENCE
Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

In advance of examination of the above-identified application, which is a 37 C.F.R. §1.53(b) divisional application of U.S. Ser. No. 08/701,265 filed August 22, 1996, please enter the following amendment.

IN THE TITLE:

Please delete the title and insert therefor --NUCLEIC ACIDS ENCODING PF4A RECEPTOR--.

IN THE SPECIFICATION:

Please delete lines 12-15 on page 1 and insert therefor

--This is a divisional application of copending U.S. Serial No. 08/701,265 filed August 22, 1996, which is a continuation application of U.S. Serial No. 08/664,228 filed June 6, 1996, now abandoned, which is a continuation application of U.S. Serial No. 08/076,093 filed June 11, 1993, now U.S. Patent No. 5,543,503, which is a continuation-in-part application of U.S. Serial

No. 07/810,782 filed December 19, 1991, now abandoned, which is a continuation-in-part application of U.S. Serial No. 07/677,211 filed March 29, 1991, now abandoned to which applications priority is claimed under 35 U.S.C. §120.--

On page 5, lines 30-33, please delete "Figs. 2a-2c (SEQ ID NO. 1) (hereinafter referred to collectively as Fig. 2) depicts the amino acid and nucleotide sequences of the IL-8 receptor cDNA insert from clone pRK5B.il8rl.1" and insert therefor --Figs. 2a-2c (hereinafter referred to collectively as Fig. 2) depict the amino acid (SEQ ID NO. 2) and nucleotide (SEQ ID NO. 1) sequences of the IL-8 receptor cDNA insert from clone pRK5B.il8rl.1--

On page 6, lines 22-26, please delete "Figs. 4 (SEQ ID NO.2) and 5 (SEQ ID NO.3) depict the DNA and an imputed polypeptide sequences for two additional PF4AR members identified by probing lambda libraries from a human monocyte-like cell line (HL-60) and human PBLs using a large fragment of the IL-8 receptor DNA." and insert therefor

--Figs. 4a-c (hereinafter collectively referred to as Fig. 4) depict the DNA sequence (SEQ ID NO.3) and an imputed polypeptide sequence (SEQ ID NO.4) for an additional chemokine superfamily receptor identified by probing lambda libraries from a human monocyte-like cell line (HL-60) and human PBLs using a large fragment of the IL-8 receptor DNA.

Figs. 5a-c (hereinafter collectively referred to as Fig. 5) depict the DNA sequence (SEQ ID NO. 5) and an imputed polypeptide sequence (SEQ ID NO.6) for yet another chemokine superfamily receptor identified by probing lambda libraries from a human monocyte-like cell line (HL-60) and human PBLs using a large fragment of the IL-8 receptor DNA.--

Please amend the specification by replacing the original Sequence Listing pages 78-88 with the attached revised Sequence Listing as pages 78-88.

IN THE CLAIMS:

Please cancel claims 1-19, without prejudice.

Please add the following claims:

--20. An isolated nucleic acid molecule encoding a platelet factor 4 superfamily receptor (PF4AR) polypeptide comprising a stretch of at least 10 contiguous amino acid residues selected from an extracellular region of a receptor polypeptide having the amino acid sequence of Fig. 4 (SEQ ID NO. 4).

21. The nucleic acid molecule of claim 20 wherein the extracellular region is the N-terminal extracellular region.

22. The nucleic acid molecule of claim 20 wherein the PF4AR polypeptide comprises an amino acid sequence spanning an extracellular region of a receptor polypeptide having the amino acid sequence of Fig. 4 (SEQ ID NO. 4).

23. The nucleic acid molecule of claim 22 wherein the extracellular region is the N-terminal extracellular region.

24. The nucleic acid molecule of claim 20 wherein the PF4AR polypeptide comprises the amino acid sequence of Fig. 4 (SEQ ID NO. 4).

25. A DNA molecule comprising a stretch of at least about 45 contiguous nucleotides selected from or complementary to the DNA sequence of Fig. 4 (SEQ ID NO. 3).

26. The DNA molecule of claim 25 comprising the DNA sequence of Fig. 4 (SEQ ID NO. 3) or its complement.

27. The nucleic acid molecule of claim 20 operably linked to a promoter.

28. An expression vector comprising the nucleic acid molecule of claim 20 operably linked to control sequences recognized by a host cell transformed with the vector.

29. A host cell transformed with the vector of claim 28.

30. A method of using the nucleic acid molecule of claim 20 for the expression of the PF4AR polypeptide encoded by the nucleic acid molecule, comprising culturing a host cell transformed with a vector comprising the nucleic acid molecule operably linked to control sequences recognized by the host cell under conditions that allow expression of the polypeptide.

31. The method of claim 30 further comprising recovering the polypeptide from the host cell.

32. A method for determining the presence or absence of a platelet factor 4 superfamily receptor (PF4AR) nucleic acid in a sample, comprising the steps of:

(a) selecting a probe comprising at least 20 contiguous nucleotides selected from the nucleic acid sequence of Fig. 4 (SEQ ID NO. 3) or at least 20 contiguous nucleotides complementary to the nucleic acid sequence of Fig. 4 (SEQ ID NO. 3),

(b) hybridizing the probe to any PF4AR nucleic acid present in the sample to form a probe/PF4AR nucleic acid complex,

(c) detecting the presence or absence of the probe/PF4AR nucleic acid complex in the sample, and

(d) determining the presence or absence of PF4AR nucleic acid in the sample based on the result of step (c).

33. A method of amplifying a platelet factor 4 superfamily receptor (PF4AR) single stranded nucleic acid in a sample, comprising the steps of:

- (a) selecting an oligonucleotide primer having a 3' terminus consisting of at least 20 contiguous nucleotides selected from the nucleic acid sequence of Fig. 4 (SEQ ID NO. 3) or at least 20 contiguous nucleotides complementary to the nucleic acid sequence of Fig. 4 (SEQ ID NO. 3),
- (b) hybridizing the oligonucleotide primer to the single stranded nucleic acid in the sample, and
- (c) performing a nucleic acid polymerase reaction wherein the hybridized oligonucleotide primer primes the synthesis of a second strand complementary to the single stranded nucleic acid to form an amplified nucleic acid.--

REMARKS

Claims 1-19 are pending in this application. Claims 1-19 are now canceled and new claims 20-33 are added. Thus, claims 20-33 are active in the case.

Amendments

The specification is amended to recite the file history of the present application.

The Sequence Listing in the specification is amended to provide separate SEQ ID numbers for the paired amino acid and nucleotide sequences given a common number in the original Sequence Listing. The specification is further amended to refer to the correct SEQ ID numbers.

Claims 1-19 are canceled and new claims 20-33 are added in order to introduce claims relating to the subject matter of non-elected Claim Group III set forth in the Restriction Requirement and Office Action mailed March 19, 1997 in parent application U.S. Serial No. 08/701,265. Claim Group III encompassed claims 27-40 of parent application U.S. Serial No. 08/701,265, drawn to nucleic acid molecules encoding PF4AR polypeptides, vectors and host cells containing such nucleic acid molecules, and methods of using the same.

Claim 20 is drawn to "[a]n isolated nucleic acid molecule encoding a platelet factor 4

superfamily receptor (PF4AR) polypeptide comprising a stretch of at least 10 contiguous amino acid residues selected from an extracellular region of a receptor polypeptide having the amino acid sequence of Fig. 4 (SEQ ID NO. 4)", as supported, at least, on page 4, line 30 to page 5, line 2, page 6, lines 22-26, page 11, line 7 to page 12, line 11, page 21, lines 8-20, and page 21, line 31 to page 22, line 12 and in Example 2 of the specification and in Fig. 4, and in original claims 6 and 7 of parent application Ser. No. 07/810,782 filed December 19, 1991, now abandoned, the entire disclosure of which is incorporated by reference on page 1, lines 12-15 and page 61, lines 3-4 of the present application.

Claim 21 is drawn to the "nucleic acid molecule of claim 20 wherein the extracellular region is the N-terminal extracellular region", as supported, at least, on page 4, line 30 to page 5, line 2, page 6, lines 22-26, page 11, line 7 to page 12, line 11, page 21, lines 8-20, and page 21, line 31 to page 22, line 12 and in Example 2 of the specification and in Fig. 4, and in original claims 6 and 7 of parent application Ser. No. 07/810,782.

Claim 22 is drawn to the "nucleic acid molecule of claim 20 wherein the PF4AR polypeptide comprises an amino acid sequence spanning an extracellular region of a receptor polypeptide having the amino acid sequence of Fig. 4 (SEQ ID NO. 4)", as supported, at least, on page 4, line 30 to page 5, line 2, page 6, lines 22-26, page 11, line 7 to page 12, line 11, page 21, lines 8-20, and page 21, line 31 to page 22, line 12 and in Example 2 of the specification and in Fig. 4, and in original claims 6 and 7 of parent application Ser. No. 07/810,782.

Claim 23 is drawn to the "nucleic acid molecule of claim 22 wherein the extracellular region is the N-terminal extracellular region", as supported, at least, on page 4, line 30 to page 5, line 2, page 6, lines 22-26, page 11, line 7 to page 12, line 11, page 21, lines 8-20, and page 21, line 31 to page 22, line 12 and in Example 2 of the specification and in Fig. 4, and in original claims 6 and 7 of parent application Ser. No. 07/810,782.

Claim 24 is drawn to the "nucleic acid molecule of claim 20 wherein the PF4AR polypeptide comprises the amino acid sequence of Fig. 4 (SEQ ID NO. 4)", as supported, at least, on page 4, line 30 to page 5, line 2, page 6, lines 22-26, page 11, line 7 to page 12, line 11, page 13, lines 14-25, and page 21, line 31 to page 22, line 12 and in Example 2 of the specification and in Fig. 4, and in original claims 6 and 7 of parent application Ser. No.

07/810,782.

Claim 25 is drawn to a "DNA molecule comprising a stretch of at least about 45 contiguous nucleotides selected from or complementary to the DNA sequence of Fig. 4 (SEQ ID NO. 3)", as supported, at least, on page 4, line 30 to page 5, line 2, page 6, lines 22-26, and page 13, lines 14-25 and in Example 2 of the specification and in Fig. 4, and in original claims 6-8 of parent application Ser. No. 07/810,782.

Claim 26 is drawn to the "DNA molecule of claim 25 comprising the DNA sequence of Fig. 4 (SEQ ID NO. 3) or its complement", as supported, at least, on page 4, line 30 to page 5, line 2, page 6, lines 22-26, and page 13, lines 14-25 and in Example 2 of the specification and in Fig. 4, and in original claim 7 of parent application Ser. No. 07/810,782.

Claim 27 is drawn to the "nucleic acid molecule of claim 20 operably linked to a promoter", as supported, at least, on page 4, line 30 to page 5, line 2, page 5, lines 3-6, page 6, lines 22-26, page 11, line 7 to page 12, line 11, page 14, lines 11-32, page 21, lines 8-20, page 21, line 31 to page 22, line 12, and page 32, line 20 to page 35, line 16 and in Example 2 of the specification and in Fig. 4, and in original claims 6 and 9 of parent application Ser. No. 07/810,782.

Claim 28 is drawn to an "expression vector comprising the nucleic acid molecule of claim 20 operably linked to control sequences recognized by a host cell transformed with the vector", as supported, at least, on page 4, line 30 to page 5, line 2, page 5, lines 3-6, page 6, lines 22-26, page 11, line 7 to page 12, line 11, page 14, lines 11-32, page 21, lines 8-20, page 21, line 31 to page 22, line 12, and page 28, line 23 to page 37, line 19 and in Example 2 of the specification and in Fig. 4, and in original claims 6 and 10 of parent application Ser. No. 07/810,782.

Claim 29 is drawn to a "host cell transformed with the vector of claim 28", as supported, at least, on page 4, line 30 to page 5, line 2, page 5, lines 3-6, page 6, lines 22-26, page 11, line 7 to page 12, line 11, page 14, lines 11-32, page 21, lines 8-20, page 21, line 31 to page 22, line 12, page 28, line 23 to page 37, line 19, and page 37, line 20 to page 41, line 4 and in Example 2 of the specification and in Fig. 4, and in original claims 6, 10 and 11 of parent application Ser. No. 07/810,782.

Claim 30 and 31 are drawn to a "method of using the nucleic acid molecule of claim

20 for the expression of the PF4AR polypeptide encoded by the nucleic acid molecule, comprising culturing a host cell transformed with a vector comprising the nucleic acid molecule operably linked to control sequences recognized by the host cell under conditions that allow expression of the polypeptide" and to "recovering the polypeptide from the host cell", respectively, as supported, at least, on page 4, line 30 to page 5, line 2, page 5, lines 3-10, page 6, lines 22-26, page 11, line 7 to page 12, line 11, page 14, lines 11-32, page 21, lines 8-20, page 21, line 31 to page 22, line 12, page 28, line 23 to page 37, line 19, page 37, line 20 to page 41, line 4, and page 41, line 5 to page 44, line 23 and in Example 2 of the specification and in Fig. 4, and in original claims 12 and 13 of parent application Ser. No. 07/810,782.

Claim 32 is drawn to a "method for determining the presence or absence of a platelet factor 4 superfamily receptor (PF4AR) nucleic acid in a sample, comprising the steps of: (a) selecting a probe comprising at least 20 contiguous nucleotides selected from the nucleic acid sequence of Fig. 4 (SEQ ID NO. 3) or at least 20 contiguous nucleotides complementary to the nucleic acid sequence of Fig. 4 (SEQ ID NO. 3), (b) hybridizing the probe to any PF4AR nucleic acid present in the sample to form a probe/PF4AR nucleic acid complex, (c) detecting the presence or absence of the probe/PF4AR nucleic acid complex in the sample, and (d) determining the presence or absence of PF4AR nucleic acid in the sample based on the result of step (c)", as supported, at least, on page 5, lines 10-11, page 13, lines 14-25, page 16, line 20 to page 17, line 21, and page 55, lines 22-27 and in Example 2 of the specification and in Fig. 4, and in original claim 14 of parent application Ser. No. 07/810,782.

Claim 33 is drawn to a "method of amplifying a platelet factor 4 superfamily receptor (PF4AR) single stranded nucleic acid in a sample, comprising the steps of: (a) selecting an oligonucleotide primer having a 3' terminus consisting of at least 20 contiguous nucleotides selected from the nucleic acid sequence of Fig. 4 (SEQ ID NO. 3) or at least 20 contiguous nucleotides complementary to the nucleic acid sequence of Fig. 4 (SEQ ID NO. 3), (b) hybridizing the oligonucleotide primer to the single stranded nucleic acid in the sample, and (c) performing a nucleic acid polymerase reaction wherein the hybridized oligonucleotide primer primes the synthesis of a second strand complementary to the single stranded

nucleic acid to form an amplified nucleic acid", as supported, at least, page 13, lines 14-25, page 16, line 20 to page 17, line 21, and page 18, lines 12-20 and in Example 2 of the specification and in Fig. 4, and in original claim 15 of parent application Ser. No. 07/810,782.

No new matter is believed to be added hereby.

Applicants respectfully request entry of the above amendments and early examination of the application.

Respectfully submitted,
GENENTECH, INC.

Date: June 24, 1998

By: 
Richard B. Love
Reg. No. 34,659

1 DNA Way
So. San Francisco, CA 94080-4990
Phone: (650) 225-5530
Fax: (650) 952-9881

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<p>In re Rule 53(b) Divisional Application of James Lee et al. Serial No.: 08/701,265 Filed: 22 August 1996 For: ANTIBODIES TO HUMAN PF4A RECEPTOR AND COMPOSITIONS THEREOF</p>	<p>Group Art Unit: 1644 Examiner: P. Nolan</p> <p>CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on</p> <p style="text-align: center;">June 24, 1998</p> <p style="text-align: center;">Yvonne E. Carter</p>
---	---

CERTIFICATE RE: SEQUENCE LISTING

RESPONSE UNDER 37 CFR § 1.821(f) and (g)

BOX SEQUENCE
Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

I hereby state that the Sequence Listing submitted herewith is submitted in paper copy and a computer-readable diskette, and that the content of the paper and computer readable copies are the same. I further state that this submission includes no new matter.

Respectfully submitted,
GENENTECH, INC.

Date: June 24, 1998

By: 
Richard B. Love
Reg. No. 34,659

1 DNA Way
So. San Francisco, CA 94080-4990
Phone: (650) 225-5530
Fax: (650) 952-9881

SEQUENCE LISTING

(1) GENERAL INFORMATION:

5 (i) APPLICANT: Lee, James
Wood, William I.

10 (ii) TITLE OF INVENTION: PF4A Receptors

15 (iii) NUMBER OF SEQUENCES: 6

20 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Genentech, Inc.
(B) STREET: 1 DNA Way
(C) CITY: South San Francisco
(D) STATE: California
(E) COUNTRY: USA
(F) ZIP: 94080

25 (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: WinPatin (Genentech)

30 (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE: 24-June-1998
(C) CLASSIFICATION:

35 (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 08/701265
(B) FILING DATE: 22-AUG-1996

40 (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 08/664228
(B) FILING DATE: 06-JUN-1996

(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 08/076093
(B) FILING DATE: 11-JUN-1993

45 (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 07/810782
(B) FILING DATE: 19-DEC-1991

50 (viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Love, Richard B.
(B) REGISTRATION NUMBER: 34,659
(C) REFERENCE/DOCKET NUMBER: P0706P2C2

55 (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 415/225-5530
(B) TELEFAX: 415/952-9881
(C) TELEX: 910/371-7168

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1933 base pairs
(B) TYPE: Nucleic Acid
(C) STRANDEDNESS: Single
(D) TOPOLOGY: Linear

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CCTGGCCGGT GCTTCAGTTA GATCAAACCA TTGCTGAAAC TGAAGAGGAC 50
10 ATGTCAAATA TTACAGATCC ACAGATGTGG GATTTGATG ATCTAAATT 100
CACTGGCATG CCACCTGCAG ATGAAGATTA CAGCCCCTGT ATGCTAGAAA 150
15 CTGAGACACT CAACAAGTAT GTTGTGATCA TCGCCTATGC CCTAGTGTTC 200
CTGCTGAGCC TGCTGGAAA CTCCCTGGTG ATGCTGGTCA TCTTATACAG 250
CAGGGTCGGC CGCTCCGTCA CTGATGTCTA CCTGCTGAAC CTGGCCTTGG 300
20 CCGACCTACT CTTTGCCCTG ACCTGCCCA TCTGGGCCGC CTCCAAGGTG 350
AATGGCTGGA TTTTGCGAC ATTCCGTGCA AAGGTGGTCT CACTCCTGAA 400
25 GGAAGTCAAC TTCTACAGTG GCATCCTGCT GTTGGCCTGC ATCAGTGTGG 450
ACCGTTACCT GGCCATTGTC CATGCCACAC GCACACTGAC CCAGAACGCT 500
CACTGGTCA AGTTTGGTTG TCTTGGCTGC TGGGGACTGT CTATGAATCT 550
30 GTCCCTGCC C TTCTCCTT TCCGCCAGGC TTACCATCCA AACAAATTCCA 600
GTCCAGTTG CTATGAGGTC CTGGGAAATG ACACAGCAAA ATGGCGGATG 650
GTGTTGCGGA TCCTGCCTCA CACCTTGCG TTCATCGTGC CGCTGTTGT 700
35 CATGCTGTTG TGCTATGGAT TCACCCCTGCG TACACTGTTT AAGGCCACA 750
TGGGCAGAA GCACCGAGCC ATGAGGGTCA TCTTGCTGT CGTCCTCATC 800
40 TTCCTGCTTT GCTGGCTGCC CTACAACCTG GTCCTGCTGG CAGACACCCCT 850
CATGAGGACC CAGGTGATCC AGGAGACCTG TGAGGCCGC AACAAACATCG 900
GCCGGGCCCT GGATGCCACT GAGATTCTGG GATTTCTCCA TAGCTGCCTC 950
45 AACCCCATCA TCTACGCCCT CATCGGCCAA AATTTGCGC ATGGATTCT 1000
CAAGATCCTG GCTATGCATG GCCTGGTCAG CAAGGAGTTC TTGGCACGTC 1050
50 ATCGTGTAC CTCCTACACT TCTTCGTCTG TCAATGTCTC TTCCAACCTC 1100
TGAAAACCAT CGATGAAGGA ATATCTCTTC TCAGAAGGAA AGAATAACCA 1150
ACACCCCTGAG GTTGTGTGTG GAAGGTGATC TGGCTCTGGA CAGGCACCTAT 1200
55 CTGGGTTTG GGGGGACGCT ATAGGATGTG GGGAAAGTTAG GAACTGGTGT 1250
CTTCAGGGGC CACACCAACC TTCTGAGGAG CTGTTGAGGT ACCTCCAAGG 1300

ACCGGCCTT GCACCTCCAT GGAAACGAAG CACCATCATT CCCGTTGAAC 1350
GTCACATCTT TAACCCACTA ACTGGCTAAT TAGCATGGCC ACATCTGAGC 1400
CCCGAATCTG ACATTAGATG AGAGAACAGG GCTGAAGCTG TGTCCCTCATG 1450
5 AGGGCTGGAT GCTCTCGTTG ACCCTCACAG GAGCATCTCC TCAACTCTGA 1500
GTGTTAAGCG TTGAGGCCACC AAGCTGGTGG CTCTGTGTGC TCTGATCCGA 1550
10 GCTCAGGGGG GTGGTTTCC CATCTCAGGT GTGTTGCAGT GTCTGCTGGA 1600
GACATTGAGG CAGGCAC TGC CAAAACATCA ACCTGCCAGC TGGCCTTG 1650
15 AGGAGCTGGA AACACATGTT CCCCTGGGG GTGGTGGATG AACAAAGAGA 1700
AAGAGGGTTT GGAAGCCAGA TCTATGCCAC AAGAACCCCC TTTACCCCCA 1750
TGACCAACAT CGCAGACACA TGTGCTGGCC ACCTGCTGAG CCCCAAGTGG 1800
20 AACGAGACAA GCAGCCCTTA GCCCTTCCCC TCTGCAGCTT CCAGGCTGGC 1850
GTGCAGCATH AGCATCCCTA GAAAGCCATG TGCAGCCACC AGTCCATTGG 1900
GCAGGCAGAT GTTCCTAATA AAGCTTCTGT TCC 1933

25 (2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 350 amino acids
(B) TYPE: Amino Acid
(D) TOPOLOGY: Linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

35 Met Ser Asn Ile Thr Asp Pro Gln Met Trp Asp Phe Asp Asp Leu
1 5 10 15
Asn Phe Thr Gly Met Pro Pro Ala Asp Glu Asp Tyr Ser Pro Cys
20 25 30
40 Met Leu Glu Thr Glu Thr Leu Asn Lys Tyr Val Val Ile Ile Ala
35 40 45
Tyr Ala Leu Val Phe Leu Leu Ser Leu Leu Gly Asn Ser Leu Val
45 50 55 60
Met Leu Val Ile Leu Tyr Ser Arg Val Gly Arg Ser Val Thr Asp
65 70 75
50 Val Tyr Leu Leu Asn Leu Ala Leu Asp Leu Leu Phe Ala Leu
80 85 90
Thr Leu Pro Ile Trp Ala Ala Ser Lys Val Asn Gly Trp Ile Phe
95 100 105
55 Gly Thr Phe Leu Cys Lys Val Val Ser Leu Leu Lys Glu Val Asn
110 115 120

Phe Tyr Ser Gly Ile Leu Leu Leu Ala Cys Ile Ser Val Asp Arg
 125 130 135
 Tyr Leu Ala Ile Val His Ala Thr Arg Thr Leu Thr Gln Lys Arg
 140 145 150
 5 His Leu Val Lys Phe Val Cys Leu Gly Cys Trp Gly Leu Ser Met
 155 160 165
 Asn Leu Ser Leu Pro Phe Phe Leu Phe Arg Gln Ala Tyr His Pro
 10 170 175 180
 Asn Asn Ser Ser Pro Val Cys Tyr Glu Val Leu Gly Asn Asp Thr
 185 190 195
 15 Ala Lys Trp Arg Met Val Leu Arg Ile Leu Pro His Thr Phe Gly
 200 205 210
 Phe Ile Val Pro Leu Phe Val Met Leu Phe Cys Tyr Gly Phe Thr
 215 220 225
 20 Leu Arg Thr Leu Phe Lys Ala His Met Gly Gln Lys His Arg Ala
 230 235 240
 25 Met Arg Val Ile Phe Ala Val Val Leu Ile Phe Leu Leu Cys Trp
 245 250 255
 Leu Pro Tyr Asn Leu Val Leu Leu Ala Asp Thr Leu Met Arg Thr
 260 265 270
 30 Gln Val Ile Gln Glu Thr Cys Glu Arg Arg Asn Asn Ile Gly Arg
 275 280 285
 Ala Leu Asp Ala Thr Glu Ile Leu Gly Phe Leu His Ser Cys Leu
 290 295 300
 35 Asn Pro Ile Ile Tyr Ala Phe Ile Gly Gln Asn Phe Arg His Gly
 305 310 315
 40 Phe Leu Lys Ile Leu Ala Met His Gly Leu Val Ser Lys Glu Phe
 320 325 330
 Leu Ala Arg His Arg Val Thr Ser Tyr Thr Ser Ser Ser Val Asn
 335 340 345
 45 Val Ser Ser Asn Leu
 350

(2) INFORMATION FOR SEQ ID NO:3:

- 50 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1737 base pairs
 (B) TYPE: Nucleic Acid
 (C) STRANDEDNESS: Single
 (D) TOPOLOGY: Linear

- 55 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GAATTCCAGT GTGCTGGCGG CGCGCGCAA AGTGACGCCG AGGGCCTGAG 50
TGCTCCAGTA GCCACCGCAT CTGGAGAACC AGCGGTTACC ATGGAGGGGA 100
TCAGTATATA CACTTCAGAT AACTACACCG AGGAAATGGG CTCAGGGGAC 150
5 TATGACTCCA TGAAGGAACC CTGTTCCGT GAAGAAAATG CTAATTCAA 200
TAAAATCTTC CTGCCCACCA TCTACTCCAT CATCTTCTTA ACTGGCATTG 250
10 TGGGCAATGG ATTGGTCATC CTGGTCATGG GTTACCAGAA GAAACTGAGA 300
AGCATGACGG ACAAGTACAG GCTGCACCTG TCAGTGGCCG ACCTCCTCTT 350
15 TGTCATCACG CTTCCCTTCT GGGCAGTTGA TGCCGTGGCA AACTGGTACT 400
TTGGGAACCTT CCTATGCAAG GCAGTCCATG TCATCTACAC AGTCAACCTC 450
TACAGCAGTG TCCTCATCCT GGCCTTCATC AGTCTGGACC GCTACCTGGC 500
20 CATCGTCCAC GCCACCAACA GTCAGAGGCC AAGGAAGCTG TTGGCTGAAA 550
AGGTGGTCTA TGGTGGCGTC TGGATCCCTG CCCTCCTGCT GACTATTCCC 600
25 GACTTCATCT TTGCCAACGT CAGTGAGGCA GATGACAGAT ATATCTGTGA 650
CCGCTTCTAC CCCAATGACT TGTGGGTGGT TGTGTTCCAG TTTCAGCACA 700
TCATGGTTGG CCTTATCCTG CCTGGTATTG TCATCCTGTC CTGCTATTGC 750
30 ATTATCATCT CCAAGCTGTC ACACCTCAAG GGCCACCAGA AGCGCAAGGC 800
CCTCAAGACC ACAGTCATCC TCATCCTGGC TTTCTTCGCC TGTGGCTGC 850
35 CTTACTACAT TGGGATCAGC ATCGACTCCT TCATCCTCCT GGAAATCATC 900
AAGCAAGGGT GTGAGTTGA GAACACTGTG CACAAGTGGA TTTCCATCAC 950
CGAGGCCCTA GCTTTCTTCC ACTGTTGTCT GAACCCCATC CTCTATGCTT 1000
40 TCCTGGAGC CAAATTAAA ACCTCTGCC AGCACGCCT CACCTCTGTG 1050
AGCAGAGGGT CCAGCCTCAA GATCCTCTCC AAAGGAAAGC GAGGTGGACA 1100
45 TTCATCTGTT TCCACTGAGT CTGAGTCTTC AAGTTTCAC TCCAGCTAAC 1150
ACAGATGTAA AAGACTTTT TTTATACGAT AAATAACTTT TTTTTAAGTT 1200
ACACATTTT CAGATATAAA AGACTGACCA ATATTGTACA GTTTTATTG 1250
50 CTTGTTGGAT TTTTGTCTTG TGTTCTTAA GTTTTGTA AGTTAATTG 1300
ACTTATTTAT ATAAATTAAA TTTGTTTCAT ATTGATGTGT GTCTAGGCAG 1350
GACCTGTGGC CAAGTTCTTA GTTGCTGTAT GTCTCGTGGT AGGACTGTAG 1400
55 AAAAGGGAAC TGAACATTCC AGAGCGTGTA GTGAATCACG TAAAGCTAGA 1450
AATGATCCCC AGCTGTTAT GCATAGATAA TCTCTCCATT CCCGTGGAAC 1500

5 GTTTTCCTG TTCTTAAGAC GTGATTTGC TGTAGAAGAT GGCACTTATA 1550
ACCAAAGCCC AAAGTGGTAT AGAAATGCTG GTTTTCAGT TTTCAGGAGT 1600
GGGTTGATT CAGCACCTAC AGTGTACAGT CTTGTATTAA GTTGTAAATA 1650
AAAGTACATG TTAAACTTAA AAAAAAAA AAAAAAAA AAAAAAAA 1700
AAAAAAA AAAGCGGCCG CCAGCACACT GGAATTC 1737

10 (2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 352 amino acids
(B) TYPE: Amino Acid
15 (D) TOPOLOGY: Linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

20 Met Glu Gly Ile Ser Ile Tyr Thr Ser Asp Asn Tyr Thr Glu Glu
1 5 10 15
Met Gly Ser Gly Asp Tyr Asp Ser Met Lys Glu Pro Cys Phe Arg
20 25 30
Glu Glu Asn Ala Asn Phe Asn Lys Ile Phe Leu Pro Thr Ile Tyr
35 40 45
Ser Ile Ile Phe Leu Thr Gly Ile Val Gly Asn Gly Leu Val Ile
50 55 60
Leu Val Met Gly Tyr Gln Lys Lys Leu Arg Ser Met Thr Asp Lys
65 70 75
Tyr Arg Leu His Leu Ser Val Ala Asp Leu Leu Phe Val Ile Thr
80 85 90
Leu Pro Phe Trp Ala Val Asp Ala Val Ala Asn Trp Tyr Phe Gly
95 100 105
Asn Phe Leu Cys Lys Ala Val His Val Ile Tyr Thr Val Asn Leu
110 115 120
Tyr Ser Ser Val Leu Ile Leu Ala Phe Ile Ser Leu Asp Arg Tyr
125 130 135
Leu Ala Ile Val His Ala Thr Asn Ser Gln Arg Pro Arg Lys Leu
140 145 150
Leu Ala Glu Lys Val Val Tyr Val Gly Val Trp Ile Pro Ala Leu
155 160 165
Leu Leu Thr Ile Pro Asp Phe Ile Phe Ala Asn Val Ser Glu Ala
170 175 180
Asp Asp Arg Tyr Ile Cys Asp Arg Phe Tyr Pro Asn Asp Leu Trp
185 190 195
Val Val Val Phe Gln Phe Gln His Ile Met Val Gly Leu Ile Leu

	200	205	210
	Pro Gly Ile Val Ile Leu Ser Cys Tyr Cys Ile Ile Ile Ser Lys		
	215	220	225
5	Leu Ser His Ser Lys Gly His Gln Lys Arg Lys Ala Leu Lys Thr		
	230	235	240
	Thr Val Ile Leu Ile Leu Ala Phe Phe Ala Cys Trp Leu Pro Tyr		
10	245	250	255
	Tyr Ile Gly Ile Ser Ile Asp Ser Phe Ile Leu Leu Glu Ile Ile		
	260	265	270
15	Lys Gln Gly Cys Glu Phe Glu Asn Thr Val His Lys Trp Ile Ser		
	275	280	285
	Ile Thr Glu Ala Leu Ala Phe Phe His Cys Cys Leu Asn Pro Ile		
	290	295	300
20	Leu Tyr Ala Phe Leu Gly Ala Lys Phe Lys Thr Ser Ala Gln His		
	305	310	315
	Ala Leu Thr Ser Val Ser Arg Gly Ser Ser Leu Lys Ile Leu Ser		
25	320	325	330
	Lys Gly Lys Arg Gly Gly His Ser Ser Val Ser Thr Glu Ser Glu		
	335	340	345
	Ser Ser Ser Phe His Ser Ser		
30	350	352	

(2) INFORMATION FOR SEQ ID NO:5:

- 35 (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1679 base pairs
 - (B) TYPE: Nucleic Acid
 - (C) STRANDEDNESS: Single
 - (D) TOPOLOGY: Linear

40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

	GAATTCCAGT GTGCTGGCGG CCGCCCAGTG TGCTGGCGGC GGCAGTTGAG 50
45	GGAAAGGACA GAGGTTATGA GTGCCTGCAA GAGTGGCAGC CTGGAGTAGA 100
	GAAAACACTA AAGGTGGAGT CAAAAGACCT GAGTTCAAGT CCCAGCTCTG 150
	CCACTGGTTA GCTGTGGGAT CTCGGAAAAG ACCCAGTGAA AAAAAAAA 200
50	AAAGTGATGA GTTGTGAGGC AGGTCGCGGC CCTACTGCCT CAGGAGACGA 250
	TGCGCAGCTC ATTTGCTTAA ATTTGCAGCT GACGGCTGCC ACCTCTCTAG 300
55	AGGCACCTGG CGGGGAGCCT CTCAACATAA GACAGTGACC AGTCTGGTGA 350
	CTCACAGCCG GCACAGCCAT GAACTACCCG CTAACGCTGG AAATGGACCT 400

CGAGAACCTG GAGGACCTGT TCTGGAACT GGACAGATTG GACAACATA 450
ACGACACCTC CCTGGTGGAA AATCATCTCT GCCCTGCCAC AGAGGGGCC 500
CTCATGGCCT CCTTCAAGGC CGTGTTCGTG CCCGTGGCCT ACAGCCTCAT 550
5 CTTCCCTCTG GGC GTGATCG GCAACGTCCT GGTGCTGGTG ATCCTGGAGC 600
GGCACCGGCA GACACGCAGT TCCACGGAGA CCTTCCTGTT CCACCTGGCC 650
10 GTGGCCGACC TCCTGCTGGT CTTCATCTTG CCCTTGCCG TGGCCGAGGG 700
CTCTGTGGC TG GGTCTCTGG GGACCTTCCT CTGCAA AACT GTGATTGCC 750
15 TGCACAAAGT CAACTTCTAC TGCAGCAGCC TGCTCCTGGC CTGCATGCC 800
GTGGACCGCT ACCTGGCCAT TGTCCACGCC GTCCATGCC ACCGCCACCG 850
CCGCCTCCTC TCCATCCACA TCACCTGTGG GACCATCTGG CTGGTGGCT 900
20 TCCTCCTTGC CTTGCCAGAG ATTCTCTTCG CCAAAGTCAG CCAAGGCCAT 950
CACAACAAC CCCTGCCACG TTGCACCTTC TCCCAGAGA ACCAAGCAGA 1000
AACGCATGCC TGGTTCACCT CCCGATTCT CTACCATGTG GCGGGATTCC 1050
25 TGCTGCCCAT GCTGGTGATG GGCTGGTGCT ACGTGGGGT AGTGCACAGG 1100
TTGCGCCAGG CCCAGCGGCG CCCTCAGCGG CAGAAGGCAG TCAGGGTGGC 1150
30 CATCCTGGTG ACAAGCATCT TCTTCCTCTG CTGGTCACCC TACCACATCG 1200
TCATTTCTCT GGACACCCCTG GCGAGGCTGA AGGCCGTGGA CAATACCTGC 1250
AAGCTGAATG GCTCTCTCCC CGTGGCCATC ACCATGTGTG AGTCCTGGG 1300
35 CCTGGCCAC TGCTGCCTCA ACCCCATGCT CTACACTTTC GCCGGCGTGA 1350
AGTTCCGCAG TGACCTGTG CGGCTCCTGA CGAAGCTGGG CTGTACCGGC 1400
40 CCTGCCTCCC TGTGCCAGCT CTTCCCTAGC TGGCGCAGGA GCAGTCTCTC 1450
TGAGTCAGAG AATGCCACCT CTCTCACCAC GTTCTAGGTC CCAGTGTCCC 1500
CTTTTATTGC TGCTTTCTT TG GGGCAGGC AGTGATGCTG GATGCTCCTT 1550
45 CCAACAGGAG CTGGGATCCT AAGGGCTCAC CGTGGCTAAG AGTGTCTAG 1600
GAGTATCCTC ATTTGGGTA GCTAGAGGAA CCAACCCCCA TTTCTAGAAC 1650
50 ATCCCGCGC CGCCAGCACA CTGGAATTC 1679

(2) INFORMATION FOR SEQ ID NO:6:

- 55 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 372 amino acids
(B) TYPE: Amino Acid
(D) TOPOLOGY: Linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Met Asn Tyr Pro Leu Thr Leu Glu Met Asp Leu Glu Asn Leu Glu
1 5 10 15

5 Asp Leu Phe Trp Glu Leu Asp Arg Leu Asp Asn Tyr Asn Asp Thr
20 25 30

Ser Leu Val Glu Asn His Leu Cys Pro Ala Thr Glu Gly Pro Leu
10 35 40 45

Met Ala Ser Phe Lys Ala Val Phe Val Pro Val Ala Tyr Ser Leu
50 55 60

Ile Phe Leu Leu Gly Val Ile Gly Asn Val Leu Val Leu Val Ile
15 65 70 75

Leu Glu Arg His Arg Gln Thr Arg Ser Ser Thr Glu Thr Phe Leu
20 80 85 90

Phe His Leu Ala Val Ala Asp Leu Leu Leu Val Phe Ile Leu Pro
25 95 100 105

Phe Ala Val Ala Glu Gly Ser Val Gly Trp Val Leu Gly Thr Phe
110 115 120

Leu Cys Lys Thr Val Ile Ala Leu His Lys Val Asn Phe Tyr Cys
30 125 130 135

Ser Ser Leu Leu Leu Ala Cys Ile Ala Val Asp Arg Tyr Leu Ala
140 145 150

Ile Val His Ala Val His Ala Tyr Arg His Arg Arg Leu Leu Ser
35 155 160 165

Ile His Ile Thr Cys Gly Thr Ile Trp Leu Val Gly Phe Leu Leu
170 175 180

Ala Leu Pro Glu Ile Leu Phe Ala Lys Val Ser Gln Gly His His
40 185 190 195

Asn Asn Ser Leu Pro Arg Cys Thr Phe Ser Gln Glu Asn Gln Ala
200 205 210

Glu Thr His Ala Trp Phe Thr Ser Arg Phe Leu Tyr His Val Ala
45 215 220 225

Gly Phe Leu Leu Pro Met Leu Val Met Gly Trp Cys Tyr Val Gly
230 235 240

Val Val His Arg Leu Arg Gln Ala Gln Arg Arg Pro Gln Arg Gln
50 245 250 255

Lys Ala Val Arg Val Ala Ile Leu Val Thr Ser Ile Phe Phe Leu
55 260 265 270

Cys Trp Ser Pro Tyr His Ile Val Ile Phe Leu Asp Thr Leu Ala
275 280 285

Arg Leu Lys Ala Val Asp Asn Thr Cys Lys Leu Asn Gly Ser Leu
290 295 300

Pro Val Ala Ile Thr Met Cys Glu Phe Leu Gly Leu Ala His Cys
305 310 315

5 Cys Leu Asn Pro Met Leu Tyr Thr Phe Ala Gly Val Lys Phe Arg
320 325 330

Ser Asp Leu Ser Arg Leu Leu Thr Lys Leu Gly Cys Thr Gly Pro
10 335 340 345

Ala Ser Leu Cys Gln Leu Phe Pro Ser Trp Arg Arg Ser Ser Leu
350 355 360

15 Ser Glu Ser Glu Asn Ala Thr Ser Leu Thr Thr Phe
365 370 372

PATENT DUCET P0706P2CADA
EXPRESS MAIL NO. EL142012237US
MAILED: 24 JUNE 1998

5

10

ANTIBODIES TO HUMAN PF4A RECEPTORS

This application is a continuation-in-part application of copending U.S. Serial No. 07/810,782 filed December 19, 1991, which is a continuation-in-part application of copending U.S. Serial No. 15 07/677,211 filed 29 March 1991.

BACKGROUND OF THE INVENTION

Field of the Invention

This invention relates to the field of assaying platelet factor 4 superfamily members (hereafter "PF4A") and the preparation of agonists and antagonists to the members of this family, in particular, antibodies to these receptors.

Description of Background and Related Art

While interleukin-8 was initially identified as a chemoattractant for neutrophils, and was known to bind a receptor on neutrophils (Samanta et al., J. Exp. Med., 169: 1185-1189 [1989]; Besemer et al., J. Biol. Chem., 264: 17409-17415 [1989]; Grob et al. J. Biol. Chem., 265: 8311-8316 [1990]), it has in addition a wide range of pro-inflammatory activities including the stimulation of degranulation and the upregulation of the cell adhesion molecule MAC-1 and of the complement receptor CR1. Oppenheim et al., Annu. Rev. Immunol., 2: 617-648 (1991).

IL-8 is secreted by many cell types in response to pro-inflammatory stimuli such as IL-1 β , TNF, and endotoxin and is a member of a family of ten or more pro-inflammatory cytokines with an M_r ~ 10,000. Oppenheim et al., *supra*. This larger family of proteins is called the platelet factor 4 superfamily. Wolpe et al., FASEB J., 3: 2565-73 (1989). Some members of the platelet factor 4 superfamily, in general the subset referred to as C-X-C peptides (including IL-8), possess neutrophil agonist activity, e.g. neutrophil activating protein-2 (NAP-2), platelet factor 4 and NAP-3 (melanoma growth-stimulating activity [MGSA]/gro), all of which are encoded by genes on human chromosome 4. Other members of this family, the C-C peptides, encoded by genes on human chromosome 17, are not neutrophil agonists, and include RANTES, macrophage chemotactic and activating factor (MCAF). Hereafter "PF4A" means the PF4 superfamily. Oppenheim et al., *supra*.

The IL-8 receptors are members of the superfamily of seven transmembrane, G-protein linked receptors. Taylor, Biochem. J., 272: 1 (1990). This family of receptors includes several hundred different receptors among which the β -adrenergic receptor (Strader et al., FASEB, 3: 1825 [1989]; Dixon et al., EMBO J., 6: 3269 [1987]), the muscarinic and cholinergic receptors (Kubo et al., Nature, 323: 411 [1986]; Peralta et al., EMBO J., 6: 3923 [1987]), the c5a and fMet-Leu-Phe receptors. Two types of IL-8 receptors have been described: type A (IL8R-A) (Holmes et al., Science, 253: 1278 [1991]) and type B (IL8R-B) (Murphy and Tiffany, Science, 253: 1280 [1991]) receptors. These two receptors share 77% amino acid identity and have 29-34% sequence homology to C5a and fMet-Leu-Phe. Holmes et al., *supra*. IL8R-A has a high affinity (2 nM) for IL-8 only, while IL8R-B has a high affinity (2 nM) for both IL-8 and MGSA. The function and expression level of each receptor on these cells have yet to be determined.

It is an object of this invention to identify receptors for the PF4A superfamily (hereinafter "PF4AR").

It is another object of this invention to obtain DNA encoding or hybridizing to these receptors, and to express the receptors in host cells.

5 It is an additional object of this invention to provide isolates of PF4AR for diagnostic and therapeutic purposes.

A still further object is to obtain DNA encoding variants of such receptors and to prepare such variants in recombinant cell culture.

10 A yet further object is to identify and prepare antibodies to receptors for the PF4A superfamily (hereinafter "PF4AR").

It is still another object to provide a method for treating or preventing an inflammatory response in a mammal using an antibody to such receptors.

These and other objects of this invention will be apparent from the specification as a whole.

SUMMARY OF THE INVENTION

These objects are accomplished, in one aspect, by providing an isolated novel PF4AR polypeptide, including polypeptides that are related structurally to the PF4AR. Members of this class of polypeptide are hereafter generically termed PF4AR, and include derivatives and variants thereof.

Either the whole PF4AR molecule or fragments thereof (which also may be synthesized by chemical methods) fused (by recombinant expression or *in vitro* covalent methods) to an immunogenic polypeptide are used to immunize an animal to raise antibodies against a PF4AR epitope. Anti-PF4AR antibodies are recovered from the serum of immunized animals. Alternatively, monoclonal antibodies are prepared from cells of the immunized animal in conventional fashion.

Thus, in a further aspect, the invention provides an antibody that is capable of binding a PF4AR polypeptide, preferably one that does not cross-react with a receptor capable of binding another PF4

superfamily member. More preferably, the antibody is capable of binding an IL-8 receptor, most preferably an IL-8 type A receptor. Also, the preferred antibody has the isotype IgG1 and/or neutralizes the *in vitro* activity of a PF4AR polypeptide, preferably of an IL-8 type A receptor.

Specific preferred antibodies herein are the monoclonal antibodies designated 2A4, having ATCC Deposit No. HB 11377, and 9H1, having ATCC Deposit No. HB 11376.

Anti-PF4AR antibodies are useful particularly in the diagnosis (in *vitro* or *in vivo*) or (when immobilized on an insoluble matrix) the purification of the PF4AR. The antibodies are also useful in treatment of an inflammatory response in patients. Thus, in another aspect, the invention provides a composition comprising the antibody and a pharmaceutically acceptable carrier, as well as a method for treating an inflammatory disorder which method comprises administering to a mammal in need of such treatment an effective amount of this composition.

Substitutional, deletional, or insertional variants of the PF4AR are prepared by *in vitro* or recombinant methods and screened for immuno-crossreactivity with the PF4AR and for PF4AR antagonist or agonist activity.

The PF4AR also is derivatized *in vitro* to prepare immobilized PF4AR and labeled PF4AR, particularly for purposes of diagnosis of PF4AR or its antibodies, or for affinity purification of PF4AR antibodies.

The PF4AR, its derivatives, or its antibodies are formulated into physiologically acceptable vehicles, especially for therapeutic use. Such vehicles include sustained-release formulations of the PF4AR.

In still other aspects, the invention provides an isolated nucleic acid molecule encoding the PF4AR, labeled or unlabeled, and a nucleic acid sequence that is complementary to, or hybridizes

under suitable conditions to a nucleic acid sequence encoding the PF4AR.

In addition, the invention provides a replicable vector comprising the nucleic acid molecule encoding the PF4AR operably linked to control sequences recognized by a host transformed by the vector; host cells transformed with the vector; and a method of using a nucleic acid molecule encoding the PF4AR to effect the production of PF4AR, comprising expressing the nucleic acid molecule in a culture of the transformed host cells and recovering the PF4AR from the host cell culture. The nucleic acid sequence is also useful in hybridization assays for PF4AR nucleic acid. The recombinant host cells are particularly useful in assaying the appropriate PF4A members.

In further embodiments, the invention provides a method for producing PF4AR comprising inserting into the DNA of a cell containing the nucleic acid encoding the PF4AR a transcription modulatory element in sufficient proximity and orientation to the PF4AR nucleic acid to influence or destroy transcription of DNA encoding a biologically active PF4AR, with an optional further step comprising culturing the cell containing the transcription modulatory element and the PF4AR nucleic acid.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 depicts the high affinity binding of IL-8 to COS cells transfected with clone pRK5B.il8rl.1. a, Competition with unlabelled IL-8 or fMLP. b, Scatchard analysis of the IL-8 competition data; apparent $K_d = 3.6 \text{ nM}$, average of 820,000 binding sites/cell. Similar competitions with human neutrophils gave $K_d = 1.1 \text{ nM}$, 31000 binding sites/cell.

Figs. 2a-2c (SEQ ID NO.1) (hereinafter referred to collectively as Fig. 2) depicts the amino acid and nucleotide sequences of the IL-8 receptor cDNA insert from clone pRK5B.il8rl.1. The seven putative transmembrane domains are shown.

There are 4 extracellular segments and 4 intracellular segments, each being separated by one of the transmembrane domains. The extracellular segments are approximately delineated by residues 1-39, 99-111, 134-154, 175-203 and 265-290. The IL-8 receptor
5 contains 3 potential N-linked glycosylation sites in the first extracellular region and 3 more in the third extracellular loop.

Fig. 3a depicts the flow cytometry determination of the intracellular Ca^{++} response of transfected human IL-8 and fMLP receptors to their ligands. Human embryonic kidney 293 cells were
10 transfected by electroporation (Gearing et al. EMBO J., 8: 3667-3676 [1989]) with IL-8 receptor (clone pRK5B.il8r1.1), fMLP receptor (human fMLP receptor cDNA [Boulay et al., Biochem. Biophys. Res. Comm., 168: 1103-1109 (1990)]) in the vector pRK5), or vector (pRK5B; EP 307,247) DNA. After two days, the cells were loaded with 2 μM indo-1 acetoxymethyl ester in RPMI medium (Sigma)
15 for 30 min at 37°C. Intracellular Ca^{++} was measured with a Coulter 753 flow cytometer using the ratio of 405 and 525 nm fluorescence. Grynkiewicz et al., J. Biol. Chem., 260: 3440-3450 (1985).

Fig. 3b illustrates the percent of cells above 400 nM Ca_i^{++} for the time period after addition of IL-8 (about 15 sec. into each run).

Figs. 4 (SEQ ID NO.2) and 5 (SEQ ID NO.3) depict the DNA and an imputed polypeptide sequences for two additional PF4AR members identified by probing lambda libraries from a human monocyte-like cell line (HL-60) and human PBLs using a large fragment of the IL-8 receptor DNA.
25

Fig. 6 depicts the structure of the human IL-8 receptor A. 0: glycosylation site. Synthetic peptides covering the extracellular domain of the IL8R-A receptor were made to cover amino acids 2-19, 30 12-31, 99-110, 176-187, 187-203, 265-277, and 277-291.

Figs. 7A, 7B, 7C, and 7D disclose the binding of monoclonal antibody 2A4 to transfected 293 cells expressing IL8R-A (293-71) (Fig. 7A), transfected 293 cells expressing IL8R-B (293-27) (Fig.

7B), untransfected 293 cells (Fig. 7C), and human neutrophils (Fig. 7D). The solid black line is the Mab 2A4 plus F-GamIg and the gray line is no MAb plus F-GamIg (control).

5 Figs. 8A and 8B show the inhibition of 125 I-labeled IL-8 binding to human neutrophils (Fig. 8A) and to 293 transfected cells expressing IL8R-A (293-17) (Fig. 8B) by various concentrations of 2A4 (filled circles), 9H1 (open circles), IgG (open triangles), and, for Fig. 8B, no antibody (filled squares). The experiment using human neutrophils was carried out in the presence of various
10 concentrations of MGSA.

15
20
25

Figs. 9A and 9B show the binding of monoclonal antibodies 2A4, 9H1, 4C8, 6E9, and an IgG1 control to various synthetic peptides as determined by ELISA. ELISA plates were coated with 2 μ g/ml of peptides. Experiments were done in triplicates. In Fig. 9A the solid bars are peptide 2-19, the diagonal hatched bars to the right of the solid bar are peptide 12-31, the dark cross-hatching is peptide 99-100, the diagonal hatching to the right of peptide 99-100 is peptide 176-187, the open bars are peptide 187-203, the dotted bars are peptide 264-276, and the horizontal striped bars are peptide 276-290. In Fig. 9B the solid bars are peptide 2-19, the open bars are peptide 1-14, the dotted bars are peptide 1-11, and the diagonal hatching is peptide 1-13 (IL8R-B).

Figure 10 shows the concentrations of IL-8 in sputum from various patients with chronic airway inflammation (cystic fibrosis, bronchiectasis, and chronic bronchitis) and induced sputum for healthy subjects, where the open squares are in-patients and the shaded squares are out-patients.

Detailed Description of the Invention

30 By expression cloning was isolated a cDNA encoding the human neutrophil IL-8 receptor together with two other homologous receptors. The amino acid sequence shows that the IL-8 receptor is a member of the G-protein coupled receptor family with clear

similarity (29% amino acid identity) to the human neutrophil receptors for the chemoattractants f-Met-Leu-Phe (Boulay et al., *supra*) and C5a (Gerard and Gerard, *Nature*, 349: 614-617 [1991]).
5 Although the IL-8 receptor sequence may be the human homologue of what has been identified as the isoform of the rabbit f-Met-Leu-Phe receptor (Thomas et al., *J. Biol. Chem.*, 265: 20061-20064 [1990]), this invention shows that when transfected into mammalian cells, this receptor clone confers high affinity binding to IL-8 and produces a transient Ca^{++} mobilization in response to IL-8 with no
10 binding or response to f-Met-Leu-Phe.

A COS cell expression cloning strategy (Sims et al., *Science*, 241: 585-589 [1988]); D'Andrea et al., *Cell*, 57: 277-285 [1989]) was used to isolate clones encoding the IL-8 receptor. A cDNA library constructed from human neutrophil mRNA in the mammalian expression vector pRK5B was transfected into COS-7 cells as pools of 2500 clones, and the cells screened for the binding of ^{125}I -IL-8. One positive pool from the first 58 transfections was partitioned into smaller pools until a pure clone (pRK5B.il8r1.1) was obtained. Figure 1 shows the competition of ^{125}I -IL-8 binding by unlabelled IL-8 to COS cells transfected with the isolated clone. Analysis of this data gives a K_d of 3.6 nM for IL-8 binding which is within the range of 0.8 to 4 nM reported for IL-8 binding to human neutrophils. Samanta et al., *supra*, Besemer et al., *supra*, Grob et al., *supra*. There is no competition of the IL-8 binding by the chemotactic peptide f-Met-Leu-Phe (fMLP).
15
20
25

The DNA sequence of the isolated cDNA clone (Fig. 2) contains a single long open reading frame beginning with a methionine residue that matches the consensus expected for a translation initiation site. Kozak, *Nucleic Acid Res.*, 12: 857-872 (1984).
30 This open reading frame encodes a protein of 350 amino acids (translated M_r 39.5 kD). The amino acid sequence shares several features with the G-protein coupled receptors of the rhodopsin superfamily including seven hydrophobic domains that are presumed

to span the cell membrane and N-linked glycosylation sites near the N-terminus (Dixon et al., Cold Spring Harb. Sym. Quant. Biol., 53: 487-497 [1988]) (see below).

5 The encoded amino acid sequence is the most similar to a recently cloned sequence for the rabbit fMLP receptor. Thomas et al., *supra*. The similarity is sufficiently high (79% amino acid identity overall with multiple stretches of more than 20 contiguous amino acid matches) that these two sequences may well be species homologs of the same receptor. The human fMLP receptor has also
10 been cloned (Boulay et al., *supra*); it has only 26% amino acid identity with the rabbit fMLP receptor (and 29% identity to the human IL-8 receptor presented here). The considerable divergence between the rabbit and human fMLP receptor amino acid sequences has lead to the suggestion in the art (now believed to be possibly erroneous) that these may be two isoforms of the fMLP receptor.
15 Thomas et al., *supra*.

20 Neutrophils respond to the chemoattractants IL-8 and fMLP with a rapid, transient increase in the intracellular free Ca⁺⁺ concentration. Oppenheim et al., *supra*; Korchak et al., J. Biol Chem., 259: 4076-4082 (1984). In order to verify the identification of the clone isolated here as the IL-8 receptor, we have determined the intracellular Ca⁺⁺ response of transfected cells to added IL-8 as well as fMLP. We have used parallel experiments with transfected human fMLP receptor or with the expression vector as controls. Flow cytometer analysis shows a clear transient increase in intracellular Ca⁺⁺ for the transfected IL-8 receptor in response to IL-8. No response is found to fMLP. Conversely, cells transfected with the human fMLP receptor respond to fMLP but not to IL-8. No response to either chemoattractant is found in vector transfected cells. Only a subset of the cells are expected to respond in these experiments as the transfection efficiency is estimated to be 15-25%. Binding experiments
25 (Tennenberg et al., J. Immunol., 141: 3937-3944 [1988]) also failed
30

to detect any binding of ^3H -fMLP to the expressed IL-8 receptor or ^{125}I -IL-8 to the expressed human fMLP receptor. These experiments clearly demonstrate the specificity of the two receptors for their respective ligands; a result expected based on the lack of binding competition between IL-8 and fMLP for neutrophils. Oppenheim et al., *supra*. These results also demonstrate that the cloned receptors function in second message signaling in response to ligand binding.

Blot hybridization of the cloned IL-8 receptor cDNA to human neutrophil mRNA, shows strong bands of 2.4 and 3.0 kb as well as a fainter band at 3.5 kb. While it is clear from the DNA sequence data presented in Fig. 2 that the mRNA for the receptor has a long 3' untranslated region, additional work will be needed to establish whether the multiple RNA bands are due to multiple polyadenylation sites. No hybridization was detected to mRNA from U266 or Jurkat cell lines, which are of the B cell and T cell lineages. No hybridization was found for mRNA from the monocyte cell line U937 as well, in spite of the reports of low levels of IL-8 binding to these cells. Besemer et al., *supra*; Grob et al., *supra*.

Alignment of the receptor sequences for the three neutrophil chemoattractants IL-8, fMLP (Boulay et al., *supra*), and C5a (Gerard and Gerard, *supra*) shows that they form a subfamily of the G-protein coupled receptors with 29-34 % amino acid identity. This subfamily has a short third intracellular loop as compared with other G-protein coupled receptors such as the β -adrenergic (Dixon et al., *supra*) or muscarinic acetylcholine receptors. Ramachandran, et al., *BioEssays*, 10: 54-57 (1989). This loop contains determinants at least partially responsible for the binding of G-proteins to the receptors. Dixon et al., *supra*. The intracellular C-terminal region of the IL-8 receptor, while not very similar to that of the fMLP and C5a receptors does preserve a high number of serine and threonine residues that may function as phosphorylation sites. As has been noted for the C5a receptor

(Gerard and Gerard, *supra*), the N-terminal extracellular region for the IL-8 receptor has several acidic residues. These may aid in the binding of IL-8, which is quite basic (pI ~ 9.5).

I. Definitions

5 In general, the following words or phrases have the indicated definition when used in the description, examples, and claims:

The term "PF4AR" is defined as a polypeptide having a qualitative biological activity in common with the polypeptides of Figs. 2, 4, or 5. Optionally, PF4AR will have at least 30% and 10 ordinarily 75% amino acid sequence identity with any of the polypeptides of Figs. 2, 4 or 5. Optionally, PF4AR excludes the rabbit fMLP receptor (Thomas et al., *supra*), the human fMLP receptor (Boulay et al., *supra*), the human C5a receptor (Gerard and Gerard, *supra*), and/or the receptor described by Murphy and Tiffany, *supra*.

15 Identity or homology with respect to a PF4AR is defined herein to be the percentage of amino acid residues in the candidate sequence that are identical with the residues in Figs. 2, 4 or 5 after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent homology, and not considering any 20 conservative substitutions as representing residue identity. No N- nor C-terminal extensions, deletions nor insertions shall be construed as reducing identity or homology.

25 PF4AR qualitative biological activity is defined as any one of (1) immunological cross-reactivity with at least one epitope of a polypeptide set forth in Figs. 2, 4, or 5; (2) the ability to specifically bind to a member of the PF4 superfamily; or (3) any effector or functional activity of the Figs. 2, 4 or 5 polypeptides 30 as found in nature, including their ability to bind any ligands other than superfamily members.

Immunologically cross-reactive as used herein means that the candidate polypeptide is capable of competitively inhibiting the binding of a PF4AR to polyclonal antibodies or antisera raised

against a PF4AR. Such antibodies and antisera are prepared in conventional fashion by injecting an animal such as a goat or rabbit, for example, subcutaneously with the known native PF4AR in complete Freund's adjuvant, followed by booster intraperitoneal or subcutaneous injection in incomplete Freund's.

5 Included within the scope of the PF4AR as that term is used herein are polypeptides having the amino acid sequences described in Figs. 2, 4 or 5, amino acid sequence variants of such amino acid sequences, glycosylation variants of the polypeptides and covalent modifications of the polypeptides. Each of these are described in
10 more detail below.

"Isolated" PF4AR nucleic acid or polypeptide is a PF4AR nucleic acid or polypeptide that is identified and separated from at least one contaminant (nucleic acid or polypeptide respectively) with which it is ordinarily associated in nature, such as from the animal or human source of the PF4AR nucleic acid or polypeptide. In preferred embodiments, the PF4AR will be isolated to pharmaceutically acceptable levels of purity with respect to proteins of its species of origin. In preferred embodiments, PF4AR protein will be purified (1) to greater than 95% by weight of protein as determined by the Lowry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by an amino acid sequenator commercially available on the filing date hereof, or (3) to homogeneity by conventional nonreducing SDS-PAGE using Coomassie blue or, preferably, silver stain. Isolated PF4AR includes PF4AR in situ within recombinant cells since, in this instance, at least one component of the PF4AR natural environment will not be present. Isolated PF4AR includes PF4AR from one species in a recombinant cell culture of another species since the receptor in such circumstances will be devoid of source polypeptides. Ordinarily, however, isolated receptor will be prepared by at least one purification step.

Isolated PF4AR nucleic acid includes a nucleic acid that is identified and separated from at least one containment nucleic acid with which it is ordinarily associated in the natural source of the receptor nucleic acid. Isolated PF4AR nucleic acid thus is present
5 in other than in the form or setting in which it is found in nature. However, isolated receptor-encoding nucleic acid includes PF4AR nucleic acid in ordinarily receptor-expressing cells where the nucleic acid is in a chromosomal location different from that of natural cells or is otherwise flanked by a different DNA sequence than that found in nature.
10

The nucleic acid or polypeptide may be labeled for diagnostic and probe purposes, using a label as described and defined further below in the discussion of diagnostic assays.

PF4AR "nucleic acid" is defined as RNA or DNA containing greater than ten bases that encodes a polypeptide sequence within Figs. 2, 4 or 5, is complementary to nucleic acid sequence of Figs. 2, 4 or 5, hybridizes to such nucleic acid and remains stably bound to it under low stringency conditions, or encodes a polypeptide sharing at least 30% sequence identity, preferably at least 75%, and more preferably at least 85%, with the translated amino acid sequence shown in Figs. 2, 4 or 5 or a fragment thereof. Preferably the DNA which hybridizes to the nucleic acid of Figs. 2, 4 or 5 contain at least 20, more preferably 40, and more preferably 60 bases. Most preferably, the hybridizing DNA or RNA contains 45
15 or even more preferably 90 bases. Such hybridizing or complementary nucleic acid, however, is defined further as being novel and unobvious over any prior art nucleic acid including that which encodes, hybridizes under low stringency conditions, or is complementary to nucleic acid encoding rabbit fMLP receptor (Thomas et al., *supra*), human fMLP receptor or (optionally) the IL-8
20 receptor of Murphy and Tiffany, *supra*.
25
30

"High stringency conditions" are any of those that (1) employ low ionic strength and high temperature for washing, for example,

0.015 M NaCl/0.0015 M sodium citrate/0.1% NaDODSO₄ at 50°C; (2) employ during hybridization 50% (vol/vol) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM NaCl, 75 mM sodium citrate at 42°C; or (3) employ hybridization with 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 42°C, with washes at 42°C in 0.2 x SSC and 0.1% SDS.

10 Conditions of low stringency are set forth in Example 2.

The term "control sequences" refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

15 Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is 20 operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous and, in the case of a secretory leader, contiguous and in reading phase. However 25 enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, then synthetic oligonucleotide adaptors or linkers are used 30 in accord with conventional practice.

The starting plasmids herein are commercially available, are publicly available on an unrestricted basis, or can be constructed from such available plasmids in accord with published procedures. In addition, other equivalent plasmids are known in the art and will be apparent to the ordinary artisan. Methods for restriction enzyme digestion, recovery or isolation of DNA, hybridization analysis, and ligation are conventional and by this time well known to the ordinary artisan.

"Recovery" or "isolation" of a given fragment of DNA from a restriction digest means separation of the digest on polyacrylamide or agarose gel by electrophoresis, identification of the fragment of interest by comparison of its mobility versus that of marker DNA fragments of known molecular weight, removal of the gel section containing the desired fragment, and separation of the gel from DNA. This procedure is known generally. For example, see Lawn et al., Nucleic Acids Res., 9: 6103-6114 (1981), and Goeddel et al., Nucleic Acids Res., 8: 4057 (1980).

As used herein, the term "mammal" refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, horses, cats, cows, etc. Preferably, the mammal herein is human.

As used herein, the term "treatment" refers to therapy as well as prophylactic (preventative) measures.

As used herein, the term "inflammatory disorders" refers to pathological states resulting in inflammation, typically caused by neutrophil chemotaxis. Examples of such disorders include T cell inflammatory responses such as inflammatory skin diseases including psoriasis; responses associated with inflammatory bowel disease (such as Crohn's disease and ulcerative colitis); adult respiratory distress syndrome; dermatitis; meningitis; encephalitis; uveitic; allergic conditions such as eczema and asthma and other conditions involving infiltration of T cells and chronic inflammatory responses; skin hypersensitivity reactions (including poison ivy

and poison oak); atherosclerosis; leukocyte adhesion deficiency; autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus (SLE), diabetes mellitus, multiple sclerosis, Reynaud's syndrome, autoimmune thyroiditis, experimental autoimmune encephalomyelitis, Sjorgen's syndrome, juvenile onset diabetes, and immune responses associated with delayed hypersensitivity mediated by cytokines and T-lymphocytes typically found in tuberculosis, sarcoidosis, polymyositis, granulomatosis and vasculitis; pernicious anemia; diseases involving leukocyte diapedesis; CNS inflammatory disorder, multiple organ injury syndrome secondary to septicaemia or trauma; autoimmune haemolytic anemia; myethemia gravis; antigen-antibody complex mediated diseases; inflammations of the lung, including pleurisy, alveolitis, vasculitis, pneumonia, chronic bronchitis, bronchiectasis, and cystic fibrosis; etc. The preferred indications are inflammatory bowel disease such as ulcerative colitis or a chronic lung inflammation.

II. Suitable Methods for Practicing the Invention

1. Preparation of Native PF4AR and Variants

A. Isolation of DNA Encoding PF4AR

The DNA encoding of the PF4AR may be obtained from any cDNA library prepared from tissue believed to contain the PF4AR mRNA, generally HL60 or PBL libraries. The PF4AR gene may also be obtained from a genomic library. Libraries are screened with probes designed to identify the gene of interest or the protein encoded by it. The entire cDNA for the IL-8 receptor and two homologous receptors is described. Nucleic acid encoding this family of receptors is readily obtained under low stringency conditions from genomic DNA or neutrophil cDNA libraries using probes having oligonucleotide sequences from the receptor gene sequences of Figs. 2, 4 or 5. These probes usually will contain about 500 or more bases. Since the probes will hybridize perfectly to the three exemplified DNAs, there is no need to use probe pools containing degenerate sequences. Screening with the probes to

identify the Figs. 2, 4 or 5 receptors is more efficient if performed under conditions of high stringency.

Other PF4ARs other than those in Figs. 2, 4 or 5 are believed to exist and to contain regions of homology to the exemplified receptors. Thus probes having the sequences of the DNAs in Figs. 2, 4 or 5 can be used to screen for these receptors as well. The best candidates for probes are long sequences (greater than about 100 bases) that represent sequences that are highly homologous among the three exemplified human receptors. IL-8 cDNA encoding the IL-8 residues 15-34, 78-94, 176-193, 264-282 and 299-312 (and comparable probes from other receptors of the IL-8R family) are useful, particularly in probing for IL-8 receptor DNA. Probes useful for the receptor of Fig. 4 (and isolated proteins characteristic of the Fig. 5 receptor) are represented by sequences comprising residues 1-48, 77-92, 107-137, 156-177, 189-226, 239-257 and 271-315. Homologous probes and residues of the Fig. 4 receptor also are useful, i.e. residues 1-35, 64-78, 94-124, 143-164, 176-197, 219-239 and 251-295. cDNAs comprising cDNA encoding the following regions of the Figs. 2, 4 or 5 polypeptides are useful in probing for other receptors: 92-106, 57-72, 138-154, 314-329 and 57-154.

In general, one first identifies a cell which is capable of specifically binding or which is activated by a given PF4A, typically by *in vitro* bioassays and, optionally, by cell binding analysis using the labelled PF4A. Cells identified by this process (and some are already known for individual PF4As) therefore are expressing a receptor for this PF4A. A cDNA library is prepared from such cells and is screened using the receptor probes by procedures that are conventional *per se*. In this instance, however, it is preferred to use low stringency conditions (such as those in Example 2) and then analyze the resulting positive clones for homology to the Figs. 2, 4 or 5 receptors. In general, candidate human PF4ARs will exhibit greater than about 30% amino

acid sequence homology to the Figs. 2, 4 or 5 receptors and bear a similar transmembrane loop structure.

Assays are then conducted to confirm that the hybridizing full length genes are the desired PF4AR. The candidate is simply inserted into an expression vector and transformed into a host cell that ordinarily does not bind to the candidate PF4A ligand. Transformants that acquire the ability to bind the ligand thus bear the desired receptor gene. In Example 2, we show that two additional homologous polypeptide sequences representing PR4ARs are identified using IL-8R DNA encoding residues 23-314, although the particular probe is not believed to be critical.

An alternative means to isolate genes encoding additional PF4ARs is to use polymerase chain reaction (PCR) methodology (U.S. Patent 4,683,195; Erlich, ed., PCR Technology, 1989) to amplify the target DNA or RNA, e.g. as described in section 14 of Sambrook et al., *supra*. This method requires the use of oligonucleotide primers that will be expected to hybridize to the PF4AR, and these readily are selected from the receptor cDNAs of Figs. 2, 4 or 5. Strategies for selection of oligonucleotide primers are described above.

cDNA libraries may be screened from various tissues, preferably mammalian PBL, monocyte, placental, fetal, brain, and carcinoma cell lines in order to obtain DNA encoding the receptors of Figs. 2, 4 or 5, or homologous receptors. More preferably, human or rabbit placental, fetal, brain, and carcinoma cell line cDNA libraries are screened with labelled oligonucleotide probes.

Another method for obtaining the gene of interest is to chemically synthesize it using one of the methods described in Engels et al., Agnew. Chem. Int. Ed. Engl., **28**: 716-734 (1989), specifically incorporated by reference. These methods include triester, phosphite, phosphoramidite and H-phosphonate methods, typically proceeding by oligonucleotide synthesis on solid supports. These methods may be used if the entire amino acid or

nucleic acid sequence of the gene is known, or the sequence of the nucleic acid complementary to the coding strand is available. If the desired amino acid sequence is known, one may infer potential nucleic acid sequences using known and preferred coding residues for each amino acid residue.

5 **B. Amino Acid Sequence Variants of the PF4AR**

Amino acid sequence variants of the PF4AR are prepared by introducing appropriate nucleotide changes into the PF4AR DNA, or by *in vitro* synthesis of the desired PF4AR polypeptide. Such variants include, for example, deletions from, or insertions or substitutions of, residues within the amino acid sequence shown for the receptors in Figs. 2, 4 or 5. Any combination of deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics.

The amino acid changes also may alter post-translational processing of the PF4AR, such as changing the number or position of glycosylation sites or by altering its membrane anchoring characteristics. Excluded from the scope of this invention are PF4AR variants or polypeptide sequences that are not statutorily novel and unobvious over the prior art.

In designing amino acid sequence variants of PF4ARs, the location of the mutation site and the nature of the mutation will depend on the PF4AR characteristic(s) to be modified. The sites for mutation can be modified individually or in series, e.g., by (1) substituting first with conservative amino acid choices and then with more radical selections depending upon the results achieved, (2) deleting the target residue, or (3) inserting residues of the same or a different class adjacent to the located site, or combinations of options 1-3.

A useful method for identification of certain residues or regions of the PF4AR polypeptide that are preferred locations for mutagenesis is called "alanine scanning mutagenesis" as described

by Cunningham and Wells, Science, 244: 1081-1085 (1989). Here, a residue or group of target residues are identified (e.g., charged residues such as arg, asp, his, lys, and glu) and replaced by a neutral or negatively charged amino acid (most preferably alanine or polyalanine) to affect the interaction of the amino acids with the surrounding aqueous environment in or outside the cell. Those domains demonstrating functional sensitivity to the substitutions then are refined by introducing further or other variants at or for the sites of substitution. Thus, while the site for introducing an amino acid sequence variation is predetermined, the nature of the mutation *per se* need not be predetermined. For example, to optimize the performance of a mutation at a given site, ala scanning or random mutagenesis may be conducted at the target codon or region and the expressed PF4AR variants are screened for the optimal combination of desired activity.

In general, the regions of the PF4AR molecule preferred for alterations are non-hydrophilic regions or regions that are not highly conserved. Such regions are those in which sequences of 5 or more residues are not substantially conserved in the homologous positions in the rabbit fMLP receptor, the human fMLP receptor, the human C5a receptor and the receptors of Figs. 2, 4 and 5.

PF4AR variants will exhibit at least a biological activity of the parental sequence, for example ligand binding activity or antigenic activity. Antigenically active PF4AR is a polypeptide that binds with an affinity of at least about 10^9 1/mole to an antibody raised against a naturally occurring PF4AR sequence. Ordinarily the polypeptide binds with an affinity of at least about 10^8 1/mole. Most preferably, the antigenically active PF4AR is a polypeptide that binds to an antibody raised against the receptor in its native conformation, "native conformation" generally meaning the receptor as found in nature which has not been denatured by chaotropic agents, heat or other treatment that substantially modifies the three dimensional structure of the receptor (this can

be determined, for example, by migration on nonreducing, nondenaturing sizing gels). Antibody used in determination of antigenic activity is rabbit polyclonal antibody raised by formulating the native non-rabbit receptor in Freund's complete adjuvant, subcutaneously injecting the formulation, and boosting the immune response by intraperitoneal injection of the formulation until the titer of anti-receptor antibody plateaus.

One group of variants are deletion mutants, or fragments of the sequences set forth in Figs. 2, 4, 5 or other PF4AR. In general, the fragments are those which constitute the extracellular regions of the receptors (these receptors are unlike most in that they are believed to contain a plurality of hydrophobic, transmembrane domains separated by hydrophilic sequences believed to loop into the ectoplasm). Particularly of interest are the N-terminal extracellular region containing acidic amino acid residues. However, any sequence which is capable of raising an antibody that will cross-react with the intact receptor, or which will bind to a member of the PF4 superfamily, is useful. These fragments typically will contain a consecutive sequence of at least about 5 (and ordinarily at least about 10) residues.

Amino acid sequence deletions generally range from about 1 to 30 residues, more preferably about 1 to 10 residues, and typically are contiguous. Deletions may be introduced into regions of low homology among the receptors of Figs. 2, 4 and 5 to modify the activity of the receptors. Such deletions will be more likely to modify the biological activity of the receptors more significantly than deletions made elsewhere. The number of consecutive deletions will be selected so as to preserve the tertiary structure of the PF4AR in the affected domain, e.g., beta-pleated sheet or alpha helix.

Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence

insertions of single or multiple amino acid residues. Intrasequence insertions (i.e., insertions within the PF4AR sequence) may range generally from about 1 to 10 residues, more preferably 1 to 5, most preferably 1 to 3.

5 Insertional variants of the PF4AR or its extracellular segments include the fusion to the N- or C-terminus of the PF4AR of immunogenic polypeptides, e.g., bacterial polypeptides such as beta-lactamase or an enzyme encoded by the *E. coli* trp locus, or yeast protein, and C-terminal fusions with proteins having a long
10 half-life such as immunoglobulin constant regions (or other immunoglobulin regions), albumin, or ferritin, as described in WO 89/02922 published 6 April 1989.

Another group of variants are amino acid substitution variants. These variants have at least one amino acid residue in the PF4AR molecule removed and a different residue inserted in its place. The sites of greatest interest for substitutional mutagenesis include sites identified as the active site(s) of the PF4AR, and sites where the amino acids found in the PF4AR from various species are substantially different in terms of side-chain bulk, charge, and/or hydrophobicity.
15
20

Other sites of interest are those in which particular residues of the PF4ARs of Figs. 2, 4 and 5 are identical. These positions may be important for the biological activity of the PF4AR. These sites, especially those falling within a sequence of at least three other identically conserved sites, are substituted in a relatively conservative manner. Such conservative substitutions are shown in Table 1 under the heading of preferred substitutions. If such substitutions result in a change in biological activity, then more substantial changes, denominated exemplary substitutions in Table 25 30 1, or as further described below in reference to amino acid classes, are introduced and the products screened.

Table 1

<u>Original Residue</u>	<u>Exemplary Substitutions</u>	<u>Preferred Substitutions</u>
5 Ala (A)	val; leu; ile	val
Arg (R)	lys; gln; asn	lys
Asn (N)	gln; his; lys; arg	gln
Asp (D)	glu	glu
Cys (C)	ser	ser
10 Gln (Q)	asn	asn
Glu (E)	asp	asp
Gly (G)	pro	pro
His (H)	asn; gln; lys; arg	arg
Ile (I)	leu; val; met; ala; phe; norleucine	leu
15 Leu (L)	norleucine; ile; val; met; ala; phe	ile
Lys (K)	arg; gln; asn	arg
Met (M)	leu; phe; ile	leu
20 Phe (F)	leu; val; ile; ala	leu
Pro (P)	gly	gly
Ser (S)	thr	thr
Thr (T)	ser	ser
Trp (W)	tyr	tyr
25 Tyr (Y)	trp; phe; thr; ser	phe
Val (V)	ile; leu; met; phe; ala; norleucine	leu

Substantial modifications in function or immunological identity of the PF4AR are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Naturally occurring residues are

divided into groups based on common side chain properties:

- (1) hydrophobic: norleucine, met, ala, val, leu, ile;
- (2) neutral hydrophilic: cys, ser, thr;
- (3) acidic: asp, glu;
- 5 (4) basic: asn, gln, his, lys, arg;
- (5) residues that influence chain orientation: gly, pro; and
- (6) aromatic: trp, tyr, phe.

Non-conservative substitutions will entail exchanging a member of one of these classes for another. Such substituted residues may 10 be introduced into regions of the PF4AR that are homologous with other PF4ARs, or, more preferably, into the non-homologous regions of the molecule.

Any cysteine residues not involved in maintaining the proper conformation of the PF4AR may be substituted, generally with 15 serine, to improve the oxidative stability of the molecule and prevent aberrant crosslinking.

DNA encoding amino acid sequence variants of the PF4AR is prepared by a variety of methods known in the art. These methods include, but are not limited to, isolation from a natural source 20 (in the case of naturally occurring amino acid sequence variants) or preparation by oligonucleotide-mediated (or site-directed) mutagenesis, PCR mutagenesis, and cassette mutagenesis of an earlier prepared variant or a non-variant version of the PF4AR. These techniques may utilize PF4AR nucleic acid (DNA or RNA), or 25 nucleic acid complementary to the PF4AR nucleic acid.

Oligonucleotide-mediated mutagenesis is a preferred method for preparing substitution, deletion, and insertion variants of PF4AR DNA. This technique is well known in the art, for example as described by Adelman et al., DNA, 2: 183 (1983). Briefly, the 30 PF4AR DNA is altered by hybridizing an oligonucleotide encoding the desired mutation to a DNA template, where the template is the single-stranded form of a plasmid or bacteriophage containing the unaltered or native DNA sequence of the PF4AR. After

hybridization, a DNA polymerase is used to synthesize an entire second complementary strand of the template that will thus incorporate the oligonucleotide primer, and will code for the selected alteration in the PF4AR DNA.

5 Generally, oligonucleotides of at least 25 nucleotides in length are used. An optimal oligonucleotide will have 12 to 15 nucleotides that are completely complementary to the template on either side of the nucleotide(s) coding for the mutation. This ensures that the oligonucleotide will hybridize properly to the
10 single-stranded DNA template molecule. The oligonucleotides are readily synthesized using techniques known in the art such as that described by Crea et al., Proc. Natl. Acad. Sci. USA, 75: 5765 (1978).

15 Single-stranded DNA template may also be generated by denaturing double-stranded plasmid (or other) DNA using standard techniques.

20 For alteration of the native DNA sequence (to generate amino acid sequence variants, for example), the oligonucleotide is hybridized to the single-stranded template under suitable hybridization conditions. A DNA polymerizing enzyme, usually the Klenow fragment of DNA polymerase I, is then added to synthesize the complementary strand of the template using the oligonucleotide as a primer for synthesis. A heteroduplex molecule is thus formed such that one strand of DNA encodes the mutated form of the PF4AR,
25 and the other strand (the original template) encodes the native, unaltered sequence of the PF4AR. This heteroduplex molecule is then transformed into a suitable host cell, usually a prokaryote such as *E. coli* JM101. The cells are plated onto agarose plates, and screened using the oligonucleotide primer radiolabeled with
30 32-phosphate to identify the bacterial colonies that contain the mutated DNA. The mutated region is then removed and placed in an appropriate vector for protein production, generally an expression

vector of the type typically employed for transformation of an appropriate host.

The method described immediately above may be modified such that a homoduplex molecule is created wherein both strands of the plasmid contain the mutation(s). The modifications are as follows:

5 The single-stranded oligonucleotide is annealed to the single-stranded template as described above. A mixture of three deoxyribonucleotides, deoxyriboadenosine (dATP), deoxyriboguanosine (dGTP), and deoxyribothymidine (dTTP), is combined with a modified

10 thio-deoxyribocytosine called dCTP-(aS) (which can be obtained from Amersham Corporation). This mixture is added to the template-oligonucleotide complex. Upon addition of DNA polymerase to this mixture, a strand of DNA identical to the template except for the mutated bases is generated. In addition, this new strand of DNA will contain dCTP-(aS) instead of dCTP, which serves to protect it from restriction endonuclease digestion. After the template strand of the double-stranded heteroduplex is nicked with an appropriate restriction enzyme, the template strand can be digested with ExoIII nuclease or another appropriate nuclease past the region that contains the site(s) to be mutagenized. The reaction is then stopped to leave a molecule that is only partially single-stranded. A complete double-stranded DNA homoduplex is then formed using DNA polymerase in the presence of all four deoxyribonucleotide triphosphates, ATP, and DNA ligase. This

15 20 25 30 homoduplex molecule can then be transformed into a suitable host cell such as *E. coli* JM101, as described above.

DNA encoding PF4AR mutants at more than one site may be generated in one of several ways. If the amino acids are located close together in the polypeptide chain, they may be mutated simultaneously using one oligonucleotide that codes for all of the desired amino acid substitutions. If, however, the amino acids are located some distance from each other (separated by more than about ten amino acids), it is more difficult to generate a single

oligonucleotide that encodes all of the desired changes. Instead, one of two alternative methods may be employed.

In the first method, a separate oligonucleotide is generated for each amino acid to be substituted. The oligonucleotides are 5 then annealed to the single-stranded template DNA simultaneously, and the second strand of DNA that is synthesized from the template will encode all of the desired amino acid substitutions. The alternative method involves two or more rounds of mutagenesis to produce the desired mutant. The first round is as described for 10 the single mutants: wild-type DNA is used for the template, an oligonucleotide encoding the first desired amino acid substitution(s) is annealed to this template, and the heteroduplex DNA molecule is then generated. The second round of mutagenesis utilizes the mutated DNA produced in the first round of mutagenesis as the template. Thus, this template already contains one or more mutations. The oligonucleotide encoding the additional desired amino acid substitution(s) is then annealed to this template, and the resulting strand of DNA now encodes mutations from both the first and second rounds of mutagenesis. This resultant DNA can be 15 used as a template in a third round of mutagenesis, and so on.

PCR mutagenesis is also suitable for making amino acid variants of the PF4AR. While the following discussion refers to DNA, it is understood that the technique also finds application with RNA. The PCR technique generally refers to the following 20 procedure (see Erlich, *supra*, the chapter by R. Higuchi, p. 61-70): When small amounts of template DNA are used as starting material in a PCR, primers that differ slightly in sequence from the corresponding region in a template DNA can be used to generate relatively large quantities of a specific DNA fragment that differs 25 from the template sequence only at the positions where the primers differ from the template. For introduction of a mutation into a plasmid DNA, one of the primers is designed to overlap the position 30 of the mutation and to contain the mutation; the sequence of the

other primer must be identical to a stretch of sequence of the opposite strand of the plasmid, but this sequence can be located anywhere along the plasmid DNA. It is preferred, however, that the sequence of the second primer is located within 200 nucleotides from that of the first, such that in the end the entire amplified region of DNA bounded by the primers can be easily sequenced. PCR amplification using a primer pair like the one just described results in a population of DNA fragments that differ at the position of the mutation specified by the primer, and possibly at other positions, as template copying is somewhat error-prone.

If the ratio of template to product material is extremely low, the vast majority of product DNA fragments incorporate the desired mutation(s). This product material is used to replace the corresponding region in the plasmid that served as PCR template using standard DNA technology. Mutations at separate positions can be introduced simultaneously by either using a mutant second primer, or performing a second PCR with different mutant primers and ligating the two resulting PCR fragments simultaneously to the vector fragment in a three (or more)-part ligation.

Another method for preparing variants, cassette mutagenesis, is based on the technique described by Wells et al., Gene, 34: 315 (1985).

C. Insertion of DNA into a Cloning Vehicle

The cDNA or genomic DNA encoding native or variant PF4AR is inserted into a replicable vector for further cloning (amplification of the DNA) or for expression. Many vectors are available, and selection of the appropriate vector will depend on (1) whether it is to be used for DNA amplification or for DNA expression, (2) the size of the DNA to be inserted into the vector, and (3) the host cell to be transformed with the vector. Each vector contains various components depending on its function (amplification of DNA or expression of DNA) and the host cell for which it is compatible. The vector components generally include,

but are not limited to, one or more of the following: a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence.

5 (i) Signal Sequence Component

In general, a signal sequence may be a component of the vector, or it may be a part of the PF4AR DNA that is inserted into the vector. The native pro PF4AR DNA is directed to the cell surface in our recombinant cells but it does not contain a conventional signal and no N-terminal polypeptide is cleaved during post-translational processing of the polypeptide during membrane insertion of the PF4AR.

10 (ii) Origin of Replication Component

Both expression and cloning vectors contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Generally, in cloning vectors this sequence is one that enables the vector to replicate independently of the host chromosomal DNA, and includes origins of replication or autonomously replicating sequences. Such sequences are well known for a variety of bacteria, yeast, and viruses. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2μ plasmid origin is suitable for yeast, and various viral origins (SV40, polyoma, adenovirus, VSV or BPV) are useful for cloning vectors in mammalian cells. Generally, the origin of replication component is not needed for mammalian expression vectors (the SV40 origin may typically be used only because it contains the early promoter).

20 Most expression vectors are "shuttle" vectors, i.e. they are capable of replication in at least one class of organisms but can be transfected into another organism for expression. For example, a vector is cloned in *E. coli* and then the same vector is transfected into yeast or mammalian cells for expression even

though it is not capable of replicating independently of the host cell chromosome.

DNA may also be amplified by insertion into the host genome. This is readily accomplished using *Bacillus* species as hosts, for example, by including in the vector a DNA sequence that is complementary to a sequence found in *Bacillus* genomic DNA. Transfection of *Bacillus* with this vector results in homologous recombination with the genome and insertion of the PF4AR DNA. However, the recovery of genomic DNA encoding the PF4AR is more complex than that of an exogenously replicated vector because restriction enzyme digestion is required to excise the PF4AR DNA.

10
15
20
25
30

(iii) Selection Gene Component

Expression and cloning vectors should contain a selection gene, also termed a selectable marker. This gene encodes a protein necessary for the survival or growth of transformed host cells grown in a selective culture medium. Host cells not transformed with the vector containing the selection gene will not survive in the culture medium. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g. ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g. the gene encoding D-alanine racemase for *Bacilli*.

One example of a selection scheme utilizes a drug to arrest growth of a host cell. Those cells that are successfully transformed with a heterologous gene express a protein conferring drug resistance and thus survive the selection regimen. Examples of such dominant selection use the drugs neomycin (Southern et al., J. Molec. Appl. Genet., 1: 327 [1982]), mycophenolic acid (Mulligan et al., Science, 209: 1422 [1980]) or hygromycin (Sugden et al., Mol. Cell. Biol., 5: 410-413 [1985]). The three examples given above employ bacterial genes under eukaryotic control to convey

resistance to the appropriate drug G418 or neomycin (geneticin), xgpt (mycophenolic acid), or hygromycin, respectively.

Another example of suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up the PF4AR nucleic acid, such as dihydrofolate reductase (DHFR) or thymidine kinase. The mammalian cell transformants are placed under selection pressure which only the transformants are uniquely adapted to survive by virtue of having taken up the marker. Selection pressure is imposed by culturing the transformants under conditions in which the concentration of selection agent in the medium is successively changed, thereby leading to amplification of both the selection gene and the DNA that encodes the PF4AR. Amplification is the process by which genes in greater demand for the production of a protein critical for growth are reiterated in tandem within the chromosomes of successive generations of recombinant cells. Increased quantities of the PF4AR are synthesized from the amplified DNA.

For example, cells transformed with the DHFR selection gene are first identified by culturing all of the transformants in a culture medium that contains methotrexate (Mtx), a competitive antagonist of DHFR. An appropriate host cell when wild-type DHFR is employed is the Chinese hamster ovary (CHO) cell line deficient in DHFR activity, prepared and propagated as described by Urlaub and Chasin, Proc. Natl. Acad. Sci. USA, 77: 4216 (1980). The transformed cells are then exposed to increased levels of methotrexate. This leads to the synthesis of multiple copies of the DHFR gene, and, concomitantly, multiple copies of other DNA comprising the expression vectors, such as the DNA encoding the PF4AR. This amplification technique can be used with any otherwise suitable host, e.g., ATCC No. CCL61 CHO-K1, notwithstanding the presence of endogenous DHFR if, for example, a mutant DHFR gene that is highly resistant to Mtx is employed (EP 117,060). Alternatively, host cells (particularly wild-type hosts that

contain endogenous DHFR) transformed or co-transformed with DNA sequences encoding the PF4AR, wild-type DHFR protein, and another selectable marker such as aminoglycoside 3' phosphotransferase (APH) can be selected by cell growth in medium containing a selection agent for the selectable marker such as an aminoglycosidic antibiotic, e.g., kanamycin, neomycin, or G418. See U.S. Pat. No. 4,965,199.

A suitable selection gene for use in yeast is the *trp1* gene present in the yeast plasmid YRp7. Stinchcomb et al., *Nature*, 282: 39 (1979); Kingsman et al., *Gene*, 7: 141 (1979); or Tschemper et al., *Gene*, 10: 157 (1980). The *trp1* gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076 or PEP4-1. Jones, *Genetics*, 85: 12 (1977). The presence of the *trp1* lesion in the yeast host cell genome then provides an effective environment for detecting transformation by growth in the absence of tryptophan. Similarly, Leu2-deficient yeast strains (ATCC 20,622 or 38,626) are complemented by known plasmids bearing the *Leu2* gene.

(iv) Promoter Component

Expression vectors usually contain a promoter that is recognized by the host organism and is operably linked to the PF4AR nucleic acid. Promoters are untranslated sequences located upstream (5') to the start codon of a structural gene (generally within about 100 to 1000 bp) that control the transcription and translation of a particular nucleic acid sequence, such as the PF4AR, to which they are operably linked. Such promoters typically fall into two classes, inducible and constitutive. Inducible promoters are promoters that initiate increased levels of transcription from DNA under their control in response to some change in culture conditions, e.g. the presence or absence of a nutrient or a change in temperature. At this time a large number of promoters recognized by a variety of potential host cells are well known. These promoters are operably linked to DNA encoding

the PF4AR by removing the promoter from the source DNA by restriction enzyme digestion and inserting the isolated promoter sequence into the vector. Both the native PF4AR promoter sequence and many heterologous promoters may be used to direct amplification and/or expression of the PF4AR DNA. However, heterologous promoters are preferred, as they generally permit greater transcription and higher yields of expressed PF4AR as compared to the native PF4AR promoter.

Promoters suitable for use with prokaryotic hosts include the β -lactamase and lactose promoter systems (Chang et al., Nature, 275: 615 [1978]; and Goeddel et al., Nature, 281: 544 [1979]), alkaline phosphatase, a tryptophan (trp) promoter system (Goeddel, Nucleic Acids Res., 8: 4057 [1980] and EP 36,776) and hybrid promoters such as the tac promoter (deBoer et al., Proc. Natl. Acad. Sci. USA, 80: 21-25 [1983]). However, other known bacterial promoters are suitable. Their nucleotide sequences have been published, thereby enabling a skilled worker operably to ligate them to DNA encoding the PF4AR (Siebenlist et al., Cell, 20: 269 [1980]) using linkers or adaptors to supply any required restriction sites. Promoters for use in bacterial systems also generally will contain a Shine-Dalgarno (S.D.) sequence operably linked to the DNA encoding the PF4AR.

Suitable promoting sequences for use with yeast hosts include the promoters for 3-phosphoglycerate kinase (Hitzeman et al., J. Biol. Chem., 255: 2073 [1980]) or other glycolytic enzymes (Hess et al., J. Adv. Enzyme Reg., 7: 149 [1968]; and Holland, Biochemistry, 17: 4900 [1978]), such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase.

Other yeast promoters, which are inducible promoters having the additional advantage of transcription controlled by growth

conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters for use in yeast expression are further described in Hitzeman et al., EP 73,657A. Yeast enhancers also are advantageously used with yeast promoters.

Promoter sequences are known for eukaryotes. Virtually all eukaryotic genes have an AT-rich region located approximately 25 to 30 bases upstream from the site where transcription is initiated. Another sequence found 70 to 80 bases upstream from the start of transcription of many genes is a CXCAAT region where X may be any nucleotide. At the 3' end of most eukaryotic genes is an AATAAA sequence that may be the signal for addition of the poly A tail to the 3' end of the coding sequence. All of these sequences are suitably inserted into mammalian expression vectors.

PF4AR transcription from vectors in mammalian host cells is controlled by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus (UK 2,211,504 published 5 July 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and most preferably Simian Virus 40 (SV40), from heterologous mammalian promoters, e.g. the actin promoter or an immunoglobulin promoter, from heat-shock promoters, and from the promoter normally associated with the PF4AR sequence, provided such promoters are compatible with the host cell systems.

The early and late promoters of the SV40 virus are conveniently obtained as an SV40 restriction fragment that also contains the SV40 viral origin of replication. Fiers et al., Nature, 273: 113 (1978); Mulligan and Berg, Science, 209: 1422-1427 (1980); Pavlakis et al., Proc. Natl. Acad. Sci. USA, 78: 7398-7402 (1981). The immediate early promoter of the human cytomegalovirus

is conveniently obtained as a HindIII E restriction fragment. Greenaway et al., Gene, 18: 355-360 (1982). A system for expressing DNA in mammalian hosts using the bovine papilloma virus as a vector is disclosed in U.S. 4,419,446. A modification of this system is described in U.S. 4,601,978. See also Gray et al., Nature, 295: 503-508 (1982) on expressing cDNA encoding immune interferon in monkey cells, Reyes et al., Nature, 297: 598-601 (1982) on expression of human β -interferon cDNA in mouse cells under the control of a thymidine kinase promoter from herpes simplex virus, Canaani and Berg, Proc. Natl. Acad. Sci. USA, 79: 5166-5170 (1982) on expression of the human interferon β 1 gene in cultured mouse and rabbit cells, and Gorman et al., Proc. Natl. Acad. Sci. USA, 79: 6777-6781 (1982) on expression of bacterial CAT sequences in CV-1 monkey kidney cells, chicken embryo fibroblasts, Chinese hamster ovary cells, HeLa cells, and mouse NIH-3T3 cells using the Rous sarcoma virus long terminal repeat as a promoter.

5
10
15
20
25
30
(v) Enhancer Element Component

Transcription of a DNA encoding the PF4AR of this invention by higher eukaryotes is often increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10-300 bp, that act on a promoter to increase its transcription. Enhancers are relatively orientation and position independent having been found 5' (Laimins et al., Proc. Natl. Acad. Sci. USA, 78: 993 [1981]) and 3' (Lusky et al., Mol. Cell Bio., 3: 1108 [1983]) to the transcription unit, within an intron (Banerji et al., Cell, 33: 729 [1983]) as well as within the coding sequence itself (Osborne et al., Mol. Cell Bio., 4: 1293 [1984]). Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin, α -fetoprotein and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication

origin, and adenovirus enhancers. See also Yaniv, Nature, 297: 17-18 (1982) on enhancing elements for activation of eukaryotic promoters. The enhancer may be spliced into the vector at a position 5' or 3' to the PF4AR DNA, but is preferably located at a site 5' from the promoter.

5 (vi) Transcription Termination Component

Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, human, or nucleated cells from other multicellular organisms) will also contain sequences necessary for 10 the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5' and, occasionally 15 3' untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding the PF4AR. The 3' untranslated regions also include 20 transcription termination sites.

Suitable vectors containing one or more of the above listed components and the desired coding and control sequences are constructed by standard ligation techniques. Isolated plasmids or 25 DNA fragments are cleaved, tailored, and religated in the form desired to generate the plasmids required.

For analysis to confirm correct sequences in plasmids constructed, the ligation mixtures are used to transform *E. coli* K12 strain 294 (ATCC 31,446) and successful transformants selected 30 by ampicillin or tetracycline resistance where appropriate. Plasmids from the transformants are prepared, analyzed by restriction endonuclease digestion, and/or sequenced by the method of Messing et al., Nucleic Acids Res., 9: 309 (1981) or by the method of Maxam et al., Methods in Enzymology, 65: 499 (1980).

Particularly useful in the practice of this invention are expression vectors that provide for the transient expression in mammalian cells of DNA encoding the PF4AR. In general, transient expression involves the use of an expression vector that is able to

replicate efficiently in a host cell, such that the host cell accumulates many copies of the expression vector and, in turn, synthesizes high levels of a desired polypeptide encoded by the expression vector. Transient expression systems, comprising a 5 suitable expression vector and a host cell, allow for the convenient positive identification of polypeptides encoded by cloned DNAs, as well as for the rapid screening of such polypeptides for desired biological or physiological properties. Thus, transient expression systems are particularly useful in the 10 invention for purposes of identifying analogs and variants of the PF4AR that have PF4AR-like activity.

Other methods, vectors, and host cells suitable for adaptation to the synthesis of the PF4AR in recombinant vertebrate cell culture are described in Gething et al., Nature, 293: 620-625 15 (1981); Mantei et al., Nature, 281: 40-46 (1979); Levinson et al., EP 117,060; and EP 117,058. A particularly useful plasmid for mammalian cell culture expression of the PF4AR is pRK5 (EP pub. no. 307,247) or pSVI6B (PCT pub. no. WO 91/08291 published 13 June 1991).

20 **D. Selection and Transformation of Host Cells**

Suitable host cells for cloning or expressing the vectors herein are the prokaryote, yeast, or higher eukaryote cells described above. Suitable prokaryotes include eubacteria, such as Gram-negative or Gram-positive organisms, for example, *E. coli*, 25 *Bacilli* such as *B. subtilis*, *Pseudomonas* species such as *P. aeruginosa*, *Salmonella typhimurium*, or *Serratia marcescens*. One preferred *E. coli* cloning host is *E. coli* 294 (ATCC 31,446), although other strains such as *E. coli* B, *E. coli* χ 1776 (ATCC 31,537), and *E. coli* W3110 (ATCC 27,325) are suitable. These 30 examples are illustrative rather than limiting. Preferably the host cell should secrete minimal amounts of proteolytic enzymes. Alternatively, *in vitro* methods of cloning, e.g. PCR or other nucleic acid polymerase reactions, are suitable.

In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable hosts for vectors containing PF4AR DNA. *Saccharomyces cerevisiae*, or common baker's yeast, is the most commonly used among lower eukaryotic host microorganisms. However, a number of other genera, species, and strains are commonly available and useful herein, such as *S. pombe* (Beach and Nurse, Nature, 290: 140 [1981]), *Kluyveromyces lactis* (Louvencourt et al., J. Bacteriol., 737 [1983]), *yarrowia* (EP 402,226), *Pichia pastoris* (EP 183,070), *Trichoderma reesia* (EP 10 244,234), *Neurospora crassa* (Case et al., Proc. Natl. Acad. Sci. USA, 76: 5259-5263 [1979]), and *Aspergillus* hosts such as *A. nidulans* (Ballance et al., Biochem. Biophys. Res. Commun., 112: 284-289 [1983]; Tilburn et al., Gene, 26: 205-221 [1983]; Yelton et al., Proc. Natl. Acad. Sci. USA, 81: 1470-1474 [1984]) and *A. niger* (Kelly and Hynes, EMBO J., 4: 475-479 [1985]).

Suitable host cells for the expression of glycosylated PF4AR polypeptide are derived from multicellular organisms. Such host cells are capable of complex processing and glycosylation activities. In principle, any higher eukaryotic cell culture is workable, whether from vertebrate or invertebrate culture. Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains and variants and corresponding permissive insect host cells from hosts such as *Spodoptera frugiperda* (caterpillar), *Aedes aegypti* (mosquito), *Aedes albopictus* (mosquito), *Drosophila melanogaster* (fruitfly), and *Bombyx mori* host cells have been identified. See, e.g., Luckow et al., Bio/Technology, 6: 47-55 (1988); Miller et al., in Genetic Engineering, Setlow, J.K. et al., 8: 277-279 (Plenum Publishing, 1986), and Maeda et al., Nature, 315: 592-594 (1985). A variety of 20 such viral strains are publicly available, e.g., the L-1 variant of *Autographa californica* NPV and the Bm-5 strain of *Bombyx mori* NPV, and such viruses may be used as the virus herein according to the 25 30

present invention, particularly for transfection of *Spodoptera frugiperda* cells.

Plant cell cultures of cotton, corn, potato, soybean, petunia, tomato, and tobacco can be utilized as hosts. Typically, plant 5 cells are transfected by incubation with certain strains of the bacterium *Agrobacterium tumefaciens*, which has been previously manipulated to contain the PF4AR DNA. During incubation of the plant cell culture with *A. tumefaciens*, the DNA encoding PF4AR is transferred to the plant cell host such that it is transfected, and 10 will, under appropriate conditions, express the PF4AR DNA. In addition, regulatory and signal sequences compatible with plant cells are available, such as the nopaline synthase promoter and polyadenylation signal sequences. Depicker et al., J. Mol. Appl. Gen., 1: 561 (1982). In addition, DNA segments isolated from the 15 upstream region of the T-DNA 780 gene are capable of activating or increasing transcription levels of plant-expressible genes in recombinant DNA-containing plant tissue. See EP 321,196 published 21 June 1989.

However, interest has been greatest in vertebrate cells, and propagation of vertebrate cells in culture (tissue culture) has become a routine procedure in recent years [Tissue Culture, Academic Press, Kruse and Patterson, editors (1973)]. Examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney 20 line (293 or 293 cells subcloned for growth in suspension culture, Graham et al., J. Gen Virol., 36: 59 (1977); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cells/-DHFR (CHO, Urlaub and Chasin, Proc. Natl. Acad. Sci. USA, 77: 4216 [1980]); mouse sertoli cells (TM4, Mather, Biol. Reprod., 23: 243-251 25 [1980]); monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human 30

lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51); TRI cells (Mather et al., Annals N.Y. Acad. Sci., 383: 44-68 [1982]); MRC 5 cells; FS4 cells; and a human hepatoma cell line (Hep G2).
5 Preferred host cells are human embryonic kidney 293 and Chinese hamster ovary cells.

Host cells are transfected and preferably transformed with the above-described expression or cloning vectors of this invention and cultured in conventional nutrient media modified as appropriate for
10 inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.

Transfection refers to the taking up of an expression vector by a host cell whether or not any coding sequences are in fact expressed. Numerous methods of transfection are known to the ordinarily skilled artisan, for example, CaPO₄ and electroporation. Successful transfection is generally recognized when any indication of the operation of this vector occurs within the host cell.
15

Transformation means introducing DNA into an organism so that the DNA is replicable, either as an extrachromosomal element or by chromosomal integrant. Depending on the host cell used, transformation is done using standard techniques appropriate to such cells. The calcium treatment employing calcium chloride, as described in section 1.82 of Sambrook et al., *supra*, is generally used for prokaryotes or other cells that contain substantial cell-wall barriers. Infection with *Agrobacterium tumefaciens* is used for transformation of certain plant cells, as described by Shaw et al., Gene, 23: 315 (1983) and WO 89/05859 published 29 June 1989. For mammalian cells without such cell walls, the calcium phosphate precipitation method described in sections 16.30-16.37 of Sambrook et al., *supra*, is preferred. General aspects of mammalian cell host system transformations have been described by Axel in U.S. 4,399,216 issued 16 August 1983. Transformations into yeast are typically carried out according to the method of Van Solingen et
20
25
30

al., J. Bact., 130: 946 (1977) and Hsiao et al., Proc. Natl. Acad. Sci. (USA), 76: 3829 (1979). However, other methods for introducing DNA into cells such as by nuclear injection, electroporation, or by protoplast fusion may also be used.

5 E. Culturing the Host Cells

Prokaryotic cells used to produce the PF4AR polypeptide of this invention are cultured in suitable media as described generally in Sambrook et al., *supra*.

The mammalian host cells used to produce the PF4AR of this invention may be cultured in a variety of media. Commercially available media such as Ham's F10 (Sigma), Minimal Essential Medium ([MEM], Sigma), RPMI-1640 (Sigma), and Dulbecco's Modified Eagle's Medium ([DMEM], Sigma) are suitable for culturing the host cells. In addition, any of the media described in Ham and Wallace, Meth. Enz., 58: 44 (1979), Barnes and Sato, Anal. Biochem., 102: 255 (1980), U.S. 4,767,704; 4,657,866; 4,927,762; or 4,560,655; WO 90/03430; WO 87/00195; U.S. Pat. Re. 30,985; or U.S. 5,122,469, the disclosures of all of which are incorporated herein by reference, may be used as culture media for the host cells. Any of these media may be supplemented as necessary with hormones and/or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleosides (such as adenosine and thymidine), antibiotics (such as Gentamycin™ drug), trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations that would be known to those skilled in the art. The culture conditions, such as temperature, pH, and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.

The host cells referred to in this disclosure encompass cells in *in vitro* culture as well as cells that are within a host animal.

It is further envisioned that the PF4AR of this invention may be produced by homologous recombination, or with recombinant production methods utilizing control elements introduced into cells already containing DNA encoding the PF4AR. For example, a powerful promoter/enhancer element, a suppressor, or an exogenous transcription modulatory element is inserted in the genome of the intended host cell in proximity and orientation sufficient to influence the transcription of DNA encoding the desired PF4AR. The control element does not encode the PF4AR of this invention, but the DNA is present in the host cell genome. One next screens for cells making the PF4AR of this invention, or increased or decreased levels of expression, as desired.

F. Detecting Gene Amplification/Expression

Gene amplification and/or expression may be measured in a sample directly, for example, by conventional Southern blotting, northern blotting to quantitate the transcription of mRNA (Thomas, Proc. Natl. Acad. Sci. USA, 77: 5201-5205 [1980]), dot blotting (DNA analysis), or *in situ* hybridization, using an appropriately labeled probe, based on the sequences provided herein. Various labels may be employed, most commonly radioisotopes, particularly ³²P. However, other techniques may also be employed, such as using biotin-modified nucleotides for introduction into a polynucleotide. The biotin then serves as the site for binding to avidin or antibodies, which may be labeled with a wide variety of labels, such as radionuclides, fluorescers, enzymes, or the like. Alternatively, antibodies may be employed that can recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes. The antibodies in turn may be labeled and the assay may be carried out where the duplex is bound to a surface, so that upon the formation of duplex

on the surface, the presence of antibody bound to the duplex can be detected.

Gene expression, alternatively, may be measured by immunological methods, such as immunohistochemical staining of tissue sections and assay of cell culture or body fluids, to quantitate directly the expression of gene product. With immunohistochemical staining techniques, a cell sample is prepared, typically by dehydration and fixation, followed by reaction with labeled antibodies specific for the gene product coupled, where the labels are usually visually detectable, such as enzymatic labels, fluorescent labels, luminescent labels, and the like. A particularly sensitive staining technique suitable for use in the present invention is described by Hsu et al., Am. J. Clin. Path., 75: 734-738 (1980).

Antibodies useful for immunohistochemical staining and/or assay of sample fluids may be either monoclonal or polyclonal, and may be prepared in any mammal. Conveniently, the antibodies may be prepared against a native PF4AR polypeptide or against a synthetic peptide based on the DNA sequences provided herein as described further in Section 4 below.

G. Purification of The PF4AR Polypeptide

The PF4AR is recovered from the culture cells by solubilizing cell membrane in detergent.

When a human PF4AR is expressed in a recombinant cell other than one of human origin, the PF4AR is completely free of proteins or polypeptides of human origin. However, it is necessary to purify the PF4AR from recombinant cell proteins or polypeptides to obtain preparations that are substantially homogeneous as to the PF4AR. As a first step, the cells are centrifuged to separate them from culture medium. The membrane and soluble protein fractions are then separated. The PF4AR may then be purified from the membrane fraction of the culture lysate by solubilization with detergents followed by suitable purification procedures:

fractionation on immunoaffinity or ion-exchange columns; ethanol precipitation; reverse phase HPLC; chromatography on silica or on a cation exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, Sephadex G-75; hydrophobic affinity resins and ligand affinity using the appropriate PF4A immobilized on a matrix.

PF4AR variants in which residues have been deleted, inserted or substituted are recovered in the same fashion as the native PF4AR, taking account of any substantial changes in properties occasioned by the variation. For example, preparation of a PF4AR fusion with another protein or polypeptide, e.g. a bacterial or viral antigen, facilitates purification; an immunoaffinity column containing antibody to the antigen can be used to adsorb the fusion. Immunoaffinity columns such as a rabbit polyclonal anti-PF4AR column can be employed to absorb the PF4AR variant by binding it to at least one remaining immune epitope. A protease inhibitor such as phenyl methyl sulfonyl fluoride (PMSF) also may be useful to inhibit proteolytic degradation during purification, and antibiotics may be included to prevent the growth of adventitious contaminants. One skilled in the art will appreciate that purification methods suitable for native PF4AR may require modification to account for changes in the character of the PF4AR or its variants upon expression in recombinant cell culture.

H. Covalent Modifications of PF4AR Polypeptides

Covalent modifications of PF4AR polypeptides are included within the scope of this invention. Both native PF4ARs and amino acid sequence variants of the PF4AR may be covalently modified. Covalent modifications of the PF4AR, fragments thereof or antibodies thereto are introduced into the molecule by reacting targeted amino acid residues of the PF4AR, fragments thereof, or PF4AR antibody with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C-terminal residues. Most commonly, PF4AR and its antibodies are covalently

bonded to detectable groups used in diagnosis, e.g. enzymes, radio isotopes, spin labels, antigens, fluorescent or chemiluminescent groups and the like.

5 Cysteinyl residues most commonly are reacted with α -haloacetates (and corresponding amines), such as chloroacetic acid or chloroacetamide, to give carboxymethyl or carboxyamidomethyl derivatives. Cysteinyl residues also are derivatized by reaction with bromotrifluoroacetone, α -bromo- β -(5-imidazole)propionic acid, chloroacetyl phosphate, N-alkylmaleimides, 3-nitro-2-pyridyl 10 disulfide, methyl 2-pyridyl disulfide, p-chloromercuribenzoate, 2-chloromercuri-4-nitrophenol, or chloro-7-nitrobenzo-2-oxa-1,3-diazole.

15 Histidyl residues are derivatized by reaction with diethyl-pyrocarbonate at pH 5.5-7.0 because this agent is relatively specific for the histidyl side chain. Para-bromophenacyl bromide also is useful; the reaction is preferably performed in 0.1M sodium cacodylate at pH 6.0.

20 Lysinyl and amino terminal residues are reacted with succinic or other carboxylic acid anhydrides. Derivatization with these agents has the effect of reversing the charge of the lysinyl residues. Other suitable reagents for derivatizing α -amino-containing residues include imidoesters such as methyl picolinimidate; pyridoxal phosphate; pyridoxal; chloroborohydride; trinitrobenzenesulfonic acid; O-methylisourea; 2,4-pentanedione; 25 and transaminase-catalyzed reaction with glyoxylate.

Arginyl residues are modified by reaction with one or several conventional reagents, among them phenylglyoxal, 2,3-butanedione, 1,2-cyclohexanedione, and ninhydrin. Derivatization of arginine residues requires that the reaction be performed in alkaline 30 conditions because of the high pK_a of the guanidine functional group. Furthermore, these reagents may react with the groups of lysine as well as the arginine epsilon-amino group.

The specific modification of tyrosyl residues may be made, with particular interest in introducing spectral labels into tyrosyl residues by reaction with aromatic diazonium compounds or tetrinitromethane. Most commonly, N-acetylimidazole and tetrinitromethane are used to form O-acetyl tyrosyl species and 3-nitro derivatives, respectively. Tyrosyl residues are iodinated using ^{125}I or ^{131}I to prepare labeled proteins for use in radioimmunoassay, the chloramine T method described above being suitable.

Carboxyl side groups (aspartyl or glutamyl) are selectively modified by reaction with carbodiimides ($\text{R}'-\text{N}=\text{C}=\text{N}-\text{R}''$), where R and R' are different alkyl groups, such as 1-cyclohexyl-3-(2-morpholinyl-4-ethyl) carbodiimide or 1-ethyl-3-(4-azonia-4,4-dimethylpentyl) carbodiimide. Furthermore, aspartyl and glutamyl residues are converted to asparaginyl and glutaminyl residues by reaction with ammonium ions.

Derivatization with bifunctional agents is useful for crosslinking PF4AR, its fragments or antibodies to a water-insoluble support matrix or surface for use in methods for purifying anti-PF4AR antibodies, and vice versa. Immobilized PF4AR also is useful in screening for the PF4 superfamily members to which the receptor binds. Commonly used crosslinking agents include, e.g., 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azido-salicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis(succinimidyl-propionate), and bifunctional maleimides such as bis-N-maleimido-1,8-octane. Derivatizing agents such as methyl-3-[(p-azidophenyl)-dithio]propioimidate yield photoactivatable intermediates that are capable of forming crosslinks in the presence of light. Alternatively, reactive water-insoluble matrices such as cyanogen bromide-activated carbohydrates and the reactive substrates

described in U.S. 3,969,287; 3,691,016; 4,195,128; 4,247,642; 4,229,537; and 4,330,440 are employed for protein immobilization.

Glutamyl and asparaginyl residues are frequently deamidated to the corresponding glutamyl and aspartyl residues, respectively. 5 Alternatively, these residues are deamidated under mildly acidic conditions. Either form of these residues falls within the scope of this invention.

Other modifications include hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the α -amino groups of lysine, arginine, and histidine side chains (T.E. Creighton, Proteins: Structure and Molecular Properties, W.H. Freeman & Co., San Francisco, pp. 79-86 [1983]), acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group.

15 Another type of covalent modification of the beta-8 polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of the polypeptide. By altering is meant deleting one or more carbohydrate moieties found in the native receptor, and/or adding one or more glycosylation sites that are not present in the native receptor.

Glycosylation of polypeptides is typically either N-linked or O-linked. N-linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue. The tri-peptide sequences asparagine-X-serine and asparagine-X-threonine, where X is any amino acid except proline, are the recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain. Thus, the presence of either of these tri-peptide sequences in a polypeptide creates a potential glycosylation site. O-linked glycosylation refers to the attachment of one of the sugars N-acetylgalactosamine, galactose, or xylose, to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used. As noted

above, the IL-8 receptor contains 6 putative N-linked glycosylation sites.

5 Addition of glycosylation sites to the PF4AR polypeptide is conveniently accomplished by altering the amino acid sequence such that it contains one or more of the above-described tri-peptide sequences (for N-linked glycosylation sites). The alteration may also be made by the addition of, or substitution by, one or more serine or threonine residues to the native PF4AR sequence (for O-linked glycosylation sites). For ease, the PF4AR amino acid sequence is preferably altered through changes at the DNA level, particularly by mutating the DNA encoding the PF4AR polypeptide at preselected bases such that codons are generated that will translate into the desired amino acids. The DNA mutation(s) may be made using methods described above under the heading of "Amino Acid Sequence Variants of PF4AR Polypeptide".

15 Another means of increasing the number of carbohydrate moieties on the PF4AR polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. These procedures are advantageous in that they do not require production of the polypeptide in a host cell that has glycosylation capabilities for N- and O- linked glycosylation. Depending on the coupling mode used, the sugar(s) may be attached to (a) arginine and histidine, (b) free carboxyl groups, (c) free sulfhydryl groups such as those of cysteine, (d) free hydroxyl groups such as those of serine, threonine, or hydroxyproline, (e) aromatic residues such as those of phenylalanine, tyrosine, or tryptophan, or (f) the amide group of glutamine. These methods are described in WO 87/05330 published 11 September 1987, and in Aplin and Wriston (CRC Crit. Rev. Biochem., pp. 259-306 [1981]).

20 Removal of carbohydrate moieties present on the native PF4AR polypeptide may be accomplished chemically or enzymatically. Chemical deglycosylation requires exposure of the polypeptide to the compound trifluoromethanesulfonic acid, or an equivalent

compound. This treatment results in the cleavage of most or all sugars except the linking sugar (N-acetylglucosamine or N-acetylgalactosamine), while leaving the polypeptide intact. Chemical deglycosylation is described by Hakimuddin et al., Arch. Biochem. Biophys., 259: 52 (1987) and by Edge et al., Anal. Biochem., 118: 131 (1981). Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo- and exo-glycosidases as described by Thotakura et al., Meth. Enzymol., 138: 350 (1987).

Glycosylation at potential glycosylation sites may be prevented by the use of the compound tunicamycin as described by Duskin et al., J. Biol. Chem., 257: 3105 (1982). Tunicamycin blocks the formation of protein-N-glycoside linkages.

The PF4AR also may be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization (for example, hydroxymethylcellulose or gelatin-microcapsules and poly-[methylmethacrylate] microcapsules, respectively), in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules), or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences, 16th edition, Osol, A., Ed., (1980).

PF4AR preparations are also useful in generating antibodies, for use as standards in assays for the PF4AR (e.g. by labeling the PF4AR for use as a standard in a radioimmunoassay, enzyme-linked immunoassay, or radioreceptor assay), in affinity purification techniques, and in competitive-type receptor binding assays when labeled with radioiodine, enzymes, fluorophores, spin labels, and the like.

Since it is often difficult to predict in advance the characteristics of a variant PF4AR, it will be appreciated that some screening of the recovered variant will be needed to select the optimal variant. For example, a change in the immunological

character of the PF4AR molecule, such as affinity for a given antibody, is measured by a competitive-type immunoassay. The variant is assayed for changes in the suppression or enhancement of its activity by comparison to the activity observed for native PF4AR in the same assay. Other potential modifications of protein or polypeptide properties such as redox or thermal stability, hydrophobicity, susceptibility to proteolytic degradation, or the tendency to aggregate with carriers or into multimers are assayed by methods well known in the art.

10 3. Therapeutic Compositions and Administration of PF4AR

Therapeutic formulations of PF4AR (including its PF4AR binding fragments) or antibodies thereto are prepared for storage by mixing PF4AR having the desired degree of purity with optional physiologically acceptable carriers, excipients, or stabilizers (Remington's Pharmaceutical Sciences, *supra*), in the form of lyophilized cake or aqueous solutions. Acceptable carriers, excipients or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as Tween, Pluronics or polyethylene glycol (PEG).

The PF4AR, or antibody to be used for *in vivo* administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes, prior to or following lyophilization and reconstitution. The PF4AR ordinarily will be stored in lyophilized form or in solution.

Therapeutic PF4AR or antibody compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

5 The route of PF4AR or antibody administration is in accord with known methods, e.g. injection or infusion by intravenous, intraperitoneal, intracerebral, intramuscular, intraocular, intraarterial, or intralesional routes, or by sustained release systems as noted below. Preferably the antibody is given
10 systemically.

Suitable examples of sustained-release preparations include semipermeable polymer matrices in the form of shaped articles, e.g. films, or microcapsules. Sustained release matrices include polyesters, hydrogels, polylactides (U.S. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma ethyl-L-glutamate (Sidman et al., Biopolymers, 22: 547-556 [1983]), poly (2-hydroxyethyl-methacrylate) (Langer et al., J. Biomed. Mater. Res., 15: 167-277 [1981] and Langer, Chem. Tech., 12: 98-105 [1982]), ethylene vinyl acetate (Langer et al., *supra*) or poly-D-(-)-3-hydroxybutyric acid (EP 133,988). Sustained-release PF4AR or antibody compositions also include liposomally entrapped PF4AR or antibody. Liposomes containing PF4AR or antibody are prepared by methods known *per se*: DE 3,218,121; Epstein et al., Proc. Natl. Acad. Sci. USA, 82: 3688-3692 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA, 77: 4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese patent application 83-118008; U.S. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. % cholesterol, the selected proportion being adjusted for the optimal PF4AR or antibody therapy.

An "effective amount" of PF4AR or antibody to be employed therapeutically will depend, for example, upon the therapeutic

objectives, the route of administration, the type of PF4AR polypeptide or antibody employed, and the condition of the patient. Accordingly, it will be necessary for the therapist to titer the dosage and modify the route of administration as required to obtain
5 the optimal therapeutic effect. Typically, the clinician will administer the PF4AR or antibody until a dosage is reached that achieves the desired effect. The progress of this therapy is easily monitored by conventional assays.

In the treatment and prevention of an inflammatory disorder by
10 a PF4AR antibody, particularly an IL-8 receptor antibody, the antibody composition will be formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the antibody, the particular type of antibody, the method of administration, the scheduling of administration, and other factors known to medical practitioners. The "therapeutically effective amount" of antibody to be administered will be governed by such considerations, and is the minimum amount necessary to prevent, ameliorate, or treat the inflammatory disorder, including treating chronic respiratory diseases and reducing inflammatory responses. Such amount is preferably below the amount that is toxic to the host or renders the host significantly more
15 susceptible to infections.
20
25

As a general proposition, the initial pharmaceutically effective amount of the antibody administered parenterally per dose will be in the range of about 0.1 to 50 mg/kg of patient body weight per day, with the typical initial range of antibody used being 0.3 to 20 mg/kg/day, more preferably 0.3 to 15 mg/kg/day.
30

As noted above, however, these suggested amounts of antibody are subject to a great deal of therapeutic discretion. The key

factor in selecting an appropriate dose and scheduling is the result obtained, as indicated above.

The antibody need not be, but is optionally formulated with one or more agents currently used to prevent or treat the inflammatory disorder in question. For example, in rheumatoid arthritis, the antibody may be given in conjunction with a glucocorticosteroid. In addition, T cell receptor peptide therapy is suitably an adjunct therapy to prevent clinical signs of autoimmune encephalomyelitis. Offner et al., *supra*. The effective amount of such other agents depends on the amount of PF4AR antibody present in the formulation, the type of disorder or treatment, and other factors discussed above. These are generally used in the same dosages and with administration routes as used hereinbefore or about from 1 to 99% of the heretofore employed dosages.

4. PF4AR Antibody Preparation

Polyclonal antibodies to the PF4AR generally are raised in animals by multiple subcutaneous (sc) or intraperitoneal (ip) injections of the PF4AR and an adjuvant. Immunization with recombinant cells transformed with the PF4AR (e.g., 293, mouse, or CHO cells transformed with huPF4AR) may be satisfactory, or it may be useful to separate the PF4AR and conjugate it or a fragment containing the target amino acid sequence to a protein that is immunogenic in the species to be immunized, e.g., keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor using a bifunctional or derivatizing agent, for example, maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine residues), N-hydroxysuccinimide (through lysine residues), glutaraldehyde, succinic anhydride, SOCl₂, or R'N = C = NR, where R and R' are different alkyl groups.

Animals ordinarily are immunized against the transfected cells, or immunogenic conjugates, derivatives, or peptides every other week. 7 to 14 days after the immunization the animals are bled and the serum is assayed for anti-PF4AR titer. Preferably,

the animal is boosted with the conjugate of the same PF4AR, but conjugated to a different protein and/or through a different cross-linking agent. Conjugates also can be made in recombinant cell culture as protein fusions. Also, aggregating agents such as alum
5 are used to enhance the immune response. Less preferably, the animals are immunized by combining 1 mg or 1 μ g of PF4AR in Freund's complete adjuvant and injecting the solution intradermally at multiple sites. One month later the animals are boosted with 1/5 to 1/10 the original amount of conjugate in Freund's complete
10 adjuvant by subcutaneous injection at multiple sites. 7 to 14 days later the animals are bled and the serum is assayed for anti-PF4AR titer. Animals are boosted until the titer plateaus.

Another option is to employ combinatorial variable domain libraries and screening methods to identify the desired anti-PF4AR antibodies.
15

Monoclonal antibodies are prepared by recovering spleen cells from immunized animals and immortalizing the cells in conventional fashion, e.g. by fusion with myeloma cells or by Epstein-Barr (EB)-virus transformation and screening for clones expressing the
20 desired antibody.

The monoclonal antibody preferably is specific for each target PF4AR polypeptide, and will not cross-react with rabbit fMLP receptor (Thomas et al., J. Biol. Chem., *supra*), human fMLP receptor, human C5a receptor the low affinity IL-8 receptor, or
25 other members of the PF4AR family. Antibodies specific for the receptor of Figs. 2, 4 or 5 are preferred. The antibody is selected to be either agonistic, antagonistic, or to have no effect on the activity of a PF4 super-family member in binding to or activating the receptor.

Murphy and Tiffany, *supra*, describe a receptor having a high degree of homology to the receptor of Fig. 2. Murphy and Tiffany characterized their receptor in recombinant oocytes as being a receptor for IL-8 and having capability to bind MGSA, thus
30

suggesting that it plays a minor role in IL-8 and MGSA biological activity *in vivo*. The studies herein, however, have shown that the Murphy and Tiffany receptor exhibits IL-8 affinity as high or higher than the receptor of Fig. 2 and that as well it shows high affinity (about 1-10nM) for MGSA. Thus, antagonism of the IL-8 and/or MGSA response of lymphoid cells will likely require that both receptors be inhibited or blocked. For example, one should select an IL-8 antagonist antibody that binds to an epitope of the Fig. 2 receptor that is shared by the Murphy and Tiffany receptor. This could be readily accomplished by routine screening methods. For example, the candidate antibodies can be assayed for their ability to compete against labelled IL-8 for binding to cells bearing the Fig. 2 receptor, and then the same study conducted with cells bearing the Murphy and Tiffany receptor. Antibodies that inhibit IL-8 activation or binding to both cells are then selected as therapeutic candidates. On the other hand, antibodies that can discriminate between the Fig. 2 and Murphy and Tiffany receptors and bind only to one or the other are useful in diagnosis. The receptor of Fig. 2 binds MGSA poorly, in contrast to the Murphy and Tiffany receptor.

5. Uses of PF4AR its nucleic acid and its Antibodies

The nucleic acid encoding the PF4AR may be used as a diagnostic for tissue specific typing. For example, such procedures as *in situ* hybridization, and northern and Southern blotting, and PCR analysis may be used to determine whether DNA and/or RNA encoding the PF4AR are present in the cell type(s) being evaluated. These receptors typically are diagnostic of PBL or monocytic cells.

Isolated PF4AR polypeptide may be used in quantitative diagnostic assays as a standard or control against which samples e.g. from PBL or monocytic cells, containing unknown quantities of PF4AR may be compared. Recombinant cells which express the IL-8 receptor can be used in assays for PF4A ligands in the same fashion

as for example neutrophils are used in IL-8 assays. The PF4AR polypeptides, fragments or cells (as such, or derivatized) also can be used as immunogens in the production of antibodies to PF4AR, for the purification of such antibodies from ascites or recombinant cell culture media or for use as competitive antagonists for superfamily ligands, e.g. IL-8.

The PF4AR are useful in screening for amino acid sequence or other variants of PF4 superfamily members. For example, a bank of candidate IL-8 amino acid sequence variants are prepared by site directed mutagenesis. These are incubated in competition with labelled native IL-8 for cells bearing the IL-8 receptor of Fig. 2 in order identify agonist or antagonist IL-8 variants. Binding or cell activation are suitable assay endpoints. Alternatively, the receptor is recovered in cell-free form and binding of IL-8 and candidate variants assayed.

PF4AR antibodies are useful in diagnostic assays for PF4AR expression in specific cells or tissues wherein the antibodies are labeled in the same fashion as the PF4AR described above and/or are immobilized on an insoluble matrix. PF4AR antibodies also are useful for the affinity purification of the PF4AR from recombinant cell culture or natural sources. The PF4AR antibodies that do not detectably cross-react with other PF4ARs can be used to purify each PF4AR free from other homologous receptors. PF4AR antibodies that are PF4 antagonists are useful as anti-inflammatory agents or in the treatment of other PF4 superfamily-mediated disorders.

Suitable diagnostic assays for the PF4AR and its antibodies are well known *per se*. Such assays include competitive and sandwich assays, and steric inhibition assays. Competitive and sandwich methods employ a phase-separation step as an integral part of the method while steric inhibition assays are conducted in a single reaction mixture. Fundamentally, the same procedures are used for the assay of the PF4AR and for substances that bind the PF4AR, although certain methods will be favored depending upon the

molecular weight of the substance being assayed. Therefore, the substance to be tested is referred to herein as an analyte, irrespective of its status otherwise as an antigen or antibody, and proteins that bind to the analyte are denominated binding partners, whether they be antibodies, cell surface receptors, or antigens.

Analytical methods for the PF4AR or its antibodies all use one or more of the following reagents: labeled analyte analogue, immobilized analyte analogue, labeled binding partner, immobilized binding partner and steric conjugates. The labeled reagents also are known as "tracers."

The label used (and this is also useful to label PF4AR nucleic acid for use as a probe) is any detectable functionality that does not interfere with the binding of analyte and its binding partner. Numerous labels are known for use in immunoassay, examples including moieties that may be detected directly, such as fluorochrome, chemiluminescent, and radioactive labels, as well as moieties, such as enzymes, that must be reacted or derivatized to be detected. Examples of such labels include the radioisotopes ^{32}P , ^{14}C , ^{125}I , ^3H , and ^{131}I , fluorophores such as rare earth chelates or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, luciferases, e.g., firefly luciferase and bacterial luciferase (U.S. Pat. No. 4,737,456), luciferin, 2,3-dihydrophthalazinediones, horseradish peroxidase (HRP), alkaline phosphatase, β -galactosidase, glucoamylase, lysozyme, saccharide oxidases, e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase, heterocyclic oxidases such as uricase and xanthine oxidase, coupled with an enzyme that employs hydrogen peroxide to oxidize a dye precursor such as HRP, lactoperoxidase, or microperoxidase, biotin/avidin, spin labels, bacteriophage labels, stable free radicals, and the like.

Conventional methods are available to bind these labels covalently to proteins or polypeptides. For instance, coupling agents such as dialdehydes, carbodiimides, dimaleimides, bis-

imidates, bis-diazotized benzidine, and the like may be used to tag the antibodies with the above-described fluorescent, chemiluminescent, and enzyme labels. See, for example, U.S. Pat. Nos. 3,940,475 (fluorimetry) and 3,645,090 (enzymes); Hunter et al., Nature, 144: 945 (1962); David et al., Biochemistry, 13: 1014-1021 (1974); Pain et al., J. Immunol. Methods, 40: 219-230 (1981); and Nygren, J. Histochem. and Cytochem., 30: 407-412 (1982). Preferred labels herein are enzymes such as horseradish peroxidase and alkaline phosphatase.

The conjugation of such label, including the enzymes, to the antibody is a standard manipulative procedure for one of ordinary skill in immunoassay techniques. See, for example, O'Sullivan et al., "Methods for the Preparation of Enzyme-antibody Conjugates for Use in Enzyme Immunoassay," in Methods in Enzymology, ed. J.J. Langone and H. Van Vunakis, Vol. 73 (Academic Press, New York, New York, 1981), pp. 147-166. Such binding methods are suitable for use with PF4AR or its antibodies, all of which are proteinaceous.

Immobilization of reagents is required for certain assay methods. Immobilization entails separating the binding partner from any analyte that remains free in solution. This conventionally is accomplished by either insolubilizing the binding partner or analyte analogue before the assay procedure, as by adsorption to a water-insoluble matrix or surface (Bennich et al., U.S. 3,720,760), by covalent coupling (for example, using glutaraldehyde cross-linking), or by insolubilizing the partner or analogue afterward, e.g., by immunoprecipitation.

Other assay methods, known as competitive or sandwich assays, are well established and widely used in the commercial diagnostics industry.

Competitive assays rely on the ability of a tracer analogue to compete with the test sample analyte for a limited number of binding sites on a common binding partner. The binding partner generally is insolubilized before or after the competition and then

the tracer and analyte bound to the binding partner are separated from the unbound tracer and analyte. This separation is accomplished by decanting (where the binding partner was preinsolubilized) or by centrifuging (where the binding partner was precipitated after the competitive reaction). The amount of test sample analyte is inversely proportional to the amount of bound tracer as measured by the amount of marker substance. Dose-response curves with known amounts of analyte are prepared and compared with the test results to quantitatively determine the amount of analyte present in the test sample. These assays are called ELISA systems when enzymes are used as the detectable markers.

Another species of competitive assay, called a "homogeneous" assay, does not require a phase separation. Here, a conjugate of an enzyme with the analyte is prepared and used such that when anti-analyte binds to the analyte the presence of the anti-analyte modifies the enzyme activity. In this case, the PF4AR or its immunologically active fragments are conjugated with a bifunctional organic bridge to an enzyme such as peroxidase. Conjugates are selected for use with anti-PF4AR so that binding of the anti-PF4AR inhibits or potentiates the enzyme activity of the label. This method *per se* is widely practiced under the name of EMIT.

Steric conjugates are used in steric hindrance methods for homogeneous assay. These conjugates are synthesized by covalently linking a low-molecular-weight hapten to a small analyte so that antibody to hapten substantially is unable to bind the conjugate at the same time as anti-analyte. Under this assay procedure the analyte present in the test sample will bind anti-analyte, thereby allowing anti-hapten to bind the conjugate, resulting in a change in the character of the conjugate hapten, e.g., a change in fluorescence when the hapten is a fluorophore. Sandwich assays particularly are useful for the determination of PF4AR or PF4AR antibodies. In sequential sandwich assays an immobilized binding

partner is used to adsorb test sample analyte, the test sample is removed as by washing, the bound analyte is used to adsorb labeled binding partner, and bound material is then separated from residual tracer. The amount of bound tracer is directly proportional to test sample analyte. In "simultaneous" sandwich assays the test sample is not separated before adding the labeled binding partner. A sequential sandwich assay using an anti-PF4AR monoclonal antibody as one antibody and a polyclonal anti-PF4AR antibody as the other is useful in testing samples for PF4AR activity.

The foregoing are merely exemplary diagnostic assays for PF4AR and antibodies. Other methods now or hereafter developed for the determination of these analytes are included within the scope hereof, including the bioassays described above.

The polypeptides set forth in Figs. 4 and 5 are believed to represent receptors for different and as yet undetermined members of the PF4 superfamily (which includes both the C-C and CXC subfamilies). Like the IL-8 receptor of Fig. 2 they are members of the G-protein-coupled superfamily and bear greater similarity to the IL-8 receptor than other receptors. In preliminary experiments, recombinant cells bearing these receptors do not respond to Rantes, MCP1, IL-8 or MGSA, although they may ultimately be shown to bind other members of the PF4 superfamily or presently unknown ligands. However, whether or not the Figs. 4 or 5 polypeptides bind to members of the PF4 superfamily, the polypeptides are useful for preparing antibodies for diagnostic use in determining the tissue distribution of the receptors and thus as an immunohistochemical diagnostic for such tissues, in particular as a diagnostic for monocytic cells or PBLs since it is known that such cells express the receptors of Figs. 4 and 5. Of course, once the PF4 superfamily members are identified which bind to these receptors then the receptors can be used to diagnose the presence of the identified members or for their purification in specific affinity procedures. The DNA in Figs. 4 and 5 also is useful in

diagnostics for the presence of DNA or RNA encoding the IL-8 receptor when low stringency conditions are employed.

All references cited in this specification are expressly incorporated by reference.

5 The following examples are offered by way of illustration and not by way of limitation.

EXAMPLE 1

To obtain the clone pRK5B.il8r1.1, a cDNA (Gubler and Hoffman, 10 Gene, 25: 263-269 [1983]) library of 1,000,000 clones was constructed from human neutrophil mRNA (Chirgwin et al., Biochem., 18: 5294-5299 [1979]) in the vector pRK5B using BstXI linkers. The cDNA is produced in blunted form. Hemi-kinase bstXI linkers are ligated to the CDNA, and the linkers ligated into the PRK5B vector that had been bstXI digested, phosphatased, and the long vector fragment isolated. PRK5B is a derivative of PRK5 (EP 307,247) that contains a cytomegalovirus promoter followed by a 5' intron, bstXI cloning site, and an SV40 early polyadenylation signal, although it will be understood that any mammalian cell expression vector will be satisfactory, 58 pools of 2500 clones each were transfected into COS-7 cells by electroporation (Gearing et al., *supra*) of 20 µg of DNA into 3,750,000 cells After 2 days of growth on 150-mm dishes in medium (50:50::Ham's F12:DMEM) containing 10 % fetal calf serum, ¹²⁵I-IL-8 binding was performed. Purified human 72 amino acid IL-8 made in E. coli (Hébert et al., J. Immunology, 145: 3033-3040 15 [1990]) was labeled by the lactoperoxidase method (Morrison and Bayse, Biochem., 9: 2995-3000 [1970]) to about 1100 Ci/mmol and was at least 85 % bindable. Dishes were rinsed twice with phosphate-buffered saline, and binding was performed with 8 ml per dish of 20 growth medium containing 2.5 % fetal calf serum and about 0.5 nM ¹²⁵I-IL-8. After 2 hr at 37°C, the plates were rinsed three times 25 with phosphate-buffered saline, the bottoms cut out (Pacholczyk et al., BioTechniques, 9: 556-558 [1990]), and autoradiographed. Each 30

positive pool of 2500 cDNA clones was subsequently partitioned into pools of 800 clones, and each of these was transfected and assayed. Each positive pool in turn was subdivided through pools of 185, 30 and finally a single clone(s) until single positive clones were identified to obtain the pure isolate. Since only a portion of each pool was used for transfection it was unnecessary to rescue clones from transformants.

Binding competition was performed with electroporated COS-7 cells after 1 day of expression in 6-well dishes (about 175,000 cells/dish). Binding was performed with radioiodinated wild type IL-8 in binding medium Ca²⁺ and Mg²⁺-free Hanks buffered with 25 nM Hepes and supplemented with 0.5% bovine serum albumin [BSA]) at 4°C for about 2 hr. Wells were then washed, the cells harvested with trypsin, and counted. No specific binding was found in parallel wells containing cells transfected with DNA from the vector pRK5B. Neutrophil binding was performed as described (Pacholczyk et al., *supra*) but for 2 hr at 4°C.

EXAMPLE 2

Existing λgt10 cDNA libraries from the human cell line, HL60, and from human peripheral blood lymphocytes were screened at low stringency with a probe from the coding region of the cloned high-affinity human IL-8 receptor (Fig. 2). The probe was the 874 bp PstI/NcoI fragment of the receptor containing the coding region for amino acids 23-314. Hybridization was in 20% formamide, 4 x SSC, 50 mM sodium phosphate buffer, pH 7, 0.2 g/l sonicated salmon sperm DNA, 5 x Denhardt's, 10% dextran sulfate, at 42°C with a wash at 1 x SSC, 0.1% SDS at 50°C. A number of duplicate spots of varying intensity (about 60) were picked, plaque purified, subcloned into plasmid vectors, and sequenced. Nucleic acid sequencing began with the selection of spots of greatest intensity. Sufficient sequence was obtained for a given spot (phage) to determine whether or not evidence of structural or sequence homology with the IL-8 receptor

existed. If it did, then the remainder of the gene was obtained (if necessary) and sequenced in its entirety.

To avoid sequences all hybridizing clone the sequence was then used to probe the parental collection of IL-8 receptor DNA hybridizing clones under high stringency conditions in order to identify and discard other spots containing the same hybridizing gene. This technique was highly effective in reducing the sequencing burden. For example, one clone was represented by about one third of the initial 60 clones, and on this result alone the negative screen was able to reduce considering the work involved in sequencing the clones.

From this screen, two new gene sequences were found that are clearly related to the IL-8 receptor. The coding region for one new gene was split between two clones (8rr.20 and 8rr.15). The combined sequence of this gene (8rr.20.15) is shown in Figure 4. The complete coding region for the second gene is found on clone 8rr.9 (Figure 5). The predicted amino acid sequence of 8rr.20.15 is 34% identical with both the high and low affinity IL-8 receptor sequences. The sequence of 8rr.9 is 36% and 38% identical with the high and low affinity IL-8 receptor sequences, respectively (Holmes et al., *Science*, 253: 1278 [1991] and Murphy and Tiffany, *supra*). The amino acid sequence of 8rr.20.15 and 8rr.9 are 31% identical. Use of this probe under low stringency conditions did not produce detectable hybridization to the fMLP receptor genes that were expected to be found in these libraries.

EXAMPLE 3

Monoclonal antibodies to IL-8 type A receptor were generated by immunizing mice with synthetic peptides corresponding to various extracellular domains of IL8R-A or with stably transfected cells expressing IL8R-A, respectively. Blocking and non-blocking monoclonal antibodies were identified and their binding sites were

mapped to the N-terminal region of IL8R-A. Details are provided below:

Experimental Protocol

Recombinant human IL-8 (rHuIL-8) was produced in *E. coli* and purified as described in Hébert et al., *supra*.

For generating IL8R-A-bearing cells, human fetal kidney 293 cells were co-transfected with pRK5B.il8r1.1 (Holmes et al., *supra*) or pRK5.8rr27-1.1 (Lee et al., *J. Biol. Chem.*, **267**: 16283-16287 [1992]) and pSVENeoBal6 (Seeburg et al., *Nature*, **312**: 71-75 [1984]) plasmids in a 10:1 molar ratio, using a CaPO₄ precipitation method as described in Gorman in *DNA Cloning: A Practical Approach*, ed., Glover, D.M. (IRL: Oxford, 1984), Vol. 2, pp. 143-165. Transfected cells were selected in F12/DMEM (50:50) media containing 10% containing 10% fetal calf serum (FCS), 2 mM L-glutamine, 100 µg/ml penicillin, and 100 µg/ml streptomycin. Forty G418-resistant clonal lines were isolated from the pRK5B.il8r1.1 transfection. The IL8R-A-bearing transfected cells were selected by their ability to bind to ¹²⁵I-IL-8, and clone 293-71 was used for further study. Thirty G418-resistant clonal lines were isolated from the pRK5.8rr.27-1.1 transfection. After the ¹²⁵I-IL-8 binding experiment, clone 36 was selected for further study.

Mutants were prepared by the method of Kunkel, *Proc. Natl. Acad. Sci. USA*, **82**: 488 (1985) using the dut- ung- strain of *E. coli* CJ236 and a pUC-derived vector containing a cDNA insert coding for the IL-8 receptor A: pRK5B.IL-8r1.1. Holmes et al., *supra*. After verification of the mutant DNA sequence with the Sequenase™ version 2.0 kit (U.S. Biochemical Corp.), the mutated plasmid preparations were purified with the Qiagen™ plasmid maxi kit (Qiagen Inc., Chatsworth, CA) and used to transfect 293 cells by the calcium phosphate precipitate method of Gorman, *supra*. The cell cultures were incubated for seven hours in the presence of mutant or wild-type DNA precipitate (10 µg DNA/100 mm dish). The precipitate was then removed and the cells were cultured for an

additional 17 hours prior to fluorescence-activated cell sorter (FACS) analysis.

Peptides were synthesized via solid-phase methodology (Barany and Merrifield, in "the peptides," 2: 1-284, Gross and Meienhofer, 5 eds, [Academic Press: New York, 1980]) on either an ABI model 430 peptide synthesizer using tert-butyloxycarbonyl (t-BOC) chemistry or a Milligen model 9050 and ABI model 431 peptide synthesizer using fluorenylmethyloxycarbonyl (FMOC) chemistry. Crude peptides were purified by high-pressure liquid chromatography (HPLC) and 10 analyzed via mass spectrometry. Peptides were conjugated to soybean trypsin inhibitor using m-maleimidobenzoyl-N-hydroxysulfosuccinimide ester (Sulfo-MBS) (Pierce Co., Rockford, IL).

BALB/c mice were immunized intraperitoneally with 10 µg of synthetic peptides covering various portions of extracellular domains of IL8R-A conjugated to horse serum albumin or 10⁶ cells/100 µl of 293-71 transfected cells, resuspended in MPL/TDM (Ribi Immunochem. Research Inc., Hamilton, MT) and boosted nine times with the same amount of peptides or 16 times with transfected cells. Three days after the final boost with the antigen, spleen cells were fused with mouse myeloma P3X63Ag8U.1 (Yelton et al., 15 Curr. Top. Microbiol. Immunol., 81: 1-7 [1978]), a non-secreting clone of the myeloma P3X63Ag8 (Kohler and Milstein, Nature, 20 256: 495 [1975]) using 35% polyethylene glycol as described by Laskov et al., Cell. Immunol., 55: 251-264 (1980). Ten days after the fusion, culture supernatants were screened for the presence of monoclonal antibodies to IL8R-A by an ELISA or FACS.

Nunc™ brand 96-well immunoplates (Flow Lab, McLean, VA) were coated with 50 µl/well of 2 µg/mL IL8R-A synthetic peptide in phosphate buffered saline (PBS) overnight at 4°C. The remaining steps were carried out at room temperature as described by Kim et al., J. Imm. Methods., 156: 9 (1992). The isotypes of monoclonal antibodies were determined by coating the plates with IL8R-A

peptides overnight, blocked with 0.2% BSA, incubated with culture supernatants, followed by the addition of a predetermined amount of isotype-specific alkaline phosphatase-conjugated goat anti-mouse Ig (Fisher Biotech, Pittsburgh, PA). The level of conjugated antibodies that bound to the plate was determined by the addition of p-nitrophenyl phosphate substrate in carbonate buffer containing 1 mM of MgCl₂ (Sigma 104 phosphate substrate, Sigma, St. Louis, MO). The color reaction was measured at 405 nm with an ELISA plate reader (Titertrek multiscan, Flow Lab, McLean, VA).

Human neutrophils were prepared by using Mono-Poly Resolving medium (M-PRM) (Flow Lab, McLean, VA) according to the vendor's direction. Neutrophils or transfected cells were washed twice in the cell sorter buffer (CSB, PBS containing 1% FCS and 0.02% NaN₃) at 300 x g for 5 minutes. Twenty-five μ l of cells (4×10^6 cells/ml) were added into a 96-well U-bottom microtiter plate, mixed with 100 μ l of culture supernatant or purified monoclonal antibodies, and incubated for 30 min. on ice. After washing, cells were incubated with 100 μ l of FITC-conjugated goat-anti-mouse IgG antibodies for 30 min. at 4°C. Cells were washed twice in CSB and resuspended in 150 μ l of CSB and analyzed by a FCAScan™ assay (Becton-Dickinson).

The affinity of the monoclonal antibodies was determined by competitive inhibition of the binding of ¹²⁵I-monoclonal antibody to 293-71-transfected cells with various concentrations of unlabeled monoclonal antibodies. ¹²⁵I-monoclonal antibodies were prepared by using chloramine-T as described by Lee et al., *supra*. The specific activities of monoclonal antibodies 6C8, 6E9, 2A4, and 9H1 were 0.68 Ci/M, 0.74 Ci/M, 0.814 Ci/M, and 0.922 Ci/M, respectively. Fifty μ l of 293-17 (4×10^6 cells/ml) resuspended in Hank's buffered saline solution (HBSS) containing 0.5% BSA, were briefly incubated with 100 μ l of a fixed concentration of ¹²⁵I-monoclonal antibody plus 50 μ l of various concentrations of unlabeled monoclonal antibody for one hour at 4°C. The unbound ¹²⁵I-monoclonal antibody was

removed by centrifugation of the mixture over 0.5 ml of PBS containing 20% sucrose and 0.5% BSA at 1,500 rpm for five minutes. The ¹²⁵I-monoclonal antibody bound to the cell pellet was determined using a gamma counter. The affinity of each monoclonal antibody was determined by using Scatplot™ analysis. Munson and Rodbard, *Anal. Biochem.*, 107: 220 (1980).

The blocking ability of the monoclonal antibodies was determined by measuring their effects on the interaction of IL-8 with IL8R-A. Fifty μ l of human neutrophils or transfected cells (4×10^6 cells/ml) resuspended in the HBSS medium containing 0.5% BSA and 25 mM HEPES buffer were incubated with 50 μ l of monoclonal antibodies plus various concentrations of MGSA (0-0.5 nM) for one hour at 4°C. Cells were washed twice in the HBSS medium and resuspended to be 1×10^6 cells/ml. One hundred μ l of cells were incubated with 100 μ l of ¹²⁵I-IL-8 (1 Ci/M) for one hour at 4°C and the unbound ¹²⁵I-IL-8 was removed using 20% sucrose as described above. The ¹²⁵I-IL-8 bound to the cell pellets was counted using a gamma counter.

Results

General Characteristics of the antibodies.

For generation of monoclonal antibodies to IL8R-A, mice were immunized either with synthetic peptides corresponding to various extracellular domains of IL8R-A or with stably transfected cells expressing IL8R-A.

For the first approach, eight peptides were synthesized covering the extracellular domains of IL8R-A, residues 2-19 and 12-31 located within the N-terminal portion of IL8R-A, 99-110 within the first loop, 176-186 and 187-203 within the second loop, and 265-277 and 277-291 within the third loop as shown in Fig. 6. All of these peptides induced high-titer antibodies to each peptide in mice. However, only peptide 2-19 produced polyclonal antibodies that were able to recognize human neutrophils as well as 293-71-transfected cells expressing IL8R-A. The mice immunized with

peptide 2-19 were used to generate 36 hybridomas secreting monoclonal antibodies to peptide 2-19. Only two of these monoclonal antibodies (4C8 and 6E9) were able to recognize IL8R-A on 293-transfected cells and were selected for further

5 characterization.

In a second approach, mice were immunized with 293-71 cells producing IL8R-A (293-71). Positive antibody titers were detected only after the 16th immunization. These mice were used to obtain more than 60 positive hybridomas that secreted monoclonal 10 antibodies recognizing IL8R-A on 293-71 cells, as determined by FACS. Two out of 60 monoclonal antibodies, 2A4 and 9H1, were able to inhibit the binding of ^{125}I -IL-8 to its receptors and were chosen for further evaluation.

These four hybridomas secrete IgG1 immunoglobulin isotype (Table 2). Monoclonal antibodies 2A4 and 9H1, generated using transfected cells, have higher affinities than monoclonal antibodies 4C8 and 6E9, generated using peptides (Table 2). All four monoclonal antibodies were able to bind to human neutrophils and 293-71-transfected cells but not to 293 parent cells, as determined by FACS analysis (Figure 7). Thus, it was concluded that all these monoclonal antibodies were capable of recognizing native IL8R-A.

Table 2

5	Mab	Immunogen	Isotype	FACS Analysis		K _d (nM)
				293-71	Neutrophil	
	4C8	Peptide 2-19	IgG1	+	+	3.26
10	6E9	Peptide 2-19	IgG1	+	+	17.26
	2A4	293-71	IgG1	+	+	0.44
	9H1	293-71	IgG1	+	+	0.088

Cross reactivities to other related receptors.

It has been shown that IL-8 specific receptor, IL8R-A, shares 77% amino acid identity with IL8R-B, the common IL-8/MGSA receptor. For determining whether monoclonal antibodies generated to IL8R-A could recognize IL8R-B, 293 cells transfected with IL8R-B were stained and analyzed by FACS (Fig. 7). All four monoclonal antibodies stained the IL8R-A 293-transfected cells, but not the IL8R-B-transfected 293 cells. The inability of these monoclonal antibodies to bind to 293 cells expressing IL8R-B was not due to the lack of receptor expression, since the same level of ¹²⁵I-IL-8 was bound to IL8R-A expressing transfected cells, as well as to the IL8R-B expressing transfected cells.

Inhibition of IL-8 binding to IL8R-A.

The effect of the monoclonal antibodies on the binding of ¹²⁵I-IL-8 to the 293-71-transfected cells expressing IL8R-A (Fig. 8) was investigated. Monoclonal antibodies 2A4 and 9H1 could completely block the ¹²⁵I-IL-8 binding to the 293-71 cells, whereas monoclonal antibodies 4C8 and 6E9 showed very minimal effect.

It was further investigated whether monoclonal antibodies 2A4 and 9H1 could block IL-8 binding onto human neutrophils in the presence of various concentrations of MGSA, known to bind to IL8R-B. The addition of 475 pM of MGSA inhibited approximately 50% of IL-8 binding to human neutrophils (Fig. 8). In the presence of 475

pM of MGSA, monoclonal antibodies 2A4 and 9H1 could block up to 80% of the IL-8 binding to human neutrophils, while the control monoclonal antibody showed no further inhibition beyond that observed with MGSA alone. Thus, it was concluded that monoclonal 5 antibodies 2A4 and 9H1 could block the binding of IL-8 to IL8R-A on human neutrophils.

Epitope mapping of the IL8R-A specific monoclonal antibodies.

The epitopes recognized by these monoclonal antibodies were mapped by investigating the binding of these antibodies to synthetic peptides by ELISA (Fig. 9A and 9B) and alanine mutants of IL8R-A by FACS (Table 3). Surprisingly, both blocking and non-blocking monoclonal antibodies bound to the N-terminal peptide consisting of amino acids 2-19, but did not bind to other peptides covering different portions of extracellular loops of the receptor 15 (Fig. 9A).

The binding of monoclonal antibodies to shorter peptides consisting of residues 1-11 and 1-14 in ELISA is shown in Figure 9B. All four monoclonal antibodies bound well to peptide 1-14. However, the binding of the blocking monoclonal antibodies, 2A4 and 9H1, to peptide 1-11 was only 22% and 60% of the binding to peptide 2-19, respectively. In contrast, the binding of the non-blocking monoclonal antibodies 4C8 and 6E9 to peptide 1-11 was approximately 80% and 95% of the binding to peptide 2-19, respectively. From these results, it was concluded that epitopes of monoclonal antibodies 4C8 and 6E9 are localized within amino acids 2-11, while those of monoclonal antibodies 2A4 and 9H1 are localized within amino acids 2-14.

Table 3

Flow Cytometry Analysis of Antibodies with Cells Expressing Mutant IL-8 Type A Receptor

	<u>Amino Acid Position</u>	<u>Change From To</u>	<u>FACS Analysis</u>			
			<u>2A4</u>	<u>9H1</u>	<u>4C8</u>	<u>6E9</u>
5	6	D A	-	-	+	+
10	11	D A	++	++	+	+
	13-14	DD A	++	++	+	++
15	24-26	DED AAA	++	++	++	+

20 FACS Result: - (mean FL channel 0-10), + (Mean FL channel 10-100, ++ (Mean FL channel 100-1000).

25 A (Alanine), D (Aspartic acid), K (Lysine), E (Glutamic Acid)

30 The binding epitopes of these monoclonal antibodies were further investigated by analyzing their binding to IL8R-A mutants by FACS (Table 3). Neither monoclonal antibody 2A4 nor 9H1 could bind to the IL8R-A mutant when the aspartic acid at position 6 was substituted with alanine, suggesting Asp6 plays an important role in the binding of these blocking antibodies. This result further suggests that the conformation of the N-terminal end of the IL8R-A may play a role in the binding of these blocking monoclonal 35 antibodies.

Conclusion

40 IL-8 is a potent neutrophil chemotactic factor and has been implicated as a key mediator of neutrophil influx in many inflammatory diseases. IL-8 has been detected in many biological fluids from patients with a variety of acute and chronic inflammatory diseases such as arthritis, emphysema, cystic fibrosis, ulcerative colitis, chronic bronchitis, and

bronchiectasis. Koch et al., J. Immunol., 147: 2187-2195 (1991); Koch et al., Science, 258: 1798-1801 (1992); Terkeltaub et al., Arthr. and Rheum., 34: 894 (1991); Mahida et al., Clin. Science, 82: 273-275 (1992); Broaddus et al., Am. Rev. Resp., 146: 825 (1992). In vitro neutralization of the IL-8 in these biological fluids significantly reduces the overall chemotactic activity in the fluid. Further, the role of IL-8 is implicated in inflammatory conditions where the cellular infiltrate is predominantly neutrophil-rich, including gout, rheumatoid arthritis, adult respiratory distress syndrome, emphysema, glomerular nephritis, myocardial infarction, inflammatory bowel disease, and asthma. Lindley et al., Adv. Exp. Med., 305: 147-156 (1991). However, to what extent IL-8 contributes to inflammation *in vivo* has yet to be determined.

15 Various monoclonal antibodies directed against IL-8 have been defined, including those reported by Sticherling et al., J. Immunol., 143: 1628-1634 (1989).

20 It is anticipated that an antagonist to IL8R-A will be more effective in blocking the effect of IL-8 function *in vivo* than an antagonist to IL-8 for the following reasons: IL-8 is relatively long-lasting and resistant to proteases, possibly making it difficult to block IL-8 completely *in vivo*, the IL8R-A expression is dynamically regulated by the ligand itself, and the rapid recycling of IL-8 receptors may be essential for the chemotactic response of neutrophils and tissue damage during inflammation, caused by activated neutrophils. Thus, monoclonal antibodies to IL8R-A expressed on human neutrophils were generated with the ultimate goal of identifying neutralizing monoclonal antibodies that could be tested as receptor antagonists of various inflammation *in vivo* models.

25 30 The antibody responses to different extracellular portions of IL8R-A were induced using several synthetic peptides covering the extracellular domains of IL8R-A or IL8R-A-transfected cells as

immunogens. Both methods of immunization allowed generation of monoclonal antibodies recognizing IL8R-A on human neutrophils (Figure 6). It was much harder to generate monoclonal antibodies specific for IL8R-A by using transfected cells as an immunogen; however, monoclonal antibodies generated using transfected cells tended to have higher affinities to IL8R-A and showed blocking activities.

Polyclonal antibody responses were able to be induced to all seven peptides covering the extracellular domains of IL8R-A, residues 2-19, 12-31, 99-110, 176-186, 187-203, 265-277, and 277-291. However, only the polyclonal antibodies to peptide 2-19 recognize IL8R-A on cells. This suggests that the N-terminal amino acids may be the most immunogenic or that the most likely immunogenic sites have conformational epitopes.

A 77% sequence identity between IL8R-A and IL8R-B was reported by Holmes *et al.*, *supra*; however, the antibodies herein were specific for IL8R-A. IL8R-A does not recognize IL-1, TNF- α , MCAF, fMLP, C5 α , PAF, and LTB4, but does recognize two other members of the C-X-C family, namely, MGSA and NAP-2. Holmes *et al.*, *supra*. A recent study shows that both receptors bind IL-8 equally well with a high affinity but differ in their affinity to MGSA. Murphy and Tiffany, *supra*. Monoclonal antibodies 2A4 and 9H1 block 100% of the IL-8 binding to transfected 293 cells, 35-40% of the IL-8 binding to human neutrophils, and approximately 80% of IL-8 binding to human neutrophils in the presence of MGSA, which presumably blocked IL-8 binding to IL8R-B. Thus, the blocking monoclonal antibodies herein interfere with the interaction between IL-8 and IL8R-A, but not with the interaction between IL-8 and IL8R-B. Both monoclonal antibodies 4C8 and 6E9 showed no blocking activities in IL-8 binding to both transfected cells and human neutrophils.

The finding that both blocking and non-blocking monoclonal antibodies bind to the N-terminal amino acid residues 1-14 (Fig. 9A) is consistent with the report that the N-terminal amino acid

sequence of IL8R-A plays an important role in interacting with IL-8. Gayle et al., J. Biol. Chem., 268: 7283-7289 (1993). Further epitope mapping analysis showed some differences in the binding characteristics between blocking and non-blocking monoclonal antibodies. The epitopes of blocking monoclonal antibodies 2A4 and 9H1 were mapped within residues 2-14 of the receptor, while those of non-blocking monoclonal antibodies 4C8 and 6E9 were within 2-11 amino acid residues. The binding study using various alanine mutants shows that the aspartic acid at position 6 plays an important role in the binding of the blocking monoclonal antibodies, but not of the non-blocking monoclonal antibodies. This suggests that this negatively charged aspartic acid may be located at (or near to) the binding site of IL-8. It has been shown that positively charged IL-8 residues E₄, L₅, R₆ are essential for IL-8 binding to its receptors on human neutrophils by alanine-scanning mutagenesis (Hébert et al., J. Biol. Chem., 266: 18989-18994 [1991]) and synthesis of N-terminal truncated variants (Clark-Lewis et al., J. Biol. Chem., 266: 23128-23134 [1991]; Moser et al., J. Biol. Chem., 268: 7125-7128 [1993]). Without being limited to any one theory, it is believed that the negatively charged amino acid at position 6 in IL8R-A is in a direct or close interaction with the positively charged amino acids, E₄, L₅, R₆ in IL-8, so that the binding of blocking monoclonal antibodies is influenced by the tertiary structure of the receptor.

The N-terminal portion and the second extracellular portion of the IL8R-A appears to be highly glycosylated, especially within amino acids 2-19 of the receptor, where there are six potential glycosylation sites (Fig. 6). However, all of the monoclonal antibodies herein, whether generated by immunization of synthetic peptides or of transfected cells, bound to the synthetic peptide covering amino acids 1-14. This suggests that carbohydrates may not play an important role in the binding of these monoclonal antibodies.

EXAMPLE 4

IL-8 was found to be present at high concentration and is the major neutrophil chemotactic factor in sputum from patients with chronic bronchitis, bronchiectasis, and cystic fibrosis. Figure 10 shows the concentration of IL-8 in sputum from patients with chronic airway diseases and in sputum induced from healthy patients.

An ELISA is developed to measure rabbit IL-8 concentration using a double monoclonal antibody technique where one antibody is used as the coat and the other is the biotinylated detection antibody. In the assay buffer the sensitivity is < 12 pg/ml (linear range 12-1000 pg/ml). In 10% rabbit serum the sensitivity is 14 pg/ml (linear range 14-1000 pg/ml).

One of the two antibodies 2A4 and 9H1 described above is injected intravenously every two weeks in a dose of 1-15 mg/kg in patients having either asthma, chronic bronchitis, bronchiectesis, rheumatoid arthritis, or ulcerative colitis. For treating an acute indication, adult respiratory distress syndrome, a dose of 10-100 mg/kg of either one of the antibodies is injected a single time intravenously. It would be expected that the anti-IL8R-A antibodies that block IL8R-A activity (MAbs 2A4 and 9H1) would be effective in reducing the inflammation associated with each of the disorders described above. The antibodies are also expected to be efficacious in treating human pleurisy, vasculitis, alveolitis, and pneumonia.

Deposit of Materials

The following hybridomas have been deposited with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD, USA (ATCC):

<u>Cell Lines</u>	<u>ATCC Accession No.</u>	<u>Deposit Date</u>
2A4	HB 11377	June 8, 1993
9H1	HB 11376	June 8, 1993

These deposits were made under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations thereunder (Budapest Treaty). This assures maintenance
5 of a viable deposit for 30 years from the date of deposit. These cell lines will be made available by ATCC under the terms of the Budapest Treaty, and subject to an agreement between Genentech, Inc. and ATCC, which assures permanent and unrestricted availability of the cell lines to the public upon issuance of the
10 pertinent U.S. patent or upon laying open to the public of any U.S. or foreign patent application, whichever comes first, and assures availability of the cell lines to one determined by the U.S. Commissioner of Patents and Trademarks to be entitled thereto according to 35 USC §122 and the Commissioner's rules pursuant thereto (including 37 CFR §1.14 with particular reference to 886 OG 638).

The assignee of the present application has agreed that if the deposited cell lines should be lost or destroyed when cultivated under suitable conditions, they will be promptly replaced on notification with a specimen of the same cell line. Availability of the deposited cell lines is not to be construed as a license to practice the invention in contravention of the rights granted under the authority of any government in accordance with its patent laws.

The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by the cell lines deposited, since the deposited embodiments are intended as illustrations of one aspect of the invention and any cell lines that are functionally equivalent are within the scope of this invention. The deposit of material herein does not constitute an admission that the written description herein contained is inadequate to enable the practice of any aspect of the invention, including the best mode thereof, nor is it to be construed as

limiting the scope of the claims to the specific illustrations that it represents. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall
5 within the scope of the appended claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

5 (i) APPLICANT: Chuntharapai, Anan
Lee, James
Hebert, Caroline
K. Jin Kim

10 (ii) TITLE OF INVENTION: Antibodies to Human PF4A Receptors

(iii) NUMBER OF SEQUENCES: 3

15 (iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Genentech, Inc.
(B) STREET: 460 Point San Bruno Blvd
(C) CITY: South San Francisco
(D) STATE: California
(E) COUNTRY: USA
20 (F) ZIP: 94080

25 (v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: patin (Genentech)

30 (vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:
(B) FILING DATE: 11-JUN-1993
(C) CLASSIFICATION:

35 (vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: 07/810
(B) FILING DATE: 19-DEC-1991

40 (vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: 782
(B) FILING DATE: 29-MAR-1991

45 (vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: 07/677
(B) FILING DATE: (null)

50 (vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: 211
(B) FILING DATE: (null)

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Hasak, Janet E.

(B) REGISTRATION NUMBER: 28,616
(C) REFERENCE/DOCKET NUMBER: 706P2

5 (ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 415/225-1896
(B) TELEFAX: 415/952-9881
(C) TELEX: 910/371-7168

10 (2) INFORMATION FOR SEQ ID NO:1:

15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1933 bases
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

25 CCTGGCCGGT GCTTCAGTTA GATCAAACCA TTGCTGAAAC TGAAGAGGAC 50

30 ATG TCA AAT ATT ACA GAT CCA CAG ATG TGG GAT TTT 86
Met Ser Asn Ile Thr Asp Pro Gln Met Trp Asp Phe
1 5 10

35 GAT GAT CTA AAT TTC ACT GGC ATG CCA CCT GCA GAT GAA 125
Asp Asp Leu Asn Phe Thr Gly Met Pro Pro Ala Asp Glu
15 20 25

40 GAT TAC AGC CCC TGT ATG CTA GAA ACT GAG ACA CTC AAC 164
Asp Tyr Ser Pro Cys Met Leu Glu Thr Glu Thr Leu Asn
30 35

45 AAG TAT GTT GTG ATC ATC GCC TAT GCC CTA GTG TTC CTG 203
Lys Tyr Val Val Ile Ile Ala Tyr Ala Leu Val Phe Leu
40 45 50

50 CTG AGC CTG CTG GGA AAC TCC CTG GTG ATG CTG GTC ATC 242
Leu Ser Leu Leu Gly Asn Ser Leu Val Met Leu Val Ile
55 60

55 TTA TAC AGC AGG GTC GGC CGC TCC GTC ACT GAT GTC TAC 281
Leu Tyr Ser Arg Val Gly Arg Ser Val Thr Asp Val Tyr
65 70 75

60 CTG CTG AAC CTG GCC TTG GCC GAC CTA CTC TTT GCC CTG 320
Leu Leu Asn Leu Ala Leu Ala Asp Leu Leu Phe Ala Leu
80 85 90

ACC TTG CCC ATC TGG GCC GCC TCC AAG GTG AAT GGC TGG 359
 Thr Leu Pro Ile Trp Ala Ala Ser Lys Val Asn Gly Trp
 95 100

5 ATT TTT GGC ACA TTC CTG TGC AAG GTG GTC TCA CTC CTG 398
 Ile Phe Gly Thr Phe Leu Cys Lys Val Val Ser Leu Leu
 105 110 115

10 AAG GAA GTC AAC TTC TAC AGT GGC ATC CTG CTG TTG GCC 437
 Lys Glu Val Asn Phe Tyr Ser Gly Ile Leu Leu Leu Ala
 120 125

15 TGC ATC AGT GTG GAC CGT TAC CTG GCC ATT GTC CAT GCC 476
 Cys Ile Ser Val Asp Arg Tyr Leu Ala Ile Val His Ala
 130 135 140

ACA CGC ACA CTG ACC CAG AAG CGT CAC TTG GTC AAG TTT 515
 Thr Arg Thr Leu Thr Gln Lys Arg His Leu Val Lys Phe
 145 150 155

20 GTT TGT CTT GGC TGC TGG GGA CTG TCT ATG AAT CTG TCC 554
 Val Cys Leu Gly Cys Trp Gly Leu Ser Met Asn Leu Ser
 160 165

25 CTG CCC TTC TTC CTT TTC CGC CAG GCT TAC CAT CCA AAC 593
 Leu Pro Phe Phe Leu Phe Arg Gln Ala Tyr His Pro Asn
 170 175 180

30 AAT TCC AGT CCA GTT TGC TAT GAG GTC CTG GGA AAT GAC 632
 Asn Ser Ser Pro Val Cys Tyr Glu Val Leu Gly Asn Asp
 185 190

35 ACA GCA AAA TGG CGG ATG GTG TTG CGG ATC CTG CCT CAC 671
 Thr Ala Lys Trp Arg Met Val Leu Arg Ile Leu Pro His
 195 200 205

40 ACC TTT GGC TTC ATC GTG CCG CTG TTT GTC ATG CTG TTC 710
 Thr Phe Gly Phe Ile Val Pro Leu Phe Val Met Leu Phe
 210 215 220

TGC TAT GGA TTC ACC CTG CGT ACA CTG TTT AAG GCC CAC 749
 Cys Tyr Gly Phe Thr Leu Arg Thr Leu Phe Lys Ala His
 225 230

45 ATG GGG CAG AAG CAC CGA GCC ATG AGG GTC ATC TTT GCT 788
 Met Gly Gln Lys His Arg Ala Met Arg Val Ile Phe Ala
 235 240 245

50 GTC GTC CTC ATC TTC CTG CTT TGC TGG CTG CCC TAC AAC 827
 Val Val Leu Ile Phe Leu Leu Cys Trp Leu Pro Tyr Asn

250

255

CTG GTC CTG CTG GCA GAC ACC CTC ATG AGG ACC CAG GTG 866
 Leu Val Leu Leu Ala Asp Thr Leu Met Arg Thr Gln Val
 5 260 265 270

ATC CAG GAG ACC TGT GAG CGC CGC AAC AAC ATC GGC CGG 905
 Ile Gln Glu Thr Cys Glu Arg Arg Asn Asn Ile Gly Arg
 10 275 280 285

GCC CTG GAT GCC ACT GAG ATT CTG GGA TTT CTC CAT AGC 944
 Ala Leu Asp Ala Thr Glu Ile Leu Gly Phe Leu His Ser
 290 295

TGC CTC AAC CCC ATC ATC TAC GCC TTC ATC GGC CAA AAT 983
 Cys Leu Asn Pro Ile Ile Tyr Ala Phe Ile Gly Gln Asn
 15 300 305 310

TTT CGC CAT GGA TTC CTC AAG ATC CTG GCT ATG CAT GGC 1022
 Phe Arg His Gly Phe Leu Lys Ile Leu Ala Met His Gly
 20 315 320

CTG GTC AGC AAG GAG TTC TTG GCA CGT CAT CGT GTT ACC 1061
 Leu Val Ser Lys Glu Phe Leu Ala Arg His Arg Val Thr
 25 325 330 335

TCC TAC ACT TCT TCG TCT GTC AAT GTC TCT TCC AAC CTC 1100
 Ser Tyr Thr Ser Ser Val Asn Val Ser Ser Asn Leu
 30 340 345 350

TGAAAACCAT CGATGAAGGA ATATCTCTTC TCAGAAGGAA AGAATAACCA 1150

ACACCCCTGAG GTTGTGTGTG GAAGGTGATC TGGCTCTGGA CAGGCACTAT 1200

CTGGGTTTTG GGGGGACGCT ATAGGATGTG GGGAAAGTTAG GAACTGGTGT 1250

40 CTTCAGGGGC CACACCAACC TTCTGAGGAG CTGTTGAGGT ACCTCCAAGG 1300

ACCGGCCTT GCACCTCCAT GGAAACGAAG CACCATCATT CCCGTTGAAC 1350

45 GTCACATCTT TAACCCACTA ACTGGCTAAT TAGCATGGCC ACATCTGAGC 1400

CCCGAATCTG ACATTAGATG AGAGAACAGG GCTGAAGCTG TGTCTCATG 1450

50

AGGGCTGGAT GCTCTCGTTG ACCCTCACAG GAGCATCTCC TCAACTCTGA 1500

GTGTTAACGCG TTGAGCCACC AAGCTGGTGG CTCTGTGTGC TCTGATCCGA 1550

5

GCTCAGGGGG GTGGTTTCAC CATCTCAGGT GTGTTGCAGT GTCTGCTGGA 1600

10

GACATTGAGG CAGGCAGTGC CAAACATCA ACCTGCCAGC TGGCCTTGTG 1650

AGGAGCTGGA AACACATGTT CCCCTGGGG GTGGTGGATG AACAAAGAGA 1700

15

AAGAGGGTTT GGAAGCCAGA TCTATGCCAC AAGAACCCCC TTTACCCCCA 1750

TGACCAACAT CGCAGACACA TGTGCTGGCC ACCTGCTGAG CCCCAAGTGG 1800

20

AACGAGACAA GCAGCCCTTA GCCCTTCCCC TCTGCAGCTT CCAGGCTGGC 1850

GTGCAGCATH AGCATCCCTA GAAAGCCATG TGCAGCCACC AGTCCATTGG 1900

GCAGGCAGAT GTTCCTAATA AAGCTTCTGT TCC 1933

30

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1737 bases
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

GAATTCCAGT GTGCTGGCGG CGCGCGCAA AGTGACGCCG AGGGCCTGAG 50

45

TGCTCCAGTA GCCACCGCAT CTGGAGAACCC AGCGGTTACC ATG GAG 96
Met Glu
1

50

GGG ATC AGT ATA TAC ACT TCA GAT AAC TAC ACC GAG GAA 135

	Gly Ile Ser Ile Tyr Thr Ser Asp Asn Tyr Thr Glu Glu	
	5 10 15	
5	ATG GGC TCA GGG GAC TAT GAC TCC ATG AAG GAA CCC TGT 174	
	Met Gly Ser Gly Asp Tyr Asp Ser Met Lys Glu Pro Cys	
	20 25	
10	TTC CGT GAA GAA AAT GCT AAT TTC AAT AAA ATC TTC CTG 213	
	Phe Arg Glu Glu Asn Ala Asn Phe Asn Lys Ile Phe Leu	
	30 35 40	
15	CCC ACC ATC TAC TCC ATC ATC TTC TTA ACT GGC ATT GTG 252	
	Pro Thr Ile Tyr Ser Ile Ile Phe Leu Thr Gly Ile Val	
	45 50	
20	GGC AAT GGA TTG GTC ATC CTG GTC ATG GGT TAC CAG AAG 291	
	Gly Asn Gly Leu Val Ile Leu Val Met Gly Tyr Gln Lys	
	55 60 65	
25	AAA CTG AGA AGC ATG ACG GAC AAG TAC AGG CTG CAC CTG 330	
	Lys Leu Arg Ser Met Thr Asp Lys Tyr Arg Leu His Leu	
	70 75 80	
30	TCA GTG GCC GAC CTC CTC TTT GTC ATC ACG CTT CCC TTC 369	
	Ser Val Ala Asp Leu Leu Phe Val Ile Thr Leu Pro Phe	
	85 90	
35	TGG GCA GTT GAT GCC GTG GCA AAC TGG TAC TTT GGG AAC 408	
	Trp Ala Val Asp Ala Val Ala Asn Trp Tyr Phe Gly Asn	
	95 100 105	
40	TTC CTA TGC AAG GCA GTC CAT GTC ATC TAC ACA GTC AAC 447	
	Phe Leu Cys Lys Ala Val His Val Ile Tyr Thr Val Asn	
	110 115	
45	CTC TAC AGC AGT GTC CTC ATC CTG GCC TTC ATC AGT CTG 486	
	Leu Tyr Ser Ser Val Leu Ile Leu Ala Phe Ile Ser Leu	
	120 125 130	
50	GAC CGC TAC CTG GCC ATC GTC CAC GCC ACC AAC AGT CAG 525	
	Asp Arg Tyr Leu Ala Ile Val His Ala Thr Asn Ser Gln	
	135 140 145	
55	AGG CCA AGG AAG CTG TTG GCT GAA AAG GTG GTC TAT GTT 564	
	Arg Pro Arg Lys Leu Leu Ala Glu Lys Val Val Tyr Val	
	150 155	
60	GGC GTC TGG ATC CCT GCC CTC CTG CTG ACT ATT CCC GAC 603	
	Gly Val Trp Ile Pro Ala Leu Leu Leu Thr Ile Pro Asp	
	160 165 170	

TTC ATC TTT GCC AAC GTC AGT GAG GCA GAT GAC AGA TAT 642
 Phe Ile Phe Ala Asn Val Ser Glu Ala Asp Asp Arg Tyr
 175 180

5 ATC TGT GAC CGC TTC TAC CCC AAT GAC TTG TGG GTG GTT 681
 Ile Cys Asp Arg Phe Tyr Pro Asn Asp Leu Trp Val Val
 185 190 195

10 GTG TTC CAG TTT CAG CAC ATC ATG GTT GGC CTT ATC CTG 720
 Val Phe Gln Phe Gln His Ile Met Val Gly Leu Ile Leu
 200 205 210

CCT GGT ATT GTC ATC CTG TCC TGC TAT TGC ATT ATC ATC 759
 Pro Gly Ile Val Ile Leu Ser Cys Tyr Cys Ile Ile Ile
 15 215 220

TCC AAG CTG TCA CAC TCC AAG GGC CAC CAG AAG CGC AAG 798
 Ser Lys Leu Ser His Ser Lys Gly His Gln Lys Arg Lys
 225 230 235

20 GCC CTC AAG ACC ACA GTC ATC CTC ATC CTG GCT TTC TTC 837
 Ala Leu Lys Thr Thr Val Ile Leu Ile Leu Ala Phe Phe
 240 245

25 GCC TGT TGG CTG CCT TAC TAC ATT GGG ATC AGC ATC GAC 876
 Ala Cys Trp Leu Pro Tyr Tyr Ile Gly Ile Ser Ile Asp
 250 255 260

30 TCC TTC ATC CTC CTG GAA ATC ATC AAG CAA GGG TGT GAG 915
 Ser Phe Ile Leu Leu Glu Ile Ile Lys Gln Gly Cys Glu
 265 270 275

35 TTT GAG AAC ACT GTG CAC AAG TGG ATT TCC ATC ACC GAG 954
 Phe Glu Asn Thr Val His Lys Trp Ile Ser Ile Thr Glu
 280 285

40 GCC CTA GCT TTC TTC CAC TGT TGT CTG AAC CCC ATC CTC 993
 Ala Leu Ala Phe Phe His Cys Cys Leu Asn Pro Ile Leu
 290 295 300

TAT GCT TTC CTT GGA GCC AAA TTT AAA ACC TCT GCC CAG 1032
 Tyr Ala Phe Leu Gly Ala Lys Phe Lys Thr Ser Ala Gln
 305 310

45 CAC GCA CTC ACC TCT GTG AGC AGA GGG TCC AGC CTC AAG 1071
 His Ala Leu Thr Ser Val Ser Arg Gly Ser Ser Leu Lys
 315 320 325

50 ATC CTC TCC AAA GGA AAG CGA GGT GGA CAT TCA TCT GTT 1110
 Ile Leu Ser Lys Gly Lys Arg Gly Gly His Ser Ser Val

330

335

340

TCC ACT GAG TCT GAG TCT TCA AGT TTT CAC TCC AGC TAAC 1150
Ser Thr Glu Ser Glu Ser Ser Phe His Ser Ser

5 345 350 352

ACAGATGTAA AAGACTTTTT TTTATACGAT AAATAACTTT TTTTTAAGTT 1200

10 ACACATTTTT CAGATATAAA AGACTGACCA ATATTGTACA GTTTTTATTG 1250

CTTGGTGGAT TTTTGTCTTG TGTTTCTTTA GTTTTGTGA AGTTTAATTG 1300

15 ACTTATTTAT ATAAATTTTT TTTGTTTCAT ATTGATGTGT GTCTAGGCAG 1350

20 GACCTGTGGC CAAGTTCTTA GTTGCTGTAT GTCTCGTGGT AGGACTGTAG 1400

AAAAGGGAAC TGAACATTCC AGAGCGTGTGA GTGAATCACG TAAAGCTAGA 1450

25 AATGATCCCC AGCTGTTTAT GCATAGATAA TCTCTCCATT CCCGTGGAAC 1500

GTTTTTCCTG TTCTTAAGAC GTGATTTCGC TGTAGAAGAT GGCACTTATA 1550

30 ACCAAAGCCC AAAGTGGTAT AGAAATGCTG GTTTTCAGT TTTCAGGAGT 1600

GGGTTGATTT CAGCACCTAC AGTGTACAGT CTTGTATTAA GTTGTAAATA 1650

35 AAAGTACATG TTAAACTTAA AAAAAAAA AAAAAAAA AAAAAAAA 1700

40 AAAAAAAA AAAGCGGCCG CCAGCACACT GGAATTG 1737

(2) INFORMATION FOR SEQ ID NO:3:

- 45 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1679 bases
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
50 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GAATTCCAGT GTGCTGGCGG CCGCCCAGTG TGCTGGCGGC GGCAGTTGAG 50
 5
 GGAAAGGACA GAGGTTATGA GTGCCTGCAA GAGTGGCAGC CTGGAGTAGA 100
 10 GAAAACACTA AAGGTGGAGT CAAAAGACCT GAGTTCAAGT CCCAGCTCTG 150
 CCACTGGTTA GCTGTGGGAT CTCGGAAAAG ACCCAGTGAA AAAAAAAA 200
 15 AAAGTGATGA GTTGTGAGGC AGGTCGCGGC CCTACTGCCT CAGGAGACGA 250
 TGCGCAGCTC ATTTGCTTAA ATTTGCAGCT GACGGCTGCC ACCTCTCTAG 300
 20 AGGCACCTGG CGGGGAGCCT CTCAACATAA GACAGTGACC AGTCTGGTGA 350
 25 CTCACAGCCG GCACAGCC ATG AAC TAC CCG CTA ACG CTG GAA 392
 Met Asn Tyr Pro Leu Thr Leu Glu
 1 5
 30 ATG GAC CTC GAG AAC CTG GAG GAC CTG TTC TGG GAA CTG 431
 Met Asp Leu Glu Asn Leu Glu Asp Leu Phe Trp Glu Leu
 10 15 20
 35 GAC AGA TTG GAC AAC TAT AAC GAC ACC TCC CTG GTG GAA 470
 Asp Arg Leu Asp Asn Tyr Asn Asp Thr Ser Leu Val Glu
 25 30
 40 AAT CAT CTC TGC CCT GCC ACA GAG GGG CCC CTC ATG GCC 509
 Asn His Leu Cys Pro Ala Thr Glu Gly Pro Leu Met Ala
 35 40 45
 45 TCC TTC AAG GCC GTG TTC GTG CCC GTG GCC TAC AGC CTC 548
 Ser Phe Lys Ala Val Phe Val Pro Val Ala Tyr Ser Leu
 50 55 60
 50 ATC TTC CTC CTG GGC GTG ATC GGC AAC GTC CTG GTG CTG 587
 Ile Phe Leu Leu Gly Val Ile Gly Asn Val Leu Val Leu
 65 70
 GTG ATC CTG GAG CGG CAC CGG CAG ACA CGC AGT TCC ACG 626
 Val Ile Leu Glu Arg His Arg Gln Thr Arg Ser Ser Thr

75

80

85

GAG ACC TTC CTG TTC CAC CTG GCC GTG GCC GAC CTC CTG 665
 Glu Thr Phe Leu Phe His Leu Ala Val Ala Asp Leu Leu

5 90 95

CTG GTC TTC ATC TTG CCC TTT GCC GTG GCC GAG GGC TCT 704
 Leu Val Phe Ile Leu Pro Phe Ala Val Ala Glu Gly Ser
 100 105 110

10 GTG GGC TGG GTC CTG GGG ACC TTC CTC TGC AAA ACT GTG 743
 Val Gly Trp Val Leu Gly Thr Phe Leu Cys Lys Thr Val
 115 120 125

15 ATT GCC CTG CAC AAA GTC AAC TTC TAC TGC AGC AGC CTG 782
 Ile Ala Leu His Lys Val Asn Phe Tyr Cys Ser Ser Leu
 130 135

20 CTC CTG GCC TGC ATC GCC GTG GAC CGC TAC CTG GCC ATT 821
 Leu Leu Ala Cys Ile Ala Val Asp Arg Tyr Leu Ala Ile
 140 145 150

25 GTC CAC GCC GTC CAT GCC TAC CGC CAC CGC CGC CTC CTC 860
 Val His Ala Val His Ala Tyr Arg His Arg Arg Leu Leu
 155 160

30 TCC ATC CAC ATC ACC TGT GGG ACC ATC TGG CTG GTG GGC 899
 Ser Ile His Ile Thr Cys Gly Thr Ile Trp Leu Val Gly
 165 170 175

35 TTC CTC CTT GCC TTG CCA GAG ATT CTC TTC GCC AAA GTC 938
 Phe Leu Leu Ala Leu Pro Glu Ile Leu Phe Ala Lys Val
 180 185 190

40 AGC CAA GGC CAT CAC AAC AAC TCC CTG CCA CGT TGC ACC 977
 Ser Gln Gly His His Asn Asn Ser Leu Pro Arg Cys Thr
 195 200

45 TTC TCC CAA GAG AAC CAA GCA GAA ACG CAT GCC TGG TTC 1016
 Phe Ser Gln Glu Asn Gln Ala Glu Thr His Ala Trp Phe
 205 210 215

50 ACC TCC CGA TTC CTC TAC CAT GTG GCG GGA TTC CTG CTG 1055
 Thr Ser Arg Phe Leu Tyr His Val Ala Gly Phe Leu Leu
 220 225

CCC ATG CTG GTG ATG GGC TGG TGC TAC GTG GGG GTA GTG 1094
 Pro Met Leu Val Met Gly Trp Cys Tyr Val Gly Val Val
 230 235 240

50

CAC AGG TTG CGC CAG GCC CAG CGG CGC CCT CAG CGG CAG 1133
 His Arg Leu Arg Gln Ala Gln Arg Arg Pro Gln Arg Gln
 245 250 255

5 AAG GCA GTC AGG GTG GCC ATC CTG GTG ACA AGC ATC TTC 1172
 Lys Ala Val Arg Val Ala Ile Leu Val Thr Ser Ile Phe
 260 265

10 TTC CTC TGC TGG TCA CCC TAC CAC ATC GTC ATC TTC CTG 1211
 Phe Leu Cys Trp Ser Pro Tyr His Ile Val Ile Phe Leu
 270 275 280

15 GAC ACC CTG GCG AGG CTG AAG GCC GTG GAC AAT ACC TGC 1250
 Asp Thr Leu Ala Arg Leu Lys Ala Val Asp Asn Thr Cys
 285 290

20 AAG CTG AAT GGC TCT CTC CCC GTG GCC ATC ACC ATG TGT 1289
 Lys Leu Asn Gly Ser Leu Pro Val Ala Ile Thr Met Cys
 295 300 305

25 GAG TTC CTG GGC CTG GCC CAC TGC TGC CTC AAC CCC ATG 1328
 Glu Phe Leu Gly Leu Ala His Cys Cys Leu Asn Pro Met
 310 315 320

30 CTC TAC ACT TTC GCC GGC GTG AAG TTC CGC AGT GAC CTG 1367
 Leu Tyr Thr Phe Ala Gly Val Lys Phe Arg Ser Asp Leu
 325 330

35 TCG CGG CTC CTG ACG AAG CTG GGC TGT ACC GGC CCT GCC 1406
 Ser Arg Leu Leu Thr Lys Leu Gly Cys Thr Gly Pro Ala
 335 340 345

40 TCC CTG TGC CAG CTC TTC CCT AGC TGG CGC AGG AGC AGT 1445
 Ser Leu Cys Gln Leu Phe Pro Ser Trp Arg Arg Ser Ser
 350 355

45 CTC TCT GAG TCA GAG AAT GCC ACC TCT CTC ACC ACG TTC TA 1486
 Leu Ser Glu Ser Glu Asn Ala Thr Ser Leu Thr Thr Phe
 360 365 370 372

50 GGTC CCAGTGTCCC CTTTTATTGC TGCTTTCCCT TGGGGCAGGC 1530

AGTGATGCTG GATGCTCCTT CCAACAGGAG CTGGGATCCT AAGGGCTCAC 1580

CGTGGCTAAG AGTGTCTTAG GAGTATCCTC ATTTGGGGTA GCTAGAGGAA 1630

CCAACCCCCA TTTCTAGAAC ATCCCGCGGC CGCCAGCACA CTGGAATTC 1679

WHAT IS CLAIMED IS:

1. An antibody that is capable of binding a PF4AR polypeptide.
2. The antibody of claim 1 that does not cross-react with a receptor capable of binding another PF4 superfamily member.
3. The antibody of claim 1 wherein the PF4AR polypeptide is an IL-8 receptor.
4. The antibody of claim 3 wherein the PF4AR polypeptide is an IL-8 type A receptor.
5. The antibody of claim 4 that is a monoclonal antibody.
6. The antibody of claim 4 that has the isotype IgG1.
7. The antibody of claim 1 that neutralizes the activity of a PF4AR polypeptide.
8. The antibody of claim 4 that neutralizes the activity of an IL-8 type A receptor.
9. The antibody of claim 8 that is a monoclonal antibody designated 2A4, having ATCC Deposit No. 11377.
10. The antibody of claim 8 that is a monoclonal antibody designated 9H1, having ATCC Deposit No. 11376.
11. A composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.

12. A composition comprising the antibody of claim 4 and a pharmaceutically acceptable carrier.
13. A composition comprising the antibody of claim 8 and a pharmaceutically acceptable carrier.
14. A method for treating an inflammatory disorder comprising administering to a mammal in need of such treatment an effective amount of the composition of claim 11.
15. The method of claim 14 wherein the mammal is a human.
16. The method of claim 14 wherein the disorder is an inflammatory bowel disease or a chronic inflammation of the lung.
17. The method of claim 14 wherein the composition is administered systemically.
18. A method for treating an inflammatory disorder comprising administering to a mammal in need of such treatment an effective amount of the composition of claim 12.
19. A method for treating an inflammatory disorder comprising administering to a mammal in need of such treatment an effective amount of the composition of claim 13.

ANTIBODIES TO HUMAN PF4A RECEPTOR

5

Abstract of the Disclosure

10 cDNAs encoding a class of receptors, including the IL-8 receptors, have been identified in human tissue. Recombinantly produced PF4ARs are used in the preparation and purification of antibodies capable of binding to the receptors, and in diagnostic assays. The antibodies are advantageously used in the prevention and treatment of inflammatory conditions.

15
© 1994 Lexis. All rights reserved. Lexis is a registered trademark of Lexis-Nexis, Inc.





Figure 1

ATG TCA AAT ATT ACA GAT CCA CAG ATG TGG GAT TTT 86
 Met Ser Asn Ile Thr Asp Pro Gln Met Trp Asp Phe
 1 5 10

5

GAT GAT CTA AAT TTC ACT GGC ATG CCA CCT GCA GAT GAA 125
 Asp Asp Leu Asn Phe Thr Gly Met Pro Pro Ala Asp Glu
 15 20 25

10

GAT TAC AGC CCC TGT ATG CTA GAA ACT GAG ACA CTC AAC 164
 Asp Tyr Ser Pro Cys Met Leu Glu Thr Glu Thr Leu Asn
 30 35

15

AAG TAT GTT GTG ATC ATC GCC TAT GCC CTA GTG TTC CTG 203
 Lys Tyr Val Val Ile Ile Ala Tyr Ala Leu Val Phe Leu
 40 45 50

20

CTG AGC CTG CTG GGA AAC TCC CTG GTG ATG CTG GTC ATC 242
 Leu Ser Leu Leu Gly Asn Ser Leu Val Met Leu Val Ile
 55 60

25

TTA TAC AGC AGG GTC GGC CGC TCC GTC ACT GAT GTC TAC 281
 Leu Tyr Ser Arg Val Gly Arg Ser Val Thr Asp Val Tyr
 65 70 75

30

CTG CTG AAC CTG GCC TTG GCC GAC CTA CTC TTT GCC CTG 320
 Leu Leu Asn Leu Ala Leu Ala Asp Leu Leu Phe Ala Leu
 80 85 90

35

ACC TTG CCC ATC TGG GCC GCC TCC AAG GTG AAT GGC TGG 359
 Thr Leu Pro Ile Trp Ala Ala Ser Lys Val Asn Gly Trp
 95 100

40

ATT TTT GGC ACA TTC CTG TGC AAG GTG GTC TCA CTC CTG 398
 Ile Phe Gly Thr Phe Leu Cys Lys Val Val Ser Leu Leu
 105 110 115

45

AAG GAA GTC AAC TTC TAC AGT GGC ATC CTG CTG TTG GCC 437
 Lys Glu Val Asn Phe Tyr Ser Gly Ile Leu Leu Leu Ala
 120 125

50

TGC ATC AGT GTG GAC CGT TAC CTG GCC ATT GTC CAT GCC 476
 Cys Ile Ser Val Asp Arg Tyr Leu Ala Ile Val His Ala
 130 135 140

55

ACA CGC ACA CTG ACC CAG AAG CGT CAC TTG GTC AAG TTT 515
 Thr Arg Thr Leu Thr Gln Lys Arg His Leu Val Lys Phe
 145 150 155

60

GTT TGT CTT GGC TGC TGG GGA CTG TCT ATG AAT CTG TCC 554
 Val Cys Leu Gly Cys Trp Gly Leu Ser Met Asn Leu Ser
 160 165

65

CTG CCC TTC TTC CTT TTC CGC CAG GCT TAC CAT CCA AAC 593
 Leu Pro Phe Phe Leu Phe Arg Gln Ala Tyr His Pro Asn
 170 175 180

70

AAT TCC AGT CCA GTT TGC TAT GAG GTC CTG GGA AAT GAC 632

Fig. 2a

BOSTON 2025 06/20/98

	Asn Ser Ser Pro Val Cys Tyr Glu Val Leu Gly Asn Asp	185	190	
5	ACA GCA AAA TGG CGG ATG GTG TTG CGG ATC CTG CCT CAC 671 Thr Ala Lys Trp Arg Met Val Leu Arg Ile Leu Pro His	195	200	205
10	ACC TTT GGC TTC ATC GTG CCG CTG TTT GTC ATG CTG TTC 710 Thr Phe Gly Phe Ile Val Pro Leu Phe Val Met Leu Phe	210	215	220
15	TGC TAT GGA TTC ACC CTG CGT ACA CTG TTT AAG GCC CAC 749 Cys Tyr Gly Phe Thr Leu Arg Thr Leu Phe Lys Ala His	225	230	
20	ATG GGG CAG AAG CAC CGA GCC ATG AGG GTC ATC TTT GCT 788 Met Gly Gln Lys His Arg Ala Met Arg Val Ile Phe Ala	235	240	245
25	GTC GTC CTC ATC TTC CTG CTT TGC TGG CTG CCC TAC AAC 827 Val Val Leu Ile Phe Leu Leu Cys Trp Leu Pro Tyr Asn	250	255	
30	CTG GTC CTG CTG GCA GAC ACC CTC ATG AGG ACC CAG GTG 866 Leu Val Leu Leu Ala Asp Thr Leu Met Arg Thr Gln Val	260	265	270
35	ATC CAG GAG ACC TGT GAG CGC CGC AAC AAC ATC GGC CGG 905 Ile Gln Glu Thr Cys Glu Arg Arg Asn Asn Ile Gly Arg	275	280	285
40	GCC CTG GAT GCC ACT GAG ATT CTG GGA TTT CTC CAT AGC 944 Ala Leu Asp Ala Thr Glu Ile Leu Gly Phe Leu His Ser	290	295	
45	TGC CTC AAC CCC ATC ATC TAC GCC TTC ATC GGC CAA AAT 983 Cys Leu Asn Pro Ile Ile Tyr Ala Phe Ile Gly Gln Asn	300	305	310
50	TTT CGC CAT GGA TTC CTC AAG ATC CTG GCT ATG CAT GGC 1022 Phe Arg His Gly Phe Leu Lys Ile Leu Ala Met His Gly	315	320	
	CTG GTC AGC AAG GAG TTC TTG GCA CGT CAT CGT GTT ACC 1061 Leu Val Ser Lys Glu Phe Leu Ala Arg His Arg Val Thr	325	330	335
	TCC TAC ACT TCT TCG TCT GTC AAT GTC TCT TCC AAC CTC 1100 Ser Tyr Thr Ser Ser Ser Val Asn Val Ser Ser Asn Leu	340	345	350
	TGAAAAACCAT CGATGAAGGA ATATCTCTTC TCAGAAGGAA AGAATAACCA 1150			
55	ACACCCCTGAG GTTGTGTGTG GAAGGTGATC TGGCTCTGGA CAGGCACTAT 1200			
	CTGGGTTTG GGGGGACGCT ATAGGATGTG GGGAAAGTTAG GAACTGGTGT 1250			

Fig. 2b

CTTCAGGGGC CACACCAACC TTCTGAGGAG CTGTTGAGGT ACCCTCCAAGG 1300
5 ACCGGCCTTT GCACCTCCAT GGAAACGAAG CACCATCATT CCCGTTAAC 1350
10 GTCACATCTT TAACCCACTA ACTGGCTAAT TAGCATGGCC ACATCTGAGC 1400
15 CCCGAATCTG ACATTAGATG AGAGAACAGG GCTGAAGCTG TGTCTCATG 1450
20 AGGGCTGGAT GCTCTCGTTG ACCCTCACAG GAGCCTCTCC TCAACTCTGA 1500
25 GTGTTAAGCG TTGAGCCACC AAGCTGGTGG CTCTGTGTGC TCTGATCCGA 1550
30 GCTCAGGGGG GTGGTTTCC CATCTCAGGT GTGTTGCAGT GTCTGCTGGA 1600
35 GACATTGAGG CAGGCACATGC CAAACATCA ACCTGCCAGC TGGCCTTGTG 1650
40 AGGAGCTGGA AACACATGTT CCCCTGGGG GTGGTGGATG AACAAAGAGA 1700
45 AAGAGGTTT GGAAGCCAGA TCTATGCCAC AAGAACCCCC TTACCCCCA 1750
50 TGACCAAACAT CGCAGACACA TGTGCTGGCC ACCTGCTGAG CCCCAAGTGG 1800
55 AACGAGACAA GCAGCCCTTA GCCCTTCCCC TCTGCAGCTT CCAGGCTGGC 1850
60 GTGCAGCAGT AGCATCCCTA GAAAGCCATG TGCAGCCACC AGTCCATGG 1900
65 GCAGGCAGAT GTTCTAATA AAGCTTCTGT TCC 1933

Fig. 2c




Figure 3a




Figure 3b

GAATTCCAGT GTGCTGGCGG CGCGGCCAA AGTGACGCCG AGGGCCTGAG 50
 TGCTCCAGTA GCCACCGCAT CTGGAGAACCC AGCGGTTACC ATG GAG 96
 Met Glu
 1

GGG ATC AGT ATA TAC ACT TCA GAT AAC TAC ACC GAG GAA 135
 Gly Ile Ser Ile Tyr Thr Ser Asp Asn Tyr Thr Glu Glu
 5 10 15

ATG GGC TCA GGG GAC TAT GAC TCC ATG AAG GAA CCC TGT 174
 Met Gly Ser Gly Asp Tyr Asp Ser Met Lys Glu Pro Cys
 20 25

TTC CGT GAA GAA AAT GCT AAT TTC AAT AAA ATC TTC CTG 213
 Phe Arg Glu Glu Asn Ala Asn Phe Asn Lys Ile Phe Leu
 30 35 40

CCC ACC ATC TAC TCC ATC ATC TTC TTA ACT GGC ATT GTG 252
 Pro Thr Ile Tyr Ser Ile Ile Phe Leu Thr Gly Ile Val
 45 50

GGC AAT GGA TTG GTC ATC CTG GTC ATG GGT TAC CAG AAG 291
 Gly Asn Gly Leu Val Ile Leu Val Met Gly Tyr Gln Lys
 55 60 65

AAA CTG AGA AGC ATG ACG GAC AAG TAC AGG CTG CAC CTG 330
 Lys Leu Arg Ser Met Thr Asp Lys Tyr Arg Leu His Leu
 70 75 80

TCA GTG GCC GAC CTC CTC TTT GTC ATC ACG CTT CCC TTC 369
 Ser Val Ala Asp Leu Leu Phe Val Ile Thr Leu Pro Phe
 85 90

TGG GCA GTT GAT GCC GTG GCA AAC TGG TAC TTT GGG AAC 408
 Trp Ala Val Asp Ala Val Ala Asn Trp Tyr Phe Gly Asn
 95 100 105

TTC CTA TGC AAG GCA GTC CAT GTC ATC TAC ACA GTC AAC 447
 Phe Leu Cys Lys Ala Val His Val Ile Tyr Thr Val Asn
 110 115

CTC TAC AGC AGT GTC CTC ATC CTG GCC TTC ATC AGT CTG 486
 Leu Tyr Ser Ser Val Leu Ile Leu Ala Phe Ile Ser Leu
 120 125 130

GAC CGC TAC CTG GCC ATC GTC CAC GCC ACC AAC AGT CAG 525
 Asp Arg Tyr Leu Ala Ile Val His Ala Thr Asn Ser Gln
 135 140 145

AGG CCA AGG AAG CTG TTG GCT GAA AAG GTG GTC TAT GTT 564
 Arg Pro Arg Lys Leu Leu Ala Glu Lys Val Val Tyr Val
 150 155

GGC GTC TGG ATC CCT GCC CTC CTG CTG ACT ATT CCC GAC 603
 Gly Val Trp Ile Pro Ala Leu Leu Thr Ile Pro Asp
 160 165 170

Figure 4a

TTC ATC TTT GCC AAC GTC AGT GAG GCA GAT GAC AGA TAT 642
Phe Ile Phe Ala Asn Val Ser Glu Ala Asp Asp Arg Tyr
175 180

ATC TGT GAC CGC TTC TAC CCC AAT GAC TTG TGG GTG GTT 681
Ile Cys Asp Arg Phe Tyr Pro Asn Asp Leu Trp Val Val
185 190 195

G TG TTC CAG TTT CAG CAC ATC ATG GTT GGC CTT ATC CTG 720
Val Phe Gln Phe Gln His Ile Met Val Gly Leu Ile Leu
200 205 210

CCT GGT ATT GTC ATC CTG TCC TGC TAT TGC ATT ATC ATC 759
Pro Gly Ile Val Ile Leu Ser Cys Tyr Cys Ile Ile Ile
215 220

TCC AAG CTG TCA CAC TCC AAG GGC CAC CAG AAG CGC AAG 798
Ser Lys Leu Ser His Ser Lys Gly His Gln Lys Arg Lys
225 230 235

GCC CTC AAG ACC ACA GTC ATC CTC ATC CTG GCT TTC TTC 837
Ala Leu Lys Thr Thr Val Ile Leu Ile Leu Ala Phe Phe
240 245

GCC TGT TGG CTG CCT TAC TAC ATT GGG ATC AGC ATC GAC 876
Ala Cys Trp Leu Pro Tyr Tyr Ile Gly Ile Ser Ile Asp
250 255 260

TCC TTC ATC CTC CTG GAA ATC ATC AAG CAA GGG TGT GAG 915
Ser Phe Ile Leu Leu Glu Ile Ile Lys Gln Gly Cys Glu
265 270 275

TTT GAG AAC ACT GTG CAC AAG TGG ATT TCC ATC ACC GAG 954
Phe Glu Asn Thr Val His Lys Trp Ile Ser Ile Thr Glu
280 285

GCC CTA GCT TTC TTC CAC TGT TGT CTG AAC CCC ATC CTC 993
Ala Leu Ala Phe Phe His Cys Cys Leu Asn Pro Ile Leu
290 295 300

TAT GCT TTC CTT GGA GCC AAA TTT AAA ACC TCT GCC CAG 1032
Tyr Ala Phe Leu Gly Ala Lys Phe Lys Thr Ser Ala Gln
305 310

CAC GCA CTC ACC TCT GTG AGC AGA GGG TCC AGC CTC AAG 1071
His Ala Leu Thr Ser Val Ser Arg Gly Ser Ser Leu Lys
315 320 325

ATC CTC TCC AAA GGA AAG CGA GGT GGA CAT TCA TCT GTT 1110
Ile Leu Ser Lys Gly Lys Arg Gly Gly His Ser Ser Val
330 335 340

TCC ACT GAG TCT GAG TCT TCA AGT TTT CAC TCC AGC TAAC 1150
Ser Thr Glu Ser Ser Ser Phe His Ser Ser
345 350 352

ACAGATGTAA AAGACTTTTT TTTATACGAT AAATAACTTT TTTTTAAGTT 1200

Figure 4b

ACACATTTT CAGATATAAA AGACTGACCA ATATTGTACA GTTTTATTG 1250
CTTGTGGAT TTTGTCTTG TGTTTCTTA GTTTTGTGA AGTTAATTG 1300
ACTTATTTAT ATAAATTTT TTTGTTCAT ATTGATGTGT GTCTAGGCAG 1350
GACCTGTGGC CAAGTCTTA GTTGCTGTAT GTCTCGTGGT AGGACTGTAG 1400
AAAAGGGAAC TGAACATTCC AGAGCGTGTG GTGAATCACG TAAAGCTAGA 1450
AATGATCCCC AGCTGTTAT GCATAGATAA TCTCTCCATT CCCGTGGAAC 1500
GTTTTCCIG TTCTTAAGAC GTGATTTGC TGTAGAAGAT GGCACTTATA 1550
ACCAAAGCCC AAAGTGGTAT AGAAAATGCTG GTTTTCAGT TTTCAGGAGT 1600
GGGTTGATT CAGCACCTAC AGTGTACAGT CTTGTATTAA GTTGTAAATA 1650
AAAGTACATG TTAAACTTAA AAAAAAAA AAAAAAAA AAAAAAAA 1700
AAAAAAAAA AAAGCGGCCG CCAGCACACT GGAATTC 1737

Figure 4c

GAATTCCAGT GTGCTGGCGG CCGCCCAGTG TGCTGGCGGC GGCAGTTGAG 50

GGAAAGGACA GAGGTTATGA GTGCCTGCAA GAGTGGCAGC CTGGAGTAGA 100

GAAAAACACTA AAGGTGGAGT CAAAAGACCT GAGTCAAGT CCCAGCTCTG 150

CCACTGGTIA GCTGTGGGAT CTCGGAAAAG ACCCAGTGAA AAAAAAAA 200

AAAGTGTATGA GTTGTGAGGC AGGTGCGGGC CCTACTGCCT CAGGAGACGA 250

TGCGCAGCTC ATTTGCTTAA ATTTGCAGCT GACGGCTGCC ACCTCTCTAG 300

AGGCACCTGG CGGGGAGCCT CTCAACATAA GACAGTGACC AGTCTGGTGA 350

CTCACAGCCG GCACAGCC ATG AAC TAC CCG CTA ACG CTG GAA 392

Met Asn Tyr Pro Leu Thr Leu Glu

1 5

ATG GAC CTC GAG AAC CTG GAG GAC CTG TTC TGG GAA CTG 431

Met Asp Leu Glu Asn Leu Glu Asp Leu Phe Trp Glu Leu

10 15 20

GAC AGA TTG GAC AAC TAT AAC GAC ACC TCC CTG GTG GAA 470

Asp Arg Leu Asp Asn Tyr Asn Asp Thr Ser Leu Val Glu

25 30

AAT CAT CTC TGC CCT GCC ACA GAG GGG CCC CTC ATG GCC 509

Asn His Leu Cys Pro Ala Thr Glu Gly Pro Leu Met Ala

35 40 45

TCC TTC AAG GCC GTG TTC GTG CCC GTG GCC TAC AGC CTC 548

Ser Phe Lys Ala Val Phe Val Pro Val Ala Tyr Ser Leu

50 55 60

ATC TTC CTC CTG GGC GTG ATC GGC AAC GTC CTG GTG CTG 587

Ile Phe Leu Leu Gly Val Ile Gly Asn Val Leu Val Leu

65 70

GTG ATC CTG GAG CGG CAC CGG CAG ACA CGC AGT TCC ACG 626

Val Ile Leu Glu Arg His Arg Gln Thr Arg Ser Ser Thr

75 80 85

GAG ACC TTC CTG TTC CAC CTG GCC GTG GCC GAC CTC CTG 665

Glu Thr Phe Leu Phe His Leu Ala Val Ala Asp Leu Leu

90 95

CTG GTC TTC ATC TTG CCC TTT GCC GTG GCC GAG GGC TCT 704

Leu Val Phe Ile Leu Pro Phe Ala Val Ala Glu Gly Ser

100 105 110

Figure 5a

GTG GGC TGG GTC CTG GGG ACC TTC CTC TGC AAA ACT GTG 743
 Val Gly Trp Val Leu Gly Thr Phe Leu Cys Lys Thr Val
 115 120 125

ATT GCC CTG CAC AAA GTC AAC TTC TAC TGC AGC AGC CTG 782
 Ile Ala Leu His Lys Val Asn Phe Tyr Cys Ser Ser Leu
 130 135

CTC CTG GCC TGC ATC GCC GTG GAC CGC TAC CTG GCC ATT 821
 Leu Leu Ala Cys Ile Ala Val Asp Arg Tyr Leu Ala Ile
 140 145 150

GTC CAC GCC GTC CAT GCC TAC CGC CAC CGC CGC CTC CTC 860
 Val His Ala Val His Ala Tyr Arg His Arg Arg Leu Leu
 155 160

TCC ATC CAC ATC ACC TGT GGG ACC ATC TGG CTG GTG GGC 899
 Ser Ile His Ile Thr Cys Gly Thr Ile Trp Leu Val Gly
 165 170 175

TTC CTC CTT GCC TTG CCA GAG ATT CTC TTC GCC AAA GTC 938
 Phe Leu Leu Ala Leu Pro Glu Ile Leu Phe Ala Lys Val
 180 185 190

AGC CAA GGC CAT CAC AAC AAC TCC CTG CCA CGT TGC ACC 977
 Ser Gln Gly His His Asn Asn Ser Leu Pro Arg Cys Thr
 195 200

TTC TCC CAA GAG AAC CAA GCA GAA ACG CAT GCC TGG TTC 1016
 Phe Ser Gln Glu Asn Gln Ala Glu Thr His Ala Trp Phe
 205 210 215

ACC TCC CGA TTC CTC TAC CAT GTG GCG GGA TTC CTG CTG 1055
 Thr Ser Arg Phe Leu Tyr His Val Ala Gly Phe Leu Leu
 220 225

CCC ATG CTG GTG ATG GGC TGG TGC TAC GTG GGG GTA GTG 1094
 Pro Met Leu Val Met Gly Trp Cys Tyr Val Gly Val Val
 230 235 240

CAC AGG TTG CGC CAG GCC CAG CGG CGC CCT CAG CGG CAG 1133
 His Arg Leu Arg Gln Ala Gln Arg Arg Pro Gln Arg Gln
 245 250 255

AAG GCA GTC AGG GTG GCC ATC CTG GTG ACA AGC ATC TTC 1172
 Lys Ala Val Arg Val Ala Ile Leu Val Thr Ser Ile Phe
 260 265

TTC CTC TGC TGG TCA CCC TAC CAC ATC GTC ATC TTC CTG 1211
 Phe Leu Cys Trp Ser Pro Tyr His Ile Val Ile Phe Leu
 270 275 280

GAC ACC CTG GCG AGG CTG AAG GCC GTG GAC AAT ACC TGC 1250
 Asp Thr Leu Ala Arg Leu Lys Ala Val Asp Asn Thr Cys
 285 290

Figure 5b

AAG CTG AAT GGC TCT CTC CCC GTG GCC ATC ACC ATG TGT 1289
Lys Leu Asn Gly Ser Leu Pro Val Ala Ile Thr Met Cys
295 300 305

GAG TTC CTG GGC CTG GCC CAC TGC TGC CTC AAC CCC ATG 1328
Glu Phe Leu Gly Leu Ala His Cys Cys Leu Asn Pro Met
310 315 320

CTC TAC ACT TTC GCC GGC GTG AAG TTC CGC AGT GAC CTG 1367
Leu Tyr Thr Phe Ala Gly Val Lys Phe Arg Ser Asp Leu
325 330

TCG CGG CTC CTG ACG AAG CTG GGC TGT ACC GGC CCT GCC 1406
Ser Arg Leu Leu Thr Lys Leu Gly Cys Thr Gly Pro Ala
335 340 345

TCC CTG TGC CAG CTC TTC CCT AGC TGG CGC AGG AGC AGT 1445
Ser Leu Cys Gln Leu Phe Pro Ser Trp Arg Arg Ser Ser
350 355

CTC TCT GAG TCA GAG AAT GCC ACC TCT CTC ACC ACG TTC TA 1486
Leu Ser Glu Ser Glu Asn Ala Thr Ser Leu Thr Thr Phe
360 365 370 372

GGTC CCAGTGCCCC CTTTATTGC TGCTTTCT TGCGGCAGGC 1530

AGTGATGCTG GATGCTCCTT CCAACAGGAG CTGGGATCCT AAGGGCTCAC 1580

CGTGGCTAAG AGTGTCTAG GAGTATCCTC ATTTGGGTA GCTAGAGGAA 1630


CCAACCCCCA TTTCTAGAAC ATCCCGCGGC CGCCAGCACA CTGGAATTG 1679

Figure 5c

C1C i

Receptor Structure of Human IL-8R

卷之三









FIG. 8






Fig. 9



Concentrations of IL8 in Sputum from Patients with Chronic Airway Inflammation and Induced Sputum from Healthy Subjects



**COMBINED DECLARATION FOR PATENT APPLICATION
AND POWER OF ATTORNEY**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

PF4A RECEPTOR

the specification of which is attached hereto and is amended by preliminary amendment filed herewith.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate have a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s):	Priority Claimed
	<u>Yes</u> <u>No</u>

Number	Country	Day/Month/Year Filed
--------	---------	----------------------

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional applications(s) listed below:

Application Ser. No.	Filing Date
----------------------	-------------

I hereby claim the benefit under Title 35, United States Code, §120 of any United States applications(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

08/664,228	6 June 1996	Pending
Application Ser. No.	Filing Date	Status: Patented, Pending, Abandoned
08/076,093	11 June 1993	Patented
Application Ser. No.	Filing Date	Status: Patented, Pending, Abandoned
07/810,782	19 December 1991	Abandoned
Application Ser. No.	Filing Date	Status: Patented, Pending, Abandoned

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Walter E. Buting - Reg. No. 23,092
 Ginger R. Dreger - Reg. No. 33,055
 Richard B. Love - Reg. No. 34,659
 Diane L. Marschang - Reg. No. 35,600
 Daryl B. Winter - Reg. No. 32,637
 Timothy E. Torchia - Reg. No. 36,700

Jeffrey S. Kubinec - Reg. No. 36,575
 Stephen Raines - Reg. No. 25,912
 Janet E. Hasak - Reg. No. 28,616
 Sean A. Johnston - Reg. No. 35,910
 Dennis G. Kleid - Reg. No. 32,037
 Wendy M. Lee - Reg. No. P-40,378

Send correspondence to
 Genentech, Inc.
 Attn: Richard B. Love
 460 Point San Bruno Boulevard
 South San Francisco, CA 94080
 Telephone: (415) 225-5530


I hereby declare that all statements made herein of my own knowledge and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under Section 1001 of Title 18 of the United States Code and that willful false statements may jeopardize the validity of the application or any patent issued thereon.

The undersigned hereby authorizes the U.S. attorney or agent named herein to accept and follow instructions from his foreign patent agent as to any action to be taken in the Patent and Trademark Office regarding this application without direct communication between the U.S. attorney or agent and the undersigned. In the event of a change in the persons from whom instructions may be taken, the U.S. attorney or agent named herein will be so notified by the undersigned.

Full name of sole or first inventor

James Lee

Inventor's signature


Date
1996 August 22

Residence

705 Shelter Creek Lane, San Bruno, California 94066

Citizenship

U.S.A.


Post Office Address

P.O. Box 5058
 South San Francisco, CA 94083

Full name of second joint inventor, if any

William I. Wood

Inventor's signature



Date
8/22/96

Residence

1400 Terrytown Street, San Mateo, California 94402

Citizenship

U.S.A.

Post Office Address

460 Point San Bruno Boulevard
 South San Francisco, CA 94080